ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology

Manesh R. Patel, Gregory J. Dehmer, John W. Hirshfeld, Peter K. Smith and John A. Spertus

Circulation published online Jan 8, 2009;
DOI: 10.1161/CIRCULATIONAHA.108.191768
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
 Print ISSN: 0009-7322. Online ISSN: 1524-4539

ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization

A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology

Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography

CORONARY REVASCULARIZATION WRITING GROUP

Manesh R. Patel, MD, Chair; Gregory J. Dehmer, MD, FACC, FACP, FSCAI, FAHA*; John W. Hirshfeld, MD†; Peter K. Smith, MD, FACC‡; John A. Spertus, MD, MPH, FACC†

TECHNICAL PANEL

Frederick A. Masoudi, MD, MSPH, FACC, Moderator; Ralph G. Brindis, MD, MSH, FACC, FSCAI, Methodology Liaison; Gregory J. Dehmer, MD, FACC, FACP, FSCAI, FAHA, Writing Group Liaison*; Manesh R. Patel, MD, Writing Group Liaison; Peter K. Smith, MD, FACC, Writing Group Liaison‡; Karen J. Beckman, MD, FACC§; Charles E. Chambers, MD, FACC, FSCAI, FAHA*; T. Bruce Ferguson, Jr, MD, FACC, FAHA‖; Mario J. Garcia, MD, FACC¶; Frederick L. Grover, MD, FACC‖; David R. Holmes, Jr, MD, FACC, FSCAI*; Lloyd W. Klein, MD, FACC, FSCAI, FAHA†; Marian Limacher, MD, FACC†; Michael J. Mack, MD‖; David J. Malenka, MD, FACC††; Myung H. Park, MD, FACC#; Michael Ragosta III, MD, FACC, FSCAI*; James L. Ritchie, MD, FACC, FAHA†; Geoffrey A. Rose, MD, FACC, FASE**; Alan B. Rosenberg, MD††; Richard J. Shemin, MD, FACC, FAHA‖; William S. Weintraub, MD, FACC, FAHA††

*Society for Cardiovascular Angiography and Interventions Representative.
†American College of Cardiology Foundation Representative.
‡Society of Thoracic Surgeons Representative.
§Heart Rhythm Society Representative.
‖American Association for Thoracic Surgery/Society of Thoracic Surgeons Representative.
¶Society of Cardiovascular Computed Tomography Representative.
#Heart Failure Society of America Representative.
**American Society of Echocardiography Representative.
††American Heart Association Representative.
‡‡Former Task Force Chair during this writing effort.

This document was approved by the American College of Cardiology Foundation Board of Trustees in May 2008.

The American Heart Association requests that this document be cited as follows: Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology. *Circulation.* 2009;119:xxx–xxx.

This article has been copublished in the *Journal of the American College of Cardiology* and *Catheterization and Cardiovascular Interventions.*

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the American Heart Association (my.americanheart.org). A copy of the document is also available at http://www.americanheart.org/presenter.jhtml?identifier=3003999 by selecting either the "topic list" link or the "chronological list" link (No. LS-1938). To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development, visit http://www.americanheart.org/presenter.jhtml?identifier=3023366.

(*Circulation*. 2009;119:000-000.)

***Circulation* is available at http://circ.ahajournals.org** **DOI: 10.1161/CIRCULATIONAHA.108.191768**

ACCF APPROPRIATENESS CRITERIA TASK FORCE
Michael J. Wolk, MD, MACC, Chair; Ralph G. Brindis, MD, MPH, FACC, FSCAI‡‡;
Joseph M. Allen, MA; Pamela S. Douglas, MD, MACC, FAHA, FASE;
Robert C. Hendel, MD, FACC, FAHA; Manesh R. Patel, MD; Eric D. Peterson, MD, MPH, FACC, FAHA

TABLE OF CONTENTS

Abstract XXXX
Preface XXXX
Introduction XXXX
Methods XXXX
- Indication Development XXXX
- Scope of Indications XXXX
- Panel Selection XXXX
- Rating Process and Scoring XXXX

General Assumptions XXXX
- Table A. CAD Prognostic Index XXXX

Definitions XXXX
- Table B. Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System XXXX

Abbreviations XXXX
Results of Ratings XXXX
Coronary Revascularization Appropriateness Criteria (By Indication) XXXX
- Table 1. Patients With Acute Coronary Syndromes XXXX
- Table 2. Patients Without Prior Bypass Surgery XXXX
- Table 3. Patients With Prior Bypass Surgery (Without Acute Coronary Syndromes) XXXX

Rating Revascularization Methods XXXX
- Mode of Revascularization for High Severity of CAD (Indications 60 to 73) XXXX
- Mortality Risk XXXX
- Advanced CAD XXXX
- Table 4. Method of Revascularization: Advanced Coronary Disease, CCS Angina Greater Than or Equal to Class III, and/or Evidence of Intermediate- to High-Risk Findings on Noninvasive Testing XXXX

Discussion XXXX
- Clinical Judgment XXXX
- General Themes in Appropriateness Criteria for Revascularization XXXX
- Acute Coronary Syndromes XXXX
- Stable Ischemic Heart Disease *Without* Prior CABG XXXX
- Stable Ischemic Heart Disease *With* Prior CABG XXXX
- PCI and CABG in Patients With Advanced CAD XXXX
- Application of Criteria XXXX

Appendix A: Additional Coronary Revascularization Definitions XXXX
- Table A1. Clinical Classification of Chest Pain XXXX
- Table A2. Noninvasive Risk Stratification XXXX

Appendix B: Additional Methods XXXX
- Relationships With Industry XXXX
- Literature Review XXXX

Appendix C: ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization Participants XXXX

Appendix D: ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Coronary Revascularization Appropriateness Criteria Writing Group, Technical Panel, Task Force, and Indication Reviewers—Relationships With Industry XXXX

References XXXX

Abstract

The American College of Cardiology Foundation (ACCF), Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, and the American Association for Thoracic Surgery, along with key specialty and subspecialty societies, conducted an appropriateness review of common clinical scenarios in which coronary revascularization is frequently considered. The clinical scenarios were developed to mimic common situations encountered in everyday practice and included information on symptom status, extent of medical therapy, risk level as assessed by noninvasive testing, and coronary anatomy. Approximately 180 clinical scenarios were developed by a writing committee and scored by a separate technical panel on a scale of 1 to 9. Scores of 7 to 9 indicate that revascularization was considered appropriate and likely to improve health outcomes or survival. Scores of 1 to 3 indicate revascularization was considered inappropriate and unlikely to improve health outcomes or survival. The mid range (4 to 6) indicates a clinical scenario for which the likelihood that coronary revascularization would improve health outcomes or survival was considered uncertain. For the majority of the clinical scenarios, the panel only considered the appropriateness of revascularization irrespective of whether this was accomplished by percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). In a select subgroup of clinical scenarios in which revascularization is generally considered appropriate, the appropriateness of PCI and CABG individually as the primary mode of revascularization was considered.

In general, the use of coronary revascularization for patients with acute coronary syndromes and combinations of significant symptoms and/or ischemia was viewed favorably. In contrast, revascularization of asymptomatic patients or patients with low-risk findings on noninvasive testing and minimal medical therapy were viewed less favorably. It is anticipated that these results will have an impact on physician decision making and patient education regarding expected benefits from revascularization and will help guide future research.

Preface

The publication of appropriateness criteria reflects one of several ongoing efforts by the ACCF and its partners to assist clinicians caring for patients with cardiovascular diseases to deliver high-quality cardiovascular care. The American College of Cardiol-

ogy (ACC)/American Heart Association (AHA) practice guidelines provide a foundation for summarizing evidence-based cardiovascular care and, when evidence is lacking, provide expert consensus opinion that is approved in review by the ACCF and AHA. However, in many areas, marked variability remains in the use of cardiovascular procedures, raising questions of over- or under-use. One reason for this variability is a paucity of large randomized clinical trials conducted assessing the value of technology for specific patients, including cardiac imaging, catheterization, and coronary revascularization. As such, there are many instances in practice where the guidelines provide no recommendation, or alternatively, a Level C recommendation (expert opinion). For other areas, evidence is available but variability in clinical practice remains. In either case, appropriateness criteria provide practical tools to measure this variability to examine utilization patterns.

Appropriateness criteria are developed to serve as a supplement to ACC/AHA guideline documents. Appropriateness criteria are designed to examine the use of diagnostic and therapeutic procedures to support efficient use of medical resources during the pursuit of quality medical care. The process of appropriateness criteria development has been defined previously.[1] Briefly, the appropriateness criteria writing group combines specific clinical characteristics to create prototypical patient scenarios. These scenarios are then provided to a separate technical panel for appropriateness rating. The technical panel is created from nominations given by multiple relevant professional societies and provider-led organizations as well as from health policy and payer communities. To preserve objectivity, the technical panels are created so as to not include a majority of individuals whose livelihood is tied to the technology under study.

In making its appropriateness determinations, the technical panel is provided with summaries of the relevant evidence from the medical literature and practice guidelines. They are then asked first individually and then collectively to assess the benefits and risks of a test or procedure in the context of the potential benefits to patients' outcomes and an implicit understanding of the associated resource use and costs. After the ranking process, the final appropriateness ratings are summarized using an established rigorous methodology.[2]

Appropriateness criteria are based on current understanding of the technical capabilities and potential patient benefits of the procedures examined. Future evidence development may require these ratings to be updated. The appropriateness criteria are also developed to identify common clinical scenarios—but they cannot possibly include every conceivable clinical situation. Thus, some patients seen in clinical practice are not represented in these appropriateness criteria or have additional extenuating features compared with the clinical scenarios presented. Additionally, although appropriateness criteria indications and ratings are shaped by the practice guidelines, the appropriateness criteria often contain more detailed scenarios than the more generalized situations covered in clinical practice guidelines, and thus, subtle differences between these 2 guidance tools is possible.

Finally, appropriateness criteria are intended to assist patients and clinicians, but are not intended to diminish the acknowledged difficulty or uncertainty of clinical decision making and cannot act as substitutes for sound clinical judgment and practice experience. Rather, the aim of these criteria is to allow assessment of utilization patterns for a test or procedure. Comparing utilization patterns across a large subset of provider's patients can allow for an assessment of a provider's management strategies with those of his/her peers. The ACCF and its collaborators believe that an ongoing review of one's practice using these criteria will help guide a more effective, efficient, and equitable allocation of health care resources, and ultimately, better patient outcomes.

In developing these appropriateness criteria for coronary revascularization, the technical panel was asked to assess whether coronary revascularization for each indication was appropriate, uncertain, or inappropriate using the following definition of appropriateness:

Coronary revascularization is appropriate when the expected benefits, in terms of survival or health outcomes (symptoms, functional status, and/or quality of life) exceed the expected negative consequences of the procedure.

The technical panel scored each indication on a scale from 1 to 9 as follows:

Appropriate: Score 7 to 9

Appropriate for the indication provided, meaning coronary revascularization **is** generally acceptable and **is** a reasonable approach for the indication and is **likely** to improve the patients' health outcomes or survival.

Uncertain: Score 4 to 6

Uncertain for the indication provided, meaning coronary revascularization **may** be acceptable and **may** be a reasonable approach for the indication but with uncertainty implying that more research and/or patient information is needed to further classify the indication.

Inappropriate: Score 1 to 3

Inappropriate for the indication provided, meaning coronary revascularization is **not** generally acceptable and is **not** a reasonable approach for the indication and is **unlikely** to improve the patients' health outcomes or survival.

It is acknowledged that grouping these scores into 3 categories is somewhat arbitrary and that the numeric designations should be viewed as a continuum. Since some diversity in clinical opinions for particular clinical scenarios will exist or available research is limited or conflicting, scores in the intermediate level of appropriateness are labeled "uncertain." This identifies the need for targeted investigations to clarify the best therapy in these circumstances. It is anticipated that these appropriateness criteria will require updates as further data are generated and information from the implementation of these criteria accumulates.

To prevent bias in the scoring process, the technical panel was deliberately comprised of physicians with varying perspectives on coronary revascularization and not comprised solely of experts (eg, interventional cardiologists or cardiovascular surgeons) in the particular procedure under evaluation. Such experts, while offering important clinical and technical insights, might have a natural tendency to rate the indications within their specialty as more appropriate than nonspecialists. In addition, care was taken in providing objective, nonbiased information, including national practice guidelines and a broad range of key references, to the technical panel.

We are grateful to the technical panel, a professional group with a wide range of skills and insights, for their thoughtful and thorough deliberation of the merits of coronary revascularization for various indications. In addition to our thanks to the technical panel for their dedicated work and review, we would like to offer special thanks to the many individuals who provided a careful review of the draft indications: to Peggy Christiansen, the ACCF librarian, for her comprehensive literature searches; to Karen Caruth, who continually drove the process forward; to Lindsey Law and Kennedy Elliott, who helped map these criteria with existing ACC/AHA practice guidelines; and to Manesh Patel, MD, the chair of the writing committee, for his dedication, insight and leadership.

Frederick A. Masoudi, MD, MSPH, FACC
Moderator, Coronary Revascularization Technical Panel

Ralph G. Brindis, MD, MPH, FACC, FSCAI
Chair, Appropriateness Criteria Task Force

Introduction

This report addresses the appropriateness of coronary revascularization. The increasing prevalence of coronary artery disease (CAD), advances in surgical and percutaneous techniques for revascularization as well as concomitant medical therapy for CAD, and the costs of revascularization have resulted in heightened interest regarding the appropriateness of coronary revascularization. Clinicians, payers, and patients are interested in the specific benefits of revascularization. Importantly, inappropriate use of revascularization may be potentially harmful to patients and generate unwarranted costs to the health care system, whereas appropriate procedures should likely improve patients' clinical outcomes.

All prior appropriateness criteria publications from the ACCF and collaborating organizations have reflected an ongoing effort to critically and systematically create, review, and categorize the appropriateness of certain cardiovascular diagnostic tests. This document presents the first attempt to develop appropriateness criteria for therapeutic procedures: in this case, 2 distinct approaches to coronary artery revascularization. This is an important shift to the explicit consideration of the potential benefits and risks of a therapeutic procedure. This document presents the results of this effort, but it is critical to understand the background and scope of this document before interpreting the rating tables.

Methods

Briefly, this process combines evidence-based medicine, guidelines, and practice experience by engaging a technical panel in a modified Delphi exercise as previously described by RAND.[2]

Indication Development

The writing group for the coronary revascularization indications was comprised of members from the relevant professional societies including both practicing interventional cardiologists and a cardiothoracic surgeon. Recognizing variability in many patient factors, local practice patterns, and a lack of data comparing PCI with CABG in all possible clinical scenarios, the technical panel was asked to rate the majority of clinical indications only for the appropriateness of revascularization and not to distinguish between the specific modes of revascularization (i.e., PCI versus CABG). In addition, the writing group identified indications for patients with advanced coronary disease and symptoms, where revascularization is generally considered to be appropriate. In this section, PCI and CABG were independently evaluated for appropriateness.

Once the indications were drafted, reviewers from all participating collaborators and stakeholders, including cardiovascular and surgical societies, provided feedback regarding the clinical indications for coronary revascularization. These comments led to substantial improvements and changes in the clinical scenarios.

Scope of Indications

The indications contained in this report are purposefully broad and intended to represent the most common patient scenarios for which coronary revascularization is considered. The development of these clinical scenarios re-emphasized to the writing group the complexity of the decision-making process for revascularization and the number of variables that inform this decision. The writing group estimated that over 4,000 separate clinical scenarios would be required to incorporate all permutations of these variables. However, providing that level of granularity to this framework would be cumbersome and likely degrade the purpose of these criteria. As this was not a viable option, the indications were developed considering the following common variables:

a. The clinical presentation (eg, acute coronary syndrome, stable angina, and so on);
b. Severity of angina (asymptomatic, Canadian Cardiovascular Society [CCS] Class I, II, III, or IV);
c. Extent of ischemia on noninvasive testing and the presence or absence of other prognostic factors, such as congestive heart failure (CHF), depressed left ventricular function, or diabetes;
d. Extent of medical therapy; and
e. Extent of anatomic disease (1-, 2-, 3-vessel disease, with or without proximal left anterior descending artery [LAD] or left main coronary disease).

The clinical indications developed include coronary anatomy, as this is the focus of much of the previous literature on coronary revascularization. However, the writing group recognizes that for everyday patient care, symptom status, ischemic burden, and level of medical therapy often play a critical role in decision making even before the coronary anatomy has been defined by angiography.

Please note that the indications focus on revascularization, percutaneous or surgical, and therefore do not address diagnostic catheterization or coronary angiography. Additionally, the clinical scenarios presented are not inclusive of every possible clinical situation. For example, the use of coronary revascularization for patients with multivessel disease including 1 or more occluded vessels and clinical symptoms or ischemia was not included as a separate indication since other variations of multivessel disease are present.

Panel Selection

Stakeholders were given the opportunity to participate in the appropriateness criteria process by submitting nominees from their organizations through a call for nominations announced in the summer of 2006. From this list of nominees, the task force and writing group selected technical panel members to ensure an appropriate balance with respect to expertise. The 17-member technical panel was composed of 4 interventional cardiologists, 4 cardiovascular surgeons, 8 members representing cardiologists, other physicians who treat patients with cardiovascular disease, health outcome researchers, and 1 medical officer from a health plan.

Rating Process and Scoring

The panel members first rated indications independently. Then the panel met for a discussion of each indication. After the face-to-face discussion, panel members then independently provided their final scores for each indication. Each panel member had equal weight in producing the final result for the indications and was not forced into consensus. For each indication, the median numerical score was determined.

At the face-to-face meeting, each panelist received a personalized rating form that indicated his/her rating for each indication and the distribution of deidentified ratings of other members of the panel. In addition, the moderator received a summary rating form with similar information (including panelist identification), along with other statistics reflecting the level of agreement among panel members. The level of agreement among panelists, as defined by RAND, was analyzed for each indication based on the BIOMED rule for a panel of 14 to 16 (a simplified RAND method for determining disagreement).[2] Per the BIOMED definition, agreement was defined as an indication where 4 or fewer panelists' ratings fell outside the 3-point region containing the median score. Disagreement was defined as a situation where at least 5 panelists' ratings fell in both the appropriate and the inappropriate categories. Because the panel had 17 representatives, which exceeded the 16 addressed in this rule, an additional level of agreement analysis as described by RAND was performed that examines the interpercentile range compared to interpercentile range adjusted for symmetry.[2] This information was used by the moderator to guide the panel's discussion by highlighting areas of differences among the panelists.

Table A. CAD Prognostic Index

Extent of CAD	Prognostic Weight (0–100)	5-Year Survival Rate (%)*
1-vessel disease, 75%	23	93
>1-vessel disease, 50% to 74%	23	93
1-vessel disease, ≥95%	32	91
2-vessel disease	37	88
2-vessel disease, both ≥95%	42	86
1-vessel disease, ≥95% proximal LAD	48	83
2-vessel disease, ≥95% LAD	48	83
2-vessel disease, ≥95% proximal LAD	56	79
3-vessel disease	56	79
3-vessel disease, ≥95% in at least 1	63	73
3-vessel disease, 75% proximal LAD	67	67
3-vessel disease, ≥95% proximal LAD	74	59

*Assuming medical treatment only. CAD indicates coronary artery disease; LAD, left anterior descending coronary artery. From Califf RM, Armstrong PW, Carver JR, et al. Task Force 5. Stratification of patients into high-, medium-, and low-risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:964–1047.[4]

General Assumptions

Specific assumptions are provided that were considered by the technical panel in rating the relevant clinical indications for the appropriateness of revascularization:

1. Each clinical indication includes the patient's clinical status/symptom complex, ischemic burden by noninvasive functional testing when presented, burden of coronary atherosclerosis as determined by angiography, and intensity of medical therapy in the determination of the appropriateness of coronary revascularization.
2. Assume coronary angiography has been performed when these findings are presented in the clinical indications. The panel should rate the appropriateness of revascularization based upon the clinical features and coronary findings, and not the appropriateness of diagnostic coronary angiography.
3. Assume left main coronary artery stenosis (greater than or equal to 50% luminal diameter narrowing) or proximal LAD stenosis (greater than or equal to 70% luminal diameter narrowing) is not present unless specifically noted. Assume no other significant coronary artery stenoses are present except those noted in the clinical scenario.
4. The clinical scenarios should be rated based on the published literature regarding the risks and benefits of percutaneous and surgical coronary revascularization. Note that specific patient groups not well represented in the literature are not presented in the current clinical scenarios. However, the writing group recognizes that decisions about coronary artery revascularization in such patients are frequently required. Examples of such patients include those with end-stage renal disease or advanced age.
5. Clinical outcome is related to the extent of coronary artery disease[3] (Table A). Based on this observation and clinical guideline recommendations regarding "borderline" angiographic stenoses (50% to 60%) in epicardial (non-left main) locations, a significant coronary stenosis for the purpose of the clinical scenarios is defined as:
   - greater than or equal to 70% luminal diameter narrowing, by visual assessment, of an epicardial stenosis measured in the "worst view" angiographic projection.
   - greater than or equal to 50% luminal diameter narrowing, by visual assessment, of a left main stenosis measured in the "worst view" angiographic projection.
6. All patients are receiving standard care, including guideline-based risk-factor modification for primary or

secondary prevention in cardiovascular patients unless specifically noted.[5–9]

7. Despite the best efforts of the clinician, all patients may not achieve target goals for risk-factor modification. However, a plan of care to address risk factors is assumed to be occurring in patients represented in the indications. For patients with chronic stable angina, the writing group recognizes that there is a wide variance in the medical therapy for angina. The specific definition of maximal anti-ischemic medical therapy is presented in the definition section.
8. Operators performing percutaneous or surgical revascularization have appropriate clinical training and experience and have satisfactory outcomes as assessed by quality assurance monitoring.[10–12]
9. Revascularization by either percutaneous or surgical methods is performed in a manner consistent with established standards of care.[10–12]
10. In the clinical scenarios, no unusual extenuating circumstances exist (such as inability to comply with antiplatelet agents, do not resuscitate status, patient unwilling to consider revascularization, technically not feasible to perform revascularization, or comorbidities likely to markedly increase procedural risk substantially), unless specifically noted.

Definitions

A complete set of definitions of terms used throughout the indication set are listed in Appendix A. These definitions were provided and discussed with the technical panel prior to ratings of indications.

Maximal Anti-Ischemic Medical Therapy

As previously stated, the indications assume that patients are receiving risk-factor modification according to guideline-based recommendations. For the purposes of the clinical scenarios presented, **maximal antianginal medical therapy is defined as the use of at least 2 classes of therapies to reduce anginal symptoms.**

Stress Testing and Risk of Findings on Noninvasive Testing

Stress testing is commonly used for both diagnosis and risk stratification of patients with coronary artery disease. Using criteria defined for traditional exercise stress tests[13]:

Low-risk stress test findings: associated with a cardiac mortality of less than 1% per year;

Intermediate-risk stress test findings: associated with a 1% to 3% per year cardiac mortality;

High-risk stress test findings: associated with a greater than 3% per year cardiac mortality.

Examples of findings from noninvasive studies and their associated level of risk for cardiac mortality are presented in Table A2.[12] As noted in the footnote to this table, for certain low-risk findings, there may be additional findings that alter the assessment of risk, but these relationships have not been well studied. Implicit in these risk definitions is a measure of the amount of myocardium at risk, or ischemic myocardium. For the purpose of the clinical indications for coronary revascularization, stress test findings are presented by these risk criteria. For patients without stress test findings, please refer to the note below on invasive methods of determining hemodynamic significance. Assume that when prior testing (including an imaging procedure) is referenced in an indication, the testing was performed correctly and with sufficient quality so as to produce a meaningful and accurate result within the limits of the test performance.

Table B. Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System

Class I
Ordinary physical activity does not cause angina, such as walking, climbing stairs. Angina (occurs) with strenuous, rapid, or prolonged exertion at work or recreation.
Class II
Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Angina occurs on walking more than 2 blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal condition.
Class III
Marked limitations of ordinary physical activity. Angina occurs on walking 1 to 2 blocks on the level and climbing 1 flight of stairs in normal conditions and at a normal pace.
Class IV
Inability to carry on any physical activity without discomfort—anginal symptoms may be present at rest.

From Campeau L. Grading of angina pectoris [letter]. Circulation. 1976;54: 522–3.[14] Copyright 1976 American Heart Association, Inc. Reprinted with permission.

For the purposes of the clinical indications in this document, patients with both typical and atypical angina are classified by the feature of the CCS grading system presented in Table B. Patients with noncardiac chest pain should be considered to be asymptomatic.

High-Risk Features for Short-Term Risk of Death or Nonfatal MI for UA/NSTEMI[15]

At least 1 of the following:

- History: accelerating tempo of ischemic symptoms in preceding 48 hours
- Character of pain: prolonged ongoing (greater than 20 minutes) rest pain
- Clinical findings
  - Pulmonary edema, most likely due to ischemia
  - New or worsening mitral regurgitation murmur
  - S_3 or new/worsening rales
  - Hypotension, bradycardia, tachycardia
  - Age greater than 75 years
- Electrocardiogram
  - Angina at rest with transient ST-segment changes greater than 0.5 mm

- Bundle-branch block, new or presumed new
- Sustained ventricular tachycardia

- Cardiac marker
  - Elevated cardiac troponin T, troponin I, or creatine kinase-MB (eg, troponin T or I greater than 0.1 ng per mL)

Abbreviations

CABG = coronary artery bypass grafting
CAD = coronary artery disease
CCS = Canadian Cardiovascular Society
CCT = cardiac computed tomography
CHF = congestive heart failure
ECG = electrocardiogram
FFR = fractional flow reserve
HF = heart failure
IVUS = intravascular ultrasound
LAD = left anterior descending artery
LIMA = left internal mammary artery
LV = left ventricular
LVEF = left ventricular ejection fraction
MI = myocardial infarction
NTG = nitroglycerin
PCI = percutaneous coronary intervention
PDA = patent ductus arteriosus
STEMI = ST-segment elevation myocardial infarction
UA/NSTEMI = unstable angina/non–ST-segment elevation myocardial infarction

Results of Ratings

The final ratings for coronary revascularization (Tables 1 to 4) are listed by indication sequentially as obtained from second-round rating sheets submitted by each panelist. Figures demonstrating trends in appropriateness rating by symptom status, ischemic risk, and method of revascularization are also presented.

There was generally less variation in ratings for the indications labeled as either appropriate or inappropriate, with 76% and 70%, respectively, showing agreement as defined previously in the Methods section. There was, however, greater variability in the rating scores for indications defined as uncertain, suggesting wide variation in opinion. Several indications failed to meet the definition of agreement noted above. There were no ratings where the panel held such opposing viewpoints that the panel's votes were determined to be in "disagreement" as defined by the strict RAND definitions described previously in the Methods section.

Coronary Revascularization Appropriateness Criteria (By Indication)

Table 1. Patients With Acute Coronary Syndromes

Indication		Appropriateness Score (1–9)
1.	• STEMI • ≤12 hours from onset of symptoms • Revascularization of the culprit artery	A (9)*
2.	• STEMI • Onset of symptoms within the prior 12 to 24 hours • Severe HF, persistent ischemic symptoms, or hemodynamic or electrical instability present	A (9)
3.	• STEMI • >12 hours from symptom onset • Asymptomatic; no hemodynamic instability and no electrical instability	I (3)
4.	• STEMI with presumed successful treatment with fibrinolysis • Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present • 1-vessel CAD, presumed to be the culprit artery	A (9)
5.	• STEMI with presumed successful treatment with fibrinolysis • Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias • Normal LVEF • 1-vessel CAD presumed to be the culprit artery	U (5)
6.	• STEMI with presumed successful treatment with fibrinolysis • Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation • Depressed LVEF • 3-vessel CAD • Elective/semi-elective revascularization	A (8)

(*Continued*)

Table 1. Continued

Indication		Appropriateness Score (1–9)
7.	• STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis • Asymptomatic; no HF, no evidence of recurrent or provokable ischemia or no unstable ventricular arrhythmias during index hospitalization • Normal LVEF • Revascularization of a non-infarct-related artery during index hospitalization	I (2)
8.	• STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization • Symptoms of recurrent myocardial ischemia and/or high-risk findings on noninvasive stress testing performed after index hospitalization • Revascularization of 1 or more additional coronary arteries	A (8)
9.	• UA/NSTEMI and high-risk features for short-term risk of death or nonfatal MI • Revascularization of the presumed culprit artery	A (9)
10.	• UA/NSTEMI and high-risk features for short-term risk of death or nonfatal MI • Revascularization of multiple coronary arteries when the culprit artery cannot be clearly determined	A (9)
11.	• Patients with acute myocardial infarction (STEMI or NSTEMI) • Evidence of cardiogenic shock • Revascularization of 1 or more coronary arteries	A (8)

*Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodology and should not be interpreted as "degrees of appropriateness or inappropriateness."

Table 2. Patients Without Prior Bypass Surgery

		Appropriateness Score (1–9)		
		CCS Angina Class		
Indication		Asymptomatic	I or II	III or IV
12.	• 1- or 2-vessel CAD without involvement of proximal LAD • Low-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	I (1)*	I (2)	U (5)
13.	• 1- or 2-vessel CAD without involvement of proximal LAD • Low-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	I (2)	U (5)	A (7)
14.	• 1- or 2-vessel CAD without involvement of proximal LAD • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	I (3)	U (5)	U (6)
15.	• 1- or 2-vessel CAD without involvement of proximal LAD • Intermediate-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (4)	A (7)	A (8)
16.	• 1- or 2-vessel CAD without involvement of proximal LAD • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (6)	A (7)	A (8)
17.	• 1- or 2-vessel CAD without involvement of proximal LAD • High-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	A (7)	A (8)	A (9)
18.	• 1- or 2-vessel CAD without involvement of proximal LAD • No noninvasive testing performed	†	U (5)	A (7)
19.	• 1- or 2-vessel CAD with borderline stenosis "50% to 60%" • No noninvasive testing performed • No further invasive evaluation performed (ie, FFR, IVUS)	†	I (2)	I (3)
20.	• 1- or 2-vessel CAD with borderline stenosis "50% to 60%" • No noninvasive testing performed or equivocal test results present • FFR <0.75 and/or IVUS with significant reduction in cross-sectional area	I (3)	U (6)	A (7)

(*Continued*)

Table 2. Continued

Indication		Appropriateness Score (1–9)		
		CCS Angina Class		
		Asymptomatic	I or II	III or IV
21.	• 1- or 2-vessel CAD with borderline stenosis "50% to 60%" • No noninvasive testing performed or equivocal test results present • FFR or IVUS findings do not meet criteria for significant stenosis	I (1)	I (2)	I (2)
22.	• Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses • Low-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	I (1)	I (2)	I (3)
23.	• Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses • Low-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	I (1)	U (4)	U (6)
24.	• Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	I (3)	U (4)	U (6)
25.	• Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses • Intermediate-risk criteria on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (4)	U (5)	A (7)
26.	• Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (4)	U (5)	A (7)
27.	• Chronic total occlusion of 1 major epicardial coronary artery, without other coronary stenoses • High-risk criteria on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (5)	A (7)	A (8)
28.	• 1-vessel CAD involving the proximal LAD • Low-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (4)	U (5)	A (7)
29.	• 1-vessel CAD involving the proximal LAD • Low-risk findings on noninvasive testing • Receiving maximal anti-ischemic medical therapy	U (4)	A (7)	A (8)
30.	• 1-vessel CAD involving the proximal LAD • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (4)	U (6)	A (7)
31.	• 1-vessel CAD involving the proximal LAD • Intermediate-risk findings on noninvasive testing • Receiving maximal anti-ischemic medical therapy	U (5)	A (8)	A (9)
32.	• 1-vessel CAD involving the proximal LAD • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	A (7)	A (8)	A (9)
33.	• 1-vessel CAD involving the proximal LAD • High-risk findings on noninvasive testing • Receiving maximal anti-ischemic medical therapy	A (7)	A (9)	A (9)

(*Continued*)

Table 2. Continued

Indication		Appropriateness Score (1–9)		
		CCS Angina Class		
		Asymptomatic	I or II	III or IV
34.	• 2-vessel CAD involving the proximal LAD • Low-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (4)	U (6)	A (7)
35.	• 2-vessel CAD involving the proximal LAD • Low-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (5)	A (7)	A (8)
36.	• 2-vessel CAD involving the proximal LAD • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (5)	A (7)	A (8)
37.	• 2-vessel CAD involving the proximal LAD • Intermediate-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (6)	A (7)	A (9)
38.	• 2-vessel CAD involving the proximal LAD • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	A (7)	A (8)	A (9)
39.	• 2-vessel CAD involving the proximal LAD • High-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	A (8)	A (9)	A (9)
40.	• 3-vessel CAD (no left main) • Low-risk findings on noninvasive testing including normal LV systolic function • Receiving no or minimal anti-ischemic medical therapy	U (5)	U (6)	A (7)
41.	• 3-vessel CAD (no left main) • Low-risk findings on noninvasive testing including normal LV systolic function • Receiving a course of maximal anti-ischemic medical therapy	U (5)	A (7)	A (8)
42.	• 3-vessel CAD (no left main) • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	A (7)	A (7)	A (8)
43.	• 3-vessel CAD (no left main) • Intermediate risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	A (7)	A (8)	A (9)
44.	• 3-vessel CAD (no left main) • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	A (7)	A (8)	A (9)
45.	• 3-vessel CAD (no left main) • High-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	A (8)	A (9)	A (9)
46.	• 3-vessel CAD (no left main) • Abnormal LV systolic function	A (8)	A (9)Q	A (9)
47.	• Left main stenosis	A (9)	A (9)	A (9)

*Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodology and should not be interpreted as "degrees of appropriateness or inappropriateness."

†Indicates that the writing group felt the likelihood of the clinical scenario was so low that rating should not be performed.

Table 3. Patients With Prior Bypass Surgery (Without Acute Coronary Syndromes)

		Appropriateness Score (1–9)		
		CCS Angina Class		
Indication		Asymptomatic	I or II	III or IV
48.	• 1 or more stenoses in saphenous vein graft(s) • Low-risk findings on noninvasive testing including normal LV systolic function • Receiving no or minimal anti-ischemic medical therapy	I (3)	U (4)	U (6)
49.	• 1 or more stenoses in saphenous vein graft(s) • Low-risk findings on noninvasive testing including normal LV systolic function • Receiving a course of maximal anti-ischemic medical therapy	U (4)	U (6)	A (7)
50.	• 1 or more stenoses in saphenous vein graft(s) • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (4)	U (6)	A (7)
51.	• 1 or more stenoses in saphenous vein graft(s) • Intermediate-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (4)	A (7)	A (8)
52.	• 1 or more stenoses in saphenous vein graft(s) • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (6)	A (7)	A (7)
53.	• 1 or more stenoses in saphenous vein graft(s) • High-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	A (7)	A (8)	A (9)
54.	• 1 or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Low-risk findings on noninvasive testing including normal LV systolic function • Receiving no or minimal anti-ischemic medical therapy	†	I (3)	U (6)
55.	• 1 or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Low-risk findings on noninvasive testing including normal LV systolic function • Receiving a course of maximal anti-ischemic medical therapy	I (3)	U (5)	A (7)
56.	• 1 or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Intermediate-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	I (3)	U (5)	A (7)
57.	• 1 or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Intermediate-risk findings on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (4)	U (6)	A (8)
58.	• 1 or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • High-risk findings on noninvasive testing • Receiving no or minimal anti-ischemic medical therapy	U (6)	A (7)	A (8)
59.	• 1 or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • High-risk finding on noninvasive testing • Receiving a course of maximal anti-ischemic medical therapy	U (5)	A (8)	A (9)

*Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodology and should not be interpreted as "degrees of appropriateness or inappropriateness."

†Indicates that the writing group felt the likelihood of the clinical scenario was so low that rating should not be performed.

Rating Revascularization Methods

Mode of Revascularization for High Severity of CAD (Indications 60 to 73)

Recognizing a large range of variability in revascularization methods often based upon patient factors and local practice patterns, the majority of clinical indications were not intended to distinguish between the specific modes of revascularization (ie, PCI versus CABG). However, the committee recognized that among patients with extensive or complex atherosclerosis, the mode of revascularization is also of interest when revascularization is deemed appropriate. Therefore, Table 4 presents complex scenarios where the features of revascularization are considered. In these cases, the raters were asked to consider the appropriateness of PCI and CABG as the revascularization method independently of each other (such that each modality would receive separate scores based on each specific clinical indication).

Mortality Risk

Many of the known clinical factors that increase the risk of revascularization are shared between CABG and percutaneous methods. For the indications presented below, the guideline-based features of diabetes and depressed left ventricular systolic function were used to stratify patients.

Advanced CAD

The clinical scenarios below specifically apply to patients with advanced CAD. It was assumed for these clinical scenarios that all patients have unacceptable levels of symptoms despite appropriate medical therapy and evidence of intermediate- to high-risk findings on noninvasive testing. In other words, the technical panel assumed that revascularization is appropriate and focused on rating the merit of the different modes with the intent of complete coronary revascularization for each indication.

Discussion

The ratings developed in this report provide an assessment of the appropriateness of the use of coronary revascularization for the clinical scenarios presented in each of the indications. These criteria should be useful to clinicians, healthcare facilities, third-party payers engaged in the delivery of cardiovascular services, and most importantly, patients. Experience with previous appropriateness criteria has shown their value across a broad range of situations, guiding care of individual patients, educating caregivers, and affecting policy decisions regarding reimbursement.

Clinical Judgment

These indications are intended to provide guidance for patients and clinicians. This approach is not intended to diminish the acknowledged difficulty or uncertainty of clinical decision making. Appropriateness criteria are not substitutes for sound clinical judgment and practice experience. The writing group recognizes that many patients seen in clinical practice may not be represented in these appropriateness criteria or have extenuating features when compared with the clinical scenarios presented. However, these criteria provide a framework for discussions regarding revascularization between patients and physicians.

Although these ratings provide a general assessment of when revascularization may or may not be likely to improve health outcomes or survival, physicians and other stakeholders should continue to acknowledge the pivotal role of clinical judgment in determining whether revascularization is indicated for an individual patient. For example, the rating of a revascularization indication as "uncertain" should not preclude a provider from performing a revascularization procedure when there are patient- and condition-specific data to support that decision. Uncertain indications require individual physician judgment and understanding of the patient to better determine the usefulness of the procedure for a particular scenario. Indeed revascularization may be the correct treatment, if supported by mitigating characteristics of the patient. Therefore, these criteria provide a framework for discussion regarding revascularization upon which the specific clinical characteristics of an individual patient must be superimposed. Ranking of an indication as uncertain (4 to 6) **should not be viewed as excluding the use of revascularization for such patients.** Although it is considered unlikely, an indication rated as "inappropriate" may, in rare circumstances, be the best therapy for an individual patient. In contrast, a clinical situation rated as "appropriate" may not always represent reasonable practice in a specific patient with extenuating circumstances. Appropriateness also does not equate to medical necessity. Shared physician/patient decision making for many scenarios would be expected and may result in the patient deferring coronary revascularization while maintaining medical therapy.

These ratings are intended to evaluate the appropriateness of specific patient scenarios to determine overall **patterns of care** regarding revascularization. In situations where there is substantial variation between the appropriateness rating and what the clinician believes is the best recommendation for the patient, further considerations or actions, such as a second opinion, may be appropriate. Moreover, it is not anticipated that all physicians or facilities will have 100% of their revascularization procedures deemed appropriate. However related to the overall patterns of care, if the national average of appropriate procedure ratings is 80%, for example, and a physician or facility has only a 40% rate of appropriate procedures, further examination of the patterns of care may be warranted and helpful.

General Themes in Appropriateness Criteria for Revascularization

The purpose of coronary revascularization should be to improve health outcomes for the patients undergoing the procedure. As such, the technical panel was asked to rate each specific clinical indication with emphasis on the benefit imparted to health outcomes (symptoms, functional status, and/or quality of life) or survival. It should be noted that the Appropriateness Criteria for Coronary Revascularization contain no scenarios rated as "appropriate" that correlate with Class III recommendations in guideline documents. Likewise, no "inappropriate" appropriateness criteria indications correlate with Class I guideline recommendations. Although mul-

Table 4. Method of Revascularization: Advanced Coronary Disease,* CCS Angina ≥Class III, and/or Evidence of Intermediate- to High-Risk Findings on Noninvasive Testing

Indication		Appropriateness Score (1–9)	
		PCI Appropriateness Rating	CABG Appropriateness Rating
60.	• 2-vessel CAD with proximal LAD stenosis • No diabetes and normal LVEF	A $_{(8)}$*	A $_{(8)}$
61.	• 2-vessel CAD with proximal LAD stenosis • Diabetes	A $_{(7)}$	A $_{(8)}$
62.	• 2-vessel CAD with proximal LAD stenosis • Depressed LVEF	A $_{(7)}$	A $_{(8)}$
63.	• 3-vessel CAD • No diabetes and normal LVEF	U $_{(6)}$	A $_{(8)}$
64.	• 3-vessel CAD • Diabetes	U $_{(5)}$	A $_{(9)}$
65.	• 3-vessel CAD • Depressed LVEF	U $_{(4)}$	A $_{(9)}$
66.	• Isolated left main stenosis • No diabetes and normal LVEF	I $_{(3)}$	A $_{(9)}$
67.	• Isolated left main stenosis • Diabetes	I $_{(3)}$	A $_{(9)}$
68.	• Isolated left main stenosis • Depressed LVEF	I $_{(3)}$	A $_{(9)}$
69.	• Left main stenosis and additional CAD • No diabetes and normal LVEF	I $_{(3)}$	A $_{(9)}$
70.	• Left main stenosis and additional CAD • Diabetes	I $_{(2)}$	A $_{(9)}$
71.	• Left main stenosis and additional CAD • Depressed LVEF	I $_{(2)}$	A $_{(9)}$
72.	• Prior bypass surgery with native 3-vessel disease and failure of multiple bypass grafts • LIMA remains patent to a native coronary artery • Depressed LVEF	A $_{(7)}$	U $_{(6)}$
73.	• Prior bypass surgery with native 3-vessel disease and failure of multiple bypass grafts • LIMA was used as a graft but is no longer functional • Depressed LVEF	U $_{(6)}$	A $_{(8)}$

*Subscripted numbers are a reflection of the continuum as per the appropriateness criteria methodology and should not be interpreted as "degrees of appropriateness or inappropriateness."

tiple clinical and anatomic factors could have been included in the clinical scenarios, the writing group focused on symptom status, degree of medical therapy, extent of ischemia by noninvasive testing, and finally, the presence and location of significant coronary stenoses. Several themes were identified in reviewing the results for the Appropriateness Criteria for Coronary Revascularization.

Acute Coronary Syndromes

The technical panel rated the majority of clinical scenarios in these patients as appropriate for revascularization (Figure 1). However, there were 2 notable exceptions that received inappropriate ratings. First, in patients with STEMI presenting greater than 12 hours from symptom onset without ongoing symptoms of ischemia or clinical instability, immediate revascularization was deemed inappropriate. By extension, this also implies that the need for immediate angiography on presentation in such patients is unnecessary. Second, after successful treatment of the culprit artery by PCI or fibrinolysis, revascularization of nonculprit arteries before hospital discharge in patients without clinical instability, with no evidence of recurrent or provokable ischemia, and with a normal LVEF was rated as inappropriate.

Stable Ischemic Heart Disease *Without* Prior CABG

In general, the presence of high-risk findings on noninvasive testing, higher severity of symptoms, or an increasing burden of CAD tended to elevate the rating to appropriate. Inappropriate ratings tended to cluster among groups receiving no or minimal anti-ischemic treatment with low-risk findings on noninvasive testing. Figures 2 to 4 illustrate the interplay of



Figure 1. Acute coronary syndromes. The fact that the use of coronary revascularization for a particular condition is listed in this figure (appropriate, uncertain, inappropriate) does not preclude the use of other therapeutic modalities that may be equally effective. See the most current ACC/AHA UA/NSTEMI and STEMI guidelines.[15,16] A indicates appropriate; CAD, coronary artery disease; HF, heart failure; I, inappropriate; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; U, uncertain; and UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.

these elements in determining appropriateness. Four clinical scenarios (18 to 21) were included in which no functional testing was performed. Although the ability to couple the anatomic findings from coronary angiography with the physiologic evaluation available from the various diagnostic testing modalities is ideal, the writing group recognized that there are patients who undergo angiography without such testing. Revascularization was rated appropriate in such patients if they had 1- or 2-vessel disease with or without involvement of the proximal LAD and class III or IV angina. The level of medical therapy patients were receiving in this particular scenario was not specifically considered and was thus left to the judgment of the clinician. However, consistent with the pattern of care developed in these appropriateness criteria, a trial of medical therapy before performing revascularization may be appropriate in some patients. The remain-

Low-Risk Findings on Noninvasive Study							Asymptomatic					
Symptoms / Med. Rx							**Stress Test / Med. Rx**					
Class III or IV / Max Rx	U	A	A	A	A		High Risk / Max Rx	U	A	A	A	A
Class I or II / Max Rx	U	U	A	A	A		High Risk / No/min Rx	U	U	A	A	A
Asymptomatic / Max Rx	I	I	U	U	U		Int. Risk / Max Rx	U	U	U	U	A
Class III or IV / No/min Rx	I	U	A	A	A		Int. Risk / No/min Rx	I	I	U	U	A
Class I or II / No/min Rx	I	I	U	U	U		Low Risk / Max Rx	I	I	U	U	U
Asymptomatic / No/min Rx	I	I	U	U	U		Low Risk / No/min Rx	I	I	U	U	U
Coronary Anatomy	CTO of 1 vz.; no other disease	1-2 vz. disease; no Prox. LAD	1 vz. disease of Prox. LAD	2 vz. disease with Prox. LAD	3 vz. disease; no Left Main		**Coronary Anatomy**	CTO of 1 vz.; no other disease	1-2 vz. disease; no Prox. LAD	1 vz. disease of Prox. LAD	2 vz. disease with Prox. LAD	3 vz. disease; no Left Main

Figure 2. Appropriateness ratings by low-risk findings on noninvasive imaging study and asymptomatic (patients without prior bypass surgery). A indicates appropriate; CTO, chronic total occlusion; I, inappropriate; Int., intervention; Med., medical; Prox. LAD, proximal left anterior descending artery; Rx, treatment; U, uncertain; and vz., vessel.

Intermediate-Risk Findings on Noninvasive Study							CCS Class I or II Angina					
Symptoms / **Med. Rx**							**Stress Test** / **Med. Rx**					
Class III or IV / Max Rx	A	A	A	A	A		High Risk / Max Rx	A	A	A	A	A
Class I or II / Max Rx	U	A	A	A	A		High Risk / No/min Rx	U	A	A	A	A
Asymptomatic / Max Rx	U	U	U	U	A		Int. Risk / Max Rx	U	A	A	A	A
Class III or IV / No/min Rx	U	U	A	A	A		Int. Risk / No/min Rx	U	U	U	A	A
Class I or II / No/min Rx	U	U	U	A	A		Low Risk / Max Rx	U	U	A	A	A
Asymptomatic / No/min Rx	I	I	U	U	A		Low Risk / No/min Rx	I	I	U	U	U
Coronary Anatomy	CTO of 1 vz.; no other disease	1-2 vz. disease; no Prox. LAD	1 vz. disease of Prox. LAD	2 vz. disease with Prox. LAD	3 vz. disease; no Left Main		**Coronary Anatomy**	CTO of 1 vz.; no other disease	1-2 vz. disease; no Prox. LAD	1 vz. disease of Prox. LAD	2 vz. disease with Prox. LAD	3 vz. disease; no Left Main

Figure 3. Appropriateness ratings by intermediate-risk findings on noninvasive imaging study and CCS class I or II angina (patients without prior bypass surgery). CCS indicates Canadian Cardiovascular Society, other abbreviations as in Figure 2.

ing three scenarios involved patients found to have so-called intermediate severity stenoses. The ratings in these settings reflect the ability of additional evaluations performed in the catheterization laboratory (such as FFR or IVUS) to identify significant stenoses beyond their appearance by angiography alone. In patients without noninvasive testing, revascularization of intermediate stenoses without further documentation of significance by FFR or IVUS was rated as inappropriate. Revascularization of such patients who demonstrate abnormal IVUS or FFR findings and are highly symptomatic was deemed appropriate.

Stable Ischemic Heart Disease *With* Prior CABG

Similar to the pattern seen in patients without prior CABG, the presence of high-risk findings on noninvasive testing, higher severity of symptoms, or an increasing burden of disease in either the bypass grafts or native coronaries tended to increase the likelihood of an appropriate rating. The only inappropriate ratings in patients with prior CABG were noted in patients receiving no or minimal anti-ischemic therapy or having low-risk findings on noninvasive testing. More uncertain ratings occurred in this group of patients, reflecting their higher complexity, higher risk, and the limited availability of published evidence regarding management outcome.

PCI and CABG in Patients With Advanced CAD

In this group of ratings, it was assumed that revascularization was necessary, and the technical panel rated the appropriateness of the mode of revascularization (Table 4, Figure 5). CABG was rated as appropriate in all of the clinical scenarios developed, whereas PCI was rated appropriate only in patients with 2-vessel CAD with involvement of the proximal LAD and uncertain in patients with 3-vessel disease. For

High-Risk Findings on Noninvasive Study							CCS Class III or IV Angina					
Symptoms / **Med. Rx**							**Stress Test** / **Med. Rx**					
Class III or IV / Max Rx	A	A	A	A	A		High Risk / Max Rx	A	A	A	A	A
Class I or II / Max Rx	A	A	A	A	A		High Risk / No/min Rx	A	A	A	A	A
Asymptomatic / Max Rx	U	A	A	A	A		Int. Risk / Max Rx	A	A	A	A	A
Class III or IV / No/min Rx	A	A	A	A	A		Int. Risk / No/min Rx	U	U	A	A	A
Class I or II / No/min Rx	U	A	A	A	A		Low Risk / Max Rx	U	A	A	A	A
Asymptomatic / No/min Rx	U	U	A	A	A		Low Risk / No/min Rx	I	U	A	A	A
Coronary Anatomy	CTO of 1 vz.; no other disease	1-2 vz. disease; no Prox. LAD	1 vz. disease of Prox. LAD	2 vz. disease with Prox. LAD	3 vz. disease; no Left Main		**Coronary Anatomy**	CTO of 1 vz.; no other disease	1-2 vz. disease; no Prox. LAD	1 vz. disease of Prox. LAD	2 vz. disease with Prox. LAD	3 vz. disease; no Left Main

Figure 4. Appropriateness ratings by high-risk findings on noninvasive imaging study and CCS class III or IV angina (patients without prior bypass surgery). Abbreviations as in Figures 2 and 3.

	CABG			PCI		
	No diabetes and normal LVEF	Diabetes	Depressed LVEF	No diabetes and normal LVEF	Diabetes	Depressed LVEF
Two vessel coronary artery disease with proximal LAD stenosis	A	A	A	A	A	A
Three vessel coronary artery disease	A	A	A	U	U	U
Isolated left main stenosis	A	A	A	I	I	I
Left main stenosis and additional coronary artery disease	A	A	A	I	I	I

Figure 5. Method of revascularization of advanced coronary artery disease. CABG indicates coronary artery bypass grafting; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction; and PCI, percutaneous coronary intervention.

patients with left main stenosis and/or left main stenosis and multivessel CAD, CABG was deemed to be appropriate and likely to improve the patients' health outcomes or survival. PCI for this patient group was deemed not to be a reasonable approach and unlikely to improve the patients' health outcomes or survival.

Application of Criteria

There are many potential applications for appropriateness criteria. Clinicians could use the ratings for decision support or as an educational tool when considering the need for revascularization. Moreover, these criteria could be used to facilitate discussion with patients and or referring physicians about the need for revascularization. Facilities and payers may choose to use these criteria either prospectively in the design of protocols or preauthorization procedures, or retrospectively for quality reports. It is hoped that payers would use these criteria as the basis for the development of rational payment management strategies to ensure that their members receive necessary, beneficial, and cost-effective cardiovascular care, rather than for other purposes.

It is expected that services performed for appropriate indications will receive reimbursement. In contrast, services performed for inappropriate indications will likely require additional documentation to justify payment because of the unique circumstances or the clinical profile that must exist in such a patient. It is critical to emphasize that the writing group, technical panel, Appropriateness Task Force, and clinical community do not believe an uncertain rating is grounds to deny reimbursement for revascularization. Rather, uncertain ratings are those in which the available data vary and many other factors exist that may affect the decision to perform or not perform revascularization. The opinions of the technical panel often varied for these indications, reflecting that additional research is needed. Indications with high clinical volume that are rated as uncertain identify important areas for further research.

When evaluating physician or facility performance, appropriateness criteria should be used in conjunction with efforts that lead to quality improvement. Prospective preauthorization procedures, if put in place, are most effective once a retrospective review has identified a pattern of potential inappropriate use. Because these criteria are based on current scientific evidence and the deliberations of the technical panel, they should be used prospectively to generate future discussions about reimbursement, but should not be applied retrospectively to cases completed before issuance of this report or documentation of centers/providers performing an unexpectedly high proportion of inappropriate cases as compared with their peers.

The writing group recognizes that these criteria will be evaluated during routine clinical care. To that end, specific data fields such as symptom status, presence or absence of acute coronary syndrome, history of bypass surgery, extent of ischemia on noninvasive imaging, CAD burden, and degree of antianginal therapy are anticipated to provide sufficient detail to determine individual appropriateness ratings. Since a reasonable and tolerated dose of antianginal therapy may vary significantly among different patients, the writing group recommends the presence of 2 classes of antianginal therapies as a minimum standard for medical therapy.

The primary objective of this report is to provide guidance regarding the suitability of coronary revascularization for diverse clinical scenarios. As with previous appropriateness criteria documents, consensus among the raters was desirable, but an attempt to achieve complete agreement within this diverse panel would have been artificial and was not the goal of the process. Two rounds of ratings with substantial discussion among the technical panel members between the ratings did lead to some consensus among panelists. However, further attempts to drive consensus would have diluted true differences in opinion among panelists and, therefore, was not undertaken.

Future research analyzing patient outcomes for indications rated as appropriate would help ensure the equitable and efficient allocation of resources for coronary revascularization. Review of appropriateness patterns may also improve understanding of regional variations in the use of revascularization as highlighted in the Dartmouth Atlas Project.[17] Further exploration of the indications rated as "uncertain" will help generate the information required to further define the appropriateness of coronary revascularization. Additionally, the criteria will need to be updated with the publication of ongoing trials in coronary revascularization and new clinical practice guidelines.

In conclusion, this document represents the current understanding of the clinical benefit of coronary revascularization with respect to health outcomes and survival. It is intended to provide a practical guide to clinicians and patients when considering revascularization. As with other appropriateness criteria, some of these ratings will require research and further evaluation to provide the greatest information and benefit to clinical decision making. Finally, it will be necessary to periodically assess and update the indications and criteria as technology evolves and new data and field experience becomes available.

Appendix A: Additional Coronary Revascularization Definitions

Angina/Chest Pain Classification

Angina is a syndrome typically noted to include discomfort in the chest, jaw, shoulder, back, or arm that is aggravated by exertion or emotional stress and relieved by nitroglycerin. The quality of the discomfort, provoking factors, and relieving factors are used to define typical, atypical, and noncardiac chest pain. Atypical angina is generally defined by 2 of the above 3 characteristics, and noncardiac chest pain is generally defined as chest pain that meets 1 or none of the above criteria. These definitions are represented in Table A1.

The writing group assumes that noninvasive assessments of coronary anatomy (i.e., cardiac computed tomography, cardiac magnetic resonance angiography) provide anatomic information that is potentially similar to x-ray angiography. However, these modalities do not currently provide information on ischemic burden and are not assumed to be present in the clinical scenarios.

Invasive Methods of Determining Hemodynamic Significance

The writing group recognizes that not all patients referred for coronary angiography and revascularization will have previous noninvasive testing. In fact, there are several situations in which patients may be appropriately referred for coronary angiography based on symptom presentation and a high pretest probability of CAD. In these settings, there may be situations where angiography shows a coronary narrowing of questionable hemodynamic importance in a patient with symptoms that could be related to myocardial ischemia. In such patients, the use of additional invasive measurements (such as fractional flow reserve or intravascular ultrasound) at the time of diagnostic angiography may be very helpful in further defining the need for revascularization and substituted for stress test findings (Table A2).

Table A1. Clinical Classification of Chest Pain

Typical angina (definite)
1) Substernal chest discomfort with a characteristic quality and duration that is 2) provoked by exertion or emotional stress and 3) relieved by rest or NTG.
Atypical angina (probable)
Meets 2 of the above characteristics.
Noncardiac chest pain
Meets 1 or none of the typical anginal characteristics.

Modified from Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll Cardiol. 1983;1:574–575.[18]

Table A2. Noninvasive Risk Stratification

High-Risk (>3% annual mortality rate)

1. Severe resting left ventricular dysfunction (LVEF <35%)
2. High-risk treadmill score (score ≤−11)
3. Severe exercise left ventricular dysfunction (exercise LVEF <35%)
4. Stress-induced large perfusion defect (particularly if anterior)
5. Stress-induced multiple perfusion defects of moderate size
6. Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201)
7. Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (thallium-201)
8. Echocardiographic wall motion abnormality (involving greater than two segments) developing at low dose of dobutamine (less than or equal to 10 mg/kg/min) or at a low heart rate (<120 beats/min)
9. Stress echocardiographic evidence of extensive ischemia

Intermediate-Risk (1% to 3% annual mortality rate)

1. Mild/moderate resting left ventricular dysfunction (LVEF = 35% to 49%)
2. Intermediate-risk treadmill score (−11 < score <5)
3. Stress-induced moderate perfusion defect without LV dilation or increased lung intake (thallium-201)
4. Limited stress echocardiographic ischemia with a wall motion abnormality only at higher doses of dobutamine involving less than or equal to two segments

Low-Risk (less than 1% annual mortality rate)

1. Low-risk treadmill score (score ≥5)
2. Normal or small myocardial perfusion defect at rest or with stress*
3. Normal stress echocardiographic wall motion or no change of limited resting wall motion abnormalities during stress*

*Although the published data are limited, patients with these findings will probably not be at low risk in the presence of either a high-risk treadmill score or severe resting left ventricular dysfunction (LVEF<35%).

Appendix B: Additional Methods

See the earlier Methods section of the report for a description of panel selection, indication development, scope of indications, and rating process.

Relationships With Industry

The College and its partnering organizations rigorously avoid any actual, perceived, or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the technical panel. Specifically, all panelists are asked to provide disclosure statements of all relationships that might be perceived as real or potential conflicts of interest. These statements were reviewed by the Appropriateness Criteria Working Group, discussed with all members of the technical panel at the face-to-face meeting, and updated and reviewed as necessary. A table of disclosures by the technical panel and oversight working group members can be found in Appendix D.

Literature Review

The technical panel members were asked to refer to the relevant guidelines for a summary of the relevant literature, guideline recommendation tables, and reference lists provided for each indication table when completing their ratings (Online Appendix).

Appendix C: ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization Participants

Coronary Revascularization Writing Group

Manesh R. Patel, MD—Chair, Appropriateness Criteria for Coronary Revascularization Writing Group—Assistant Professor of Medicine, Division of Cardiology, Assistant Director, Cardiac Catheterization Lab, Duke University Medical Center, Durham, NC

Gregory J. Dehmer, MD, FACC, FACP, FSCAI, FAHA—Past President, Society for Cardiovascular Angiography and Interventions; Professor of Medicine, Texas A&M School of Medicine; and Director, Cardiology Division, Scott & White Clinic, Temple, Tex

John W. Hirshfeld, MD, FACC—Professor of Medicine, Hospital of The University of Pennsylvania, Department of Medicine, Cardiovascular Medicine Division, Philadelphia, Pa

Peter K. Smith, MD, FACC—Professor and Chief, Thoracic Surgery, Duke University, Durham, NC

John A. Spertus, MD, MPH, FACC—Professor, UMKC School of Medicine, Director of CV Education and Outcomes Research, MidAmerica Heart Institute of St. Luke's Hospital, Kansas City, Mo

Coronary Revascularization Technical Panel

Frederick A. Masoudi, MD, MSPH, FACC—Moderator for the Technical Panel—Associate Professor of Medicine, Denver Health Medical Center & University of Colorado at Denver and Health Sciences Center, Denver, Colo

Ralph G. Brindis, MD, MPH, FACC, FSCAI—Methodology Liaison for the Technical Panel—Regional Senior Advisor for Cardiovascular Disease, Northern California Kaiser Permanente; Clinical Professor of Medicine, University of California at San Francisco; Chief Medical Officer and Chairman, NCDR Management Board, American College of Cardiology Foundation, Washington, DC

Gregory J. Dehmer, MD, FACC, FACP, FSCAI, FAHA—Writing Group Liaison for the Technical Panel—Past President, Society for Cardiovascular Angiography and Interventions, Professor of Medicine, Texas A&M School of Medicine; and Director, Cardiology Division, Scott & White Clinic, Temple, Tex

Manesh R. Patel, MD—Writing Group Liaison for the Technical Panel—Assistant Professor of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC

Peter K. Smith, MD, FACC—Writing Group Liaison for the Technical Panel—Professor and Chief, Thoracic Surgery, Duke University, Durham, NC

Karen J. Beckman, MD, FACC—Professor of Medicine, University of Oklahoma Health Science Center, Cardiac Arrhythmia Research Institute, Oklahoma City, Okla

Charles E. Chambers, MD, FACC, FSCAI, FAHA—Professor of Medicine and Radiology, Penn State Heart and Vascular Institute, Hershey, Pa

T. Bruce Ferguson, Jr., MD, FACC, FAHA—Professor of Surgery and Physiology and Associate Director of Cardiothoracic and Vascular Surgery, East Carolina Brody School of Medicine, Division of CT and Vascular Surgery, Greenville, NC

Mario J. Garcia, MD, FACC—Professor of Medicine and Director of Non-Invasive Cardiology, Cardiovascular Institute, Mount Sinai Hospital, Mount Sinai Medical School, New York, NY

Frederick L. Grover, MD, FACC—Professor and Department Chair, Department of Surgery and Director, Lung Transplantation, University of Colorado Health Sciences Center, Denver, Colo

David R. Holmes, Jr., MD, FACC, FSCAI—Professor of Medicine, Mayo Clinic, Rochester, Minn

Lloyd W. Klein, MD, FACC, FSCAI, FAHA—Director, Clinical Cardiology Associates, Gottlieb Memorial Hospital, Melrose Park, Ill

Marian Limacher, MD, FACC—Professor of Medicine, University of Florida Division of Cardiovascular Medicine, Gainesville, Fla

Michael J. Mack, MD—Director, Cardiopulmonary Research Science Technology Institute, Baylor Healthcare System, Dallas, Tex

David J. Malenka, MD, FACC—Professor of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Myung H. Park, MD, FACC—Assistant Professor of Medicine and Director, Pulmonary Vascular Diseases Program, Lutherville, Md

Michael Ragosta, III, MD, FACC, FSCAI—Associate Professor of Internal Medicine, Department of Medicine, Division of Cardiovascular Medicine, Charlottesville, Va

James L. Ritchie, MD, FACC, FAHA—Clinical Professor of Medicine, University of Washington, Seattle Washington; and Bend Memorial Clinic, Bend, Ore

Geoffrey A. Rose, MD, FACC, FASE—Director, Cardiac Ultrasound Laboratory, Sanger Clinic/Carolinas Heart Institute, Charlotte, NC

Alan B. Rosenberg, MD—Vice President & Medical Director, WellPoint Health Networks, Chicago, Ill

Richard J. Shemin, MD, FACC, FAHA—Professor of Surgery, UCLA David Geffen School of Medicine, Chief, Division of Cardiothoracic Surgery; Executive Vice Chair, Department of Surgery; and Co-Director, Cardiovascular Center, Ronald Reagan UCLA Medical Center, Los Angeles, Calif

William S. Weintraub, MD, FACC, FAHA—Professor of Medicine; John H. Ammon Chair of Cardiology; and Director, Christiana Center for Outcomes Research, Newark, Del

External Reviewers of the Appropriateness Criteria Indications

Stephan Achenbach, MD, FACC, FESC—Professor of Medicine, Department of Cardiology, University of Erlangen, Germany

Joseph S. Alpert, MD, FAHA, FACC, MACP—Professor of Medicine, Special Assistant to the Dean, University of Arizona College of Medicine, Tucson, Ariz; Editor-in-Chief, *American Journal of Medicine*

H. Vernon Anderson, MD, FACC, FAHA—Professor of Medicine, Cardiology Division, University of Texas Health Science Center, Houston, Tex

Elliott M. Antman, MD, FACC, FAHA—Professor of Medicine, Harvard Medical School, and Director, Samuel A. Levine Cardiac Unit, Cardiovascular Division, Brigham & Women's Hospital, Boston, Mass

Lee M. Arcement, MD, MPH, FACC, FCCP—Chief of Cardiology, Chabert Medical Center, Houma, La; Division Director of Heart Failure Disease Management, Louisiana State University Health Care Services, Baton Rouge, La

R. Morton Bolman, III, MD—Professor of Surgery, Harvard Medical School, and Chief, Division of Cardiac Surgery, Brigham & Women's Hospital, Boston, Mass

Javed Butler, MBBS, MPH, FACC, FAHA—Associate Professor of Medicine and Director, Heart Failure Research, Emory University, Atlanta, Ga

Jun R. Chiong, MD, MPH, FACC, FCCP—Associate Professor of Medicine Medical Director, Advanced Heart Failure Program Loma Linda University Medical Center Loma Linda, Calif

G. William Dec, MD, FACC, FAHA—Professor of Medicine, Harvard Medical School and Chief, Cardiology Division, Massachusetts General Hospital, Boston, Mass

David P. Faxon, MD, FACC—Chief of Cardiology, Boston VA Health System, West Roxbury, Mass, and Director of Strategic Planning, Department of Medicine, Brigham and Women's Hospital, Boston, Mass

Raymond J. Gibbons, MD—Professor of Medicine, Mayo Clinic, Rochester, Minn

Robert A. Guyton, MD, FACC—Professor of Surgery and Chief of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Ga

Alice K. Jacobs, MD, FACC—Professor of Medicine, Boston University School of Medicine; Director, Cardiac Catheterization Laboratories & Interventional Cardiology, Boston Medical Center, Boston, Mass

John A. Kern, MD, FACS—Associate Professor of Surgery, Co-Director Heart and Vascular Center, University of Virginia Health System, Charlottesville, Va

Lloyd W. Klein, MD, FACC, FSCAI, FAHA—Professor of Medicine, Rush University Medical Center, Chicago, Ill

Michael J. Mack, MD—Director, Cardiopulmonary Research Science Technology Institute, Baylor Healthcare System, Dallas, Tex

L. Brent Mitchell, MD, FRCPC, FACC—Professor and Head, Department of Cardiac Sciences, Calgary Health Region and University of Calgary; Director, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada

Marc R. Moon, MD—Professor of Surgery, Barnes-Jewish Hospital/Washington University, St. Louis, Mo

Douglass A. Morrison, MD, PhD, FACC, FSCAI—Professor of Medicine, Director, Cardiac Catheterization Lab, Yakima Heart Center, Yakima, Wash

Reid T. Muller, MD, FACC, FACP—Director, Noninvasive Vascular Lab, SJH Cardiology Associates, Syracuse, NY

Sherif F. Nagueh, MD, FACC—Professor of Medicine, Methodist DeBakey Heart and Vascular Center, Houston, Tex

Navin C. Nanda, MD, FACC—Professor of Medicine and Director, Heart Station/Echocardiography Laboratories, University of Alabama at Birmingham, Birmingham, Ala

William C. Nugent, MD—Professor and Chief, Cardiothoracic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH

Myung H. Park, MD, FACC—Assistant Professor of Medicine and Director, Pulmonary Vascular Diseases Program, Division of Cardiology, University of Maryland School of Medicine, Baltimore, Md

Michael Poon, MD—Associate Clinical Professor of Medicine, New York, NY

John D. Puskas, MD—Professor of Surgery (Cardiothoracic) and Associate Chief of Cardiothoracic Surgery, Emory University; Chief of Cardiac Surgery, Emory Crawford Long Hospital, Atlanta, Ga

J. Scott Rankin, MD—Associate Clinical Professor, Vanderbilt University, Nashville, Tenn

Rita F. Redberg, MD, MSc, FACC, FAHA—Professor of Medicine, University of California at San Francisco School of Medicine, Division of Cardiology, San Francisco, Calif

Michael W. Rich, MD, FSGC, FACC—Professor of Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, Mo

Craig R. Smith, MD—Calvin F. Barber Professor of Surgery, College of Physicians & Surgeons of Columbia University, New York, NY; and Interim Chairman, Department of Surgery and Chief, Division of Cardiothoracic Surgery, New York Presbyterian Hospital, New York, NY

Barry F. Uretsky, MD, FACC, FSCAI, FAHA—Professor of Medicine, University of Texas Medical Branch, Galveston, Tex; and Director of Cardiology and Cardiovascular Services Sparks Health System, Fort Smith, Ark

Edward D. Verrier, MD, FACS, FACC, FAHA—Professor and Chief, Division of Cardiothoracic Surgery, University of Washington, Seattle, Wash

Susan J. Zieman, MD, PhD, FACC—Assistant Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Md

ACCF Appropriateness Criteria Task Force

Michael J. Wolk, MD, MACC—Chair, Working Group—Past President, American College of Cardiology Foundation and Clinical Professor of Medicine, Weill-Cornell Medical School, New York, NY

Ralph G. Brindis, MD, MPH, FACC, FSCAI—Regional Senior Advisor for Cardiovascular Disease, Northern California Kaiser Permanente, Oakland, Calif; Clinical Professor of Medicine, University of California at San Francisco, San Francisco, Calif; Chief Medical Officer & Chairman, NCDR Management Board, American College of Cardiology Foundation, Washington, DC

Pamela S. Douglas, MD, MACC, FAHA, FASE—Past President, American College of Cardiology Foundation; Past President, American Society of Echocardiography; and Ursula Geller Professor of Research in Cardiovascular Diseases and Chief, Cardiovascular Disease, Duke University Medical Center, Durham, NC

Robert C. Hendel, MD, FACC, FAHA—Midwest Heart Specialists, Fox River Grove, Ill

Manesh R. Patel, MD—Assistant Professor of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC

Eric D. Peterson, MD, MPH, FACC, FAHA—Professor of Medicine and Director, Cardiovascular Research, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

Joseph M. Allen, MA—Director, TRIP (Translating Research into Practice), American College of Cardiology Foundation, Washington, DC

Appendix D. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Coronary Revascularization Appropriateness Criteria Writing Group, Technical Panel, Task Force, and Indication Reviewers—Relationships With Industry (In Alphabetical Order)

Committee Member	Research Grant	Speakers' Bureau/ Honoraria/ Expert Witness	Stock Ownership	Board of Directors	Consultant/ Scientific Advisory Board/ Steering Committee
Coronary Revascularization Appropriateness Criteria Writing Group					
Dr. Gregory J. Dehmer	None	None	None	None	None
Dr. John W. Hirshfeld	None	None	None	None	None
Dr. Manesh R. Patel	• Datascope • Daiichi Sankyo/Lilly	None	None	None	• Genzyme • Novartis
Dr. Peter K. Smith	None	None	None	None	None
Dr. John A. Spertus	• Amgen • Bristol-Myers Squibb/ Sanofi-Aventis Partnership • Lilly	• St Jude Medical	• Copyright for Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, and Peripheral Arterial Questionnaire • PRISM Technology		
Coronary Revascularization Appropriateness Criteria Technical Panel					
Dr. Karen J. Beckman	• Biosense Webster • CardioFocus • ProRhythm • Reliant • Stereotaxis	None	None	None	None
Dr. Charles E. Chambers	None	• GE Medical	None	None	None
Dr. T. Bruce Ferguson, Jr.	None	None	None	None	None
Dr. Mario J. Garcia	• Philips Medical Systems	• Philips Medical Systems • Vital Images	None	None	• BG Medicine • Philips Medical Systems
Dr. Frederick L. Grover	None	None	None	None	None
Dr. David R. Holmes, Jr.	None	None	None	None	None
Dr. Lloyd W. Klein	None	None	None	None	Pfizer
Dr. Marian Limacher	• Boehringer Ingelheim • Orexigen Therapeutics, Inc	None	None	None	None
Dr. Michael J. Mack	None	None	None	None	None
Dr. David J. Malenka	None	None	None	None	None
Dr. Frederick A. Masoudi	Amgen	• Amgen • Takeda • United Healthcare	None	None	None
Dr. Myung H. Park	None	• Actelion Pharmaceuticals • Gilead Sciences • United Therapeutics	None	None	• Actelion Pharmaceuticals • Gilead Sciences • United Therapeutics

(*Continued*)

Appendix D. Continued

Committee Member	Research Grant	Speakers' Bureau/ Honoraria/ Expert Witness	Stock Ownership	Board of Directors	Consultant/ Scientific Advisory Board/ Steering Committee
Dr. Michael Ragosta III	None	None	None	None	None
Dr. James L. Ritchie	None	None	None	None	None
Dr. Geoffrey A. Rose	None	None	None	None	None
Dr. Alan B. Rosenberg	None	None	• WellPoint	None	None
Dr. Richard J. Shemin	None	• Edwards Life Sciences • St Jude Medical	None	None	None
Dr. William S. Weintraub	None	None	None	None	None
ACCF Appropriateness Criteria Task Force					
Joseph M. Allen	None	None	None	None	None
Dr. Ralph G. Brindis	None	None	None	None	None
Dr. Pamela S. Douglas	• Atritech • BG Medicine • Edwards Life Sciences • LabCorp • Reata • United Healthcare	• BG Medicine • Expression Analysis • Genentech • GlaxoSmithKline Foundation • Northpoint Domain • Ortho Diagnostics • Pappas Ventures • Visen Medicad • Xceed Molecular	• CardioDX • Millennium • Northpoint Domain	None	None
Dr. Robert C. Hendel	None	None	None	None	None
Dr. Eric D. Peterson	• Bristol-Myers Squibb/ Sanofi-Aventis • Merck • Schering-Plough • St Jude Medical	None	None	None	None
Dr. Michael J. Wolk	None	None	None	None	None
Coronary Revascularization Appropriateness Criteria Indication Reviewers					
Dr. Stephan Achenbach	• Schering • Siemens Medical Solutions	None	None	None	• Bracco
Dr. Joseph S. Alpert	None	None	None	None	None
Dr. H. Vernon Anderson	None	• Bristol-Myers Squibb Pharmaceuticals • PDL Biopharma • Sanofi-Aventis Pharmaceuticals	None	None	None
Dr. Elliott M. Antman	• Accumetrics, Inc • Amgen, Inc • AstraZeneca Pharmaceuticals LP • Bayer Healthcare LLC • Beckman Coulter, Inc • Biosite Inc • Bristol-Myers Squibb Pharmaceutical Research Institute • CV Therapeutics	None	None	None	• Eli Lilly • Sanofi-Aventis

(*Continued*)

Appendix D. Continued

Committee Member	Research Grant	Speakers' Bureau/ Honoraria/ Expert Witness	Stock Ownership	Board of Directors	Consultant/ Scientific Advisory Board/ Steering Committee
	• Eli Lilly and Company • GlaxoSmithKline • Inotek Pharmaceuticals Corporation • Integrated Therapeutics Corporation • Merck & Co • Millennium Pharmaceuticals • Novartis Pharmaceuticals • Nuvelo, Inc • Ortho-Clinical Diagnostics, Inc • Pfizer, Inc • Roche Diagnostics Corporation • Roche Diagnostics GmbH • Sanofi-Aventis • Sanofi-Synthelabo Recherche • Schering-Plough Research Institute				
Dr. Lee M. Arcement	None	• GlaxoSmithKline • Nitromed	None	None	None
Dr. R. Morton Bolman	None	None	None	None	None
Dr. Javed Butler	None	• Boehringer Ingelheim • GlaxoSmithKline Pharmaceuticals • Novartis Pharmaceuticals	None	None	None
Dr. Jun R. Chiong	None	None	None	None	None
Dr. G. William Dec	None	None	None	None	None
Dr. David P. Faxon	None	None	None	None	None
Dr. Raymond J. Gibbons	• KAI Pharmaceuticals • King Pharmaceuticals • Radiant Medical TargeGen • Ther Ox	None	None	None	• Cardiovascular Clinical Studies (WOMEN Study) • Consumers Union TIMI 37A
Dr. Robert A. Guyton	None	None	None	None	• Guidant, Inc • Medtronic, Inc
Dr. Alice K. Jacobs	None	None	None	None	None
Dr. John A. Kern	None	None	None	None	None
Dr. L. Brent Mitchell	• Guidant Canada • Medtronic Canada	• Medtronic Canada	None	None	• Boehringer Ingelheim • Cardiome Pharmaceuticals • Medtronic, Inc
Dr. Marc R. Moon	None	• Edwards Life Sciences	None	None	None
Dr. Douglass A. Morrison	None	None	None	None	None
Dr. Reid T. Muller	None	None	None	None	None
Dr. Sherif F. Nagueh	None	• Medtronic	None	None	• GE Healthcare • St Jude Medical
Dr. Navin C. Nanda	None	None	None	None	• Philips

(*Continued*)

Appendix D. Continued

Committee Member	Research Grant	Speakers' Bureau/ Honoraria/ Expert Witness	Stock Ownership	Board of Directors	Consultant/ Scientific Advisory Board/ Steering Committee
Dr. William C. Nugent	None	None	None	None	None
Dr. Michael Poon	None	None	None	None	None
Dr. John D. Puskas	• Maquet • Medtronic Scanlan (royalty income)	None	None	None	• Maquet • Medtronic, Inc
Dr. J. Scott Rankin	None	None	None	None	None
Dr. Rita F. Redberg	• Blue Shield of California Foundation	None	None	None	None
Dr. Michael W. Rich	None	None	None	None	None
Dr. Craig R. Smith	None	None	None	None	None
Dr. Barry F. Uretsky	None	None	None	None	None
Dr. Edward D. Verrier	None	None	None	None	None
Dr. Susan J. Zieman	None	None	None	None	None

Staff

American College of Cardiology Foundation
John C. Lewin, MD, Chief Executive Officer
Thomas E. Arend, Jr., Esq., Chief Operating Officer
Joseph M. Allen, MA, Director, TRIP (Translating Research Into Practice)
Karen Cowdery Caruth, MBA, Senior Specialist, Appropriateness Criteria
Kennedy Elliott, Specialist, Appropriateness Criteria
Lindsey Law, MA, Senior Specialist, Appropriateness Criteria
Erin A. Barrett, Senior Specialist, Science and Clinical Policy

References

1. Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol. 2005;46:1606–13.
2. Fitch K, Bernstein SJ, Aguilar MD, et al. *The RAND/UCLA Appropriateness Method User's Manual*. Arlington, VA: RAND, 2001.
3. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Available at: http://content.onlinejacc.org/cgi/reprint/41/1/159.pdf. Accessed November 14, 2008.tk;2
4. Califf RM, Armstrong PW, Carver JR, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:1007–19.
5. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and Stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388–91.
6. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–26.
7. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol. 2006;47:2130–9.
8. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
9. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.
10. King, SB, Aversano, T, Ballard WL, et al. ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. J Am Coll Cardiol. 2007;50:82–108.
11. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol. 2004;44:e213–310.
12. Smith SC Jr., Feldman TE, Hirshfeld JW Jr. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216–35.
13. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Available at: http://www.acc.org/qualityandscience/clinical/guidelines/stable/stable_clean.pdf. Accessed November 14, 2008.
14. Campeau L. Grading of angina pectoris. Circulation. 1976;54:522–3.
15. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50:e1–157.
16. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210–47.
17. Dartmouth Atlas Project. Available at: http://www.dartmouthatlas.org/. Accessed February 5, 2008.
18. Diamond GA. A clinically relevant classification of chest discomfort. J Am Coll Cardiol. 1983;1:574–5.

Table A1: Appropriateness Criteria for Revascularization Ratings

	Indication	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
Table 1. Patients with Acute Coronary Syndromes																						
1	• STEMI • Less than or equal to 12 hours from onset of symptoms • Revascularization of the culprit artery	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.0	**A**	+
2	• STEMI • Onset of symptoms within the prior 12 to 24 hours • Severe HF, persistent ischemic symptoms or hemodynamic or electrical instability present	9	9	8	9	9	8	9	9	8	9	9	9	9	9	9	8	8	**9**	0.3	**A**	+
3	• STEMI • Greater than 12 hours from symptom onset • Asymptomatic; no hemodynamic instability and no electrical instability	3	2	3	2	3	2	7	2	3	3	4	2	5	4	3	1	3	**3**	0.9	**I**	+
4	• STEMI with presumed successful treatment with fibrinolysis • Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present • One vessel coronary artery disease presumed to be the culprit artery	9	9	8	9	9	9	9	9	8	9	9	8	8	9	9	7	8	**9**	0.4	**A**	+
5	• STEMI with presumed successful treatment with fibrinolysis • Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias • Normal LVEF • One vessel coronary artery disease presumed to be the culprit artery	4	3	4	5	6	7	6	7	2	6	6	5	6	7	5	1	5	**5**	1.3	**U**	
6	• STEMI with presumed successful treatment with fibrinolysis • Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation • Depressed LVEF • Three vessel coronary artery disease • Elective/semi-elective revascularization	9	8	7	8	7	9	9	8	7	8	8	8	7	8	8	7	6	**8**	0.6	**A**	+
7	• STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis. • Asymptomatic; no HF, no evidence of recurrent or provocable ischemia or no unstable ventricular arrhythmias during index hospitalization • Normal LVEF • Revascularization of a non-infarct related artery during index hospitalization	1	2	2	2	3	3	7	1	4	2	3	3	4	2	2	2	2	**2**	0.9	**I**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
8	• STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization • Symptoms of recurrent myocardial ischemia and/or high-risk findings on non-invasive stress testing performed after index hospitalization • Revascularization of one or more additional coronary arteries	8	8	8	9	7	8	8	8	7	9	9	7	8	8	9	9	6	8	0.6	A	+
9	• UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI • Revascularization of the presumed culprit artery	9	9	8	9	9	9	9	9	9	9	9	8	9	9	9	8	8	9	0.2	A	+
10	• UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI • Revascularization of multiple coronary arteries when the culprit artery cannot be clearly determined	9	9	9	9	9	9	8	7	8	9	9	8	8	9	8	7	8	9	0.6	A	+
11	• Patients with acute myocardial infarction (STEMI or NSTEMI) • Evidence of cardiogenic shock • Revascularization of one or more coronary arteries	8	8	8	8	8	8	9	9	9	9	7	8	7	9	8	7	8	8	0.5	A	+
Table 2. Patients without Prior Bypass Surgery																						
12	• One or two vessel coronary artery disease without involvement of proximal LAD • Low-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	1	1	1	1	1	1	3	5	1	1	1	1	2	1	1	1	2	1	0.5	I	+
b	Class I or II	1	2	1	1	2	2	5	6	2	3	3	1	5	3	2	1	2	2	1.1	I	+
c	Class III or IV	3	6	3	1	3	7	6	7	5	5	5	1	8	4	5	1	4	5	1.7	U	
13	• One or two vessel coronary artery disease without involvement of proximal LAD • Low-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	1	1	1	3	3	2	3	5	1	2	2	1	3	3	1	1	2	2	0.9	I	+
b	Class I or II	5	4	3	6	5	7	6	7	7	5	5	5	7	7	4	5	5	5	0.9	U	
c	Class III or IV	8	7	7	9	7	7	7	8	9	7	7	6	9	7	7	7	7	7	0.5	A	+
14	• One or two vessel coronary artery disease without involvement of proximal LAD • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	2	2	2	3	4	2	5	6	1	3	4	3	4	4	2	2	4	3	1.1	I	
b	Class I or II	5	4	5	6	5	7	6	7	2	4	5	4	6	7	4	5	4	5	1.0	U	+
c	Class III or IV	6	6	6	6	6	7	7	8	5	6	6	5	8	7	5	5	4	6	0.8	U	

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

	Indication	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
15	• One or two vessel coronary artery disease without involvement of proximal LAD • Intermediate-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	4	4	5	4	4	7	7	1	4	4	4	6	6	2	2	4	**4**	1.1	**U**	
b	Class I or II	6	7	7	7	6	7	7	7	7	6	7	7	8	8	6	7	6	**7**	0.4	**A**	
c	Class III or IV	8	8	8	8	8	8	8	8	9	8	8	7	9	8	8	7	8	**8**	0.2	**A**	+
16	• One or two vessel coronary artery disease without involvement of proximal LAD • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	5	7	6	6	6	7	7	7	1	5	6	4	6	9	5	2	6	**6**	1.2	**U**	
b	Class I or II	7	8	7	7	7	8	7	8	4	7	6	5	8	9	7	6	6	**7**	0.8	**A**	
c	Class III or IV	8	9	8	8	8	8	8	8	6	8	7	6	9	9	9	9	6	**8**	0.7	**A**	+
17	• One or two vessel coronary artery disease without involvement of proximal LAD • High-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	7	7	7	8	6	7	6	7	3	7	6	7	7	9	6	4	7	**7**	0.8	**A**	
b	Class I or II	8	8	8	8	7	9	7	8	7	8	8	8	8	9	8	7	7	**8**	0.4	**A**	+
c	Class III or IV	9	9	9	9	8	9	8	9	9	9	9	9	9	9	9	9	7	**9**	0.2	**A**	+
18	• One or two vessel coronary artery disease without involvement of proximal LAD • No non-invasive testing performed																					
a	Asymptomatic	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a				
b	Class I or II	3	3	4	3	6	7	3	7	3	5	6	1	6	6	6	5	4	**5**	1.5	**U**	
c	Class III or IV	4	7	7	3	8	7	7	8	6	7	7	7	8	7	7	7	7	**7**	0.6	**A**	+
19	• One or two vessel coronary artery disease with borderline stenosis “50%-60%” • No non-invasive testing performed • No further invasive evaluation performed (i.e. FFR, IVUS)																					
a	Asymptomatic	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a				
b	Class I or II	1	2	2	1	1	1	2	4	1	2	3	2	4	2	5	5	3	**2**	1.0	**I**	+
c	Class III or IV	2	3	3	1	3	4	6	5	1	3	3	3	6	2	6	5	3	**3**	1.2	**I**	

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
20	• One or two vessel coronary artery disease with borderline stenosis “50%-60%” • No non-invasive testing performed or equivocal test results present • FFR less than 0.75 and/or IVUS with significant reduction in cross sectional area																					
a	Asymptomatic	6	2	5	7	3	4	6	6	1	3	1	3	1	6	1	1	4	**3**	1.8	**I**	
b	Class I or II	7	3	6	7	5	7	7	7	4	5	4	6	5	8	2	7	5	**6**	1.4	**U**	
c	Class III or IV	7	5	7	7	7	9	8	8	4	8	6	7	7	8	3	8	6	**7**	1.1	**A**	
21	• One or two vessel coronary artery disease with borderline stenosis “50%-60%” • No non-invasive testing performed or equivocal test results present • FFR or IVUS findings do not meet criteria for significant stenosis																					
a	Asymptomatic	1	1	3	1	1	1	1	1	1	1	1	1	1	1	1	1	3	**1**	0.2	**I**	+
b	Class I or II	1	2	3	1	2	1	1	2	1	1	1	2	3	1	2	2	3	**2**	0.6	**I**	+
c	Class III or IV	1	3	4	1	3	4	1	2	1	1	1	4	5	1	2	2	3	**2**	1.1	**I**	+
22	• Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses • Low-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	1	1	1	1	1	1	1	2	1	1	1	1	1	1	1	1	2	**1**	0.1	**I**	+
b	Class I or II	2	3	3	1	2	3	1	4	1	3	3	2	3	4	2	1	2	**2**	0.8	**I**	+
c	Class III or IV	2	4	3	1	3	3	7	6	1	3	3	4	5	4	3	2	2	**3**	1.1	**I**	
23	• Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses • Low-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	1	1	1	1	1	1	1	2	1	1	1	3	1	4	1	1	2	**1**	0.4	**I**	+
b	Class I or II	2	4	4	3	2	3	6	5	4	4	4	4	6	5	4	3	5	**4**	0.8	**U**	
c	Class III or IV	5	5	6	5	5	7	8	7	7	6	6	5	8	6	6	6	5	**6**	0.8	**U**	
24	• Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	3	4	3	3	1	4	4	6	1	3	3	4	3	6	3	1	3	**3**	0.9	**I**	
b	Class I or II	3	5	4	5	3	4	5	7	1	4	5	5	6	6	4	3	4	**4**	1.1	**U**	
c	Class III or IV	5	6	6	6	5	4	6	7	1	6	6	6	8	6	6	6	4	**6**	0.8	**U**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
25	• Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses • Intermediate-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	3	4	4	4	3	4	6	7	1	4	3	4	4	6	3	1	3	**4**	1.1	**U**	
b	Class I or II	5	5	5	6	5	4	6	7	4	5	6	5	6	7	5	3	5	**5**	0.7	**U**	+
c	Class III or IV	7	7	7	7	7	7	8	8	8	7	7	6	9	7	6	7	7	**7**	0.4	**A**	+
26	• Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	4	3	4	5	1	4	7	7	1	3	4	4	5	7	4	1	3	**4**	1.4	**U**	
b	Class I or II	6	5	5	5	3	4	7	7	1	5	5	5	7	7	5	1	5	**5**	1.2	**U**	
c	Class III or IV	6	7	7	5	5	7	8	8	1	8	7	6	8	8	7	6	5	**7**	1.2	**A**	
27	• Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses • High-risk criteria on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	4	4	5	5	4	6	8	1	5	5	4	6	7	5	1	3	**5**	1.2	**U**	
b	Class I or II	7	5	7	7	7	6	8	8	5	7	7	5	7	7	7	1	5	**7**	1.0	**A**	
c	Class III or IV	8	8	8	8	8	7	8	8	8	9	8	8	9	8	8	6	7	**8**	0.4	**A**	+
28	• One vessel disease involving the proximal LAD • Low-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	4	2	4	5	4	7	2	7	1	4	4	3	4	8	4	1	3	**4**	1.4	**U**	
b	Class I or II	5	5	5	5	5	7	3	8	4	5	5	3	5	8	5	3	5	**5**	0.9	**U**	
c	Class III or IV	6	7	7	6	6	8	5	8	7	8	7	4	7	8	7	5	5	**7**	0.9	**A**	
29	• One vessel disease involving the proximal LAD • Low-risk findings on non-invasive testing • Receiving maximal anti-ischemic medical therapy																					
a	Asymptomatic	4	3	5	4	5	5	2	7	1	5	4	3	4	8	4	1	3	**4**	1.3	**U**	
b	Class I or II	7	6	7	6	6	8	7	8	7	7	7	4	7	8	7	5	6	**7**	0.7	**A**	
c	Class III or IV	8	8	8	8	7	9	9	8	8	8	8	7	9	9	8	7	7	**8**	0.5	**A**	+
30	• One vessel disease involving the proximal LAD • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	5	4	5	6	6	6	3	8	1	4	4	3	4	8	5	1	4	**4**	1.5	**U**	
b	Class I or II	6	6	6	6	7	8	5	8	4	6	6	4	6	8	6	3	5	**6**	0.9	**U**	
c	Class III or IV	7	8	7	8	8	9	7	8	7	7	7	7	8	8	7	6	6	**7**	0.6	**A**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
31	• One vessel disease involving the proximal LAD • Intermediate-risk findings on non-invasive testing • Receiving maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	5	6	5	6	7	2	8	1	6	5	4	5	8	5	2	5	**5**	1.3	**U**	
b	Class I or II	8	8	9	7	8	8	7	8	8	7	8	5	7	8	7	7	7	**8**	0.6	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	8	9	9	9	7	9	9	9	7	9	**9**	0.3	**A**	+
32	• One vessel disease involving the proximal LAD • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	7	6	7	7	7	7	5	8	4	7	7	4	7	8	7	1	5	**7**	1.1	**A**	
b	Class I or II	8	8	7	9	8	8	7	8	6	8	8	5	8	8	8	5	5	**8**	0.8	**A**	+
c	Class III or IV	9	9	9	9	9	9	8	9	8	9	9	6	9	9	9	6	6	**9**	0.6	**A**	+
33	• One vessel disease involving the proximal LAD • High-risk findings on non-invasive testing • Receiving maximal anti-ischemic medical therapy																					
a	Asymptomatic	8	7	7	9	7	7	7	8	4	7	6	5	8	8	7	4	6	**7**	0.9	**A**	
b	Class I or II	9	8	9	9	9	9	9	9	8	9	9	7	9	9	9	7	7	**9**	0.5	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	8	9	**9**	0.1	**A**	+
34	• Two vessel disease involving the proximal LAD • Low-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	4	4	4	4	3	7	6	7	1	5	4	3	4	7	4	1	4	**4**	1.2	**U**	
b	Class I or II	5	6	7	6	4	7	6	8	4	6	5	4	6	8	6	5	5	**6**	0.9	**U**	+
c	Class III or IV	7	8	8	6	5	7	7	8	8	8	7	7	8	8	7	8	5	**7**	0.8	**A**	+
35	• Two vessel disease involving the proximal LAD • Low-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	5	5	5	5	7	6	7	1	5	4	3	4	7	4	2	4	**5**	1.2	**U**	
b	Class I or II	7	7	7	7	6	8	7	8	7	7	8	6	7	9	6	6	7	**7**	0.5	**A**	+
c	Class III or IV	8	8	8	8	7	9	9	8	9	9	9	7	9	9	8	8	9	**8**	0.6	**A**	+
36	• Two vessel coronary artery disease involving the proximal LAD • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	5	5	5	5	6	7	7	8	1	5	5	3	4	7	5	2	4	**5**	1.2	**U**	
b	Class I or II	7	7	7	7	7	8	7	8	4	6	7	4	6	9	7	5	5	**7**	0.9	**A**	
c	Class III or IV	8	8	8	8	8	9	9	8	8	7	8	7	8	9	8	6	6	**8**	0.5	**A**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
37	• Two vessel coronary artery disease involving the proximal LAD • Intermediate-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	7	7	7	7	6	8	7	8	1	6	6	6	5	7	5	6	5	**6**	1.1	**U**	
b	Class I or II	8	8	7	8	8	8	9	8	7	7	7	7	7	9	7	7	7	**7**	0.6	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	8	9	9	8	8	9	9	8	9	9	**9**	0.2	**A**	+
38	• Two vessel coronary artery disease involving the proximal LAD • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	7	7	7	8	7	8	8	8	1	7	7	6	6	7	7	6	6	**7**	0.8	**A**	
b	Class I or II	8	8	8	9	8	9	8	8	4	8	8	7	7	9	8	6	7	**8**	0.7	**A**	+
c	Class III or IV	9	9	9	9	9	9	8	9	8	9	9	8	9	9	9	7	9	**9**	0.3	**A**	+
39	• Two vessel coronary artery disease involving the proximal LAD • High-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	8	8	8	9	7	8	9	8	1	8	7	7	8	7	8	6	6	**8**	1.0	**A**	+
b	Class I or II	9	9	9	9	9	9	9	9	7	9	9	7	9	9	9	7	8	**9**	0.4	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.0	**A**	+
40	• Three vessel coronary artery disease (no left main) • Low-risk findings on non-invasive testing including normal LV systolic function • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	5	4	5	5	3	7	4	7	1	5	5	6	4	7	4	3	5	**5**	1.1	**U**	
b	Class I or II	6	6	6	6	4	8	6	7	6	6	6	7	5	9	6	5	6	**6**	0.6	**U**	+
c	Class III or IV	7	7	7	7	5	9	7	8	8	7	7	8	7	9	7	6	6	**7**	0.6	**A**	+
41	• Three vessel coronary artery disease (no left main) • Low-risk findings on non-invasive testing including normal LV systolic function • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	5	6	5	4	7	6	7	1	5	5	6	4	7	4	3	5	**5**	1.1	**U**	
b	Class I or II	7	6	7	7	5	8	7	8	8	7	7	8	7	9	7	7	7	**7**	0.5	**A**	+
c	Class III or IV	8	8	8	8	6	8	8	8	9	9	8	9	8	9	8	7	9	**8**	0.5	**A**	+
42	• Three vessel coronary artery disease (no left main) • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	7	5	7	7	4	7	7	8	3	7	7	7	5	8	7	3	5	**7**	1.1	**A**	
b	Class I or II	7	6	7	7	5	8	7	8	6	7	8	7	6	9	7	6	6	**7**	0.7	**A**	
c	Class III or IV	8	7	8	8	6	9	8	8	8	8	9	8	7	9	8	6	7	**8**	0.6	**A**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

	Indication	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
43	• Three vessel coronary artery disease (no left main) • Intermediate-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	7	7	7	7	5	8	8	8	3	7	7	7	5	9	7	3	6	**7**	1.1	**A**	
b	Class I or II	8	8	8	9	6	9	8	8	8	8	8	8	8	9	8	7	7	**8**	0.4	**A**	+
c	Class III or IV	9	9	9	9	7	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.1	**A**	+
44	• Three vessel coronary artery disease (no left main) • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	7	8	7	7	7	8	8	8	4	7	7	8	7	9	7	5	7	**7**	0.7	**A**	+
b	Class I or II	8	8	8	9	8	9	9	9	8	8	8	8	8	9	7	5	8	**8**	0.5	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	7	9	**9**	0.2	**A**	+
45	• Three vessel coronary artery disease (no left main) • High-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	9	9	8	9	8	9	9	8	6	8	8	8	7	9	8	5	7	**8**	0.8	**A**	+
b	Class I or II	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	8	9	**9**	0.1	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.0	**A**	+
46	• Three vessel coronary artery disease (no left main) • Abnormal LV systolic function																					
a	Asymptomatic	9	7	9	9	7	9	9	8	7	9	7	7	6	8	6	8	8	**8**	0.9	**A**	+
b	Class I or II	9	8	9	9	8	9	9	8	9	9	9	8	8	9	8	9	9	**9**	0.4	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	9	**9**	0.1	**A**	+
47	• Left main stenosis																					
a	Asymptomatic	9	9	9	9	9	9	9	9	8	9	9	8	5	9	8	7	8	**9**	0.6	**A**	+
b	Class I or II	9	9	9	9	9	9	9	9	9	9	9	9	7	9	9	9	9	**9**	0.1	**A**	+
c	Class III or IV	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.0	**A**	+
	Table 3. Patients with Prior Bypass Surgery (without acute coronary syndromes)																					
48	• One or more stenoses in saphenous vein graft(s) • Low-risk findings on non-invasive testing including normal LV systolic function • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	5	2	3	5	2	3	4	4	1	3	2	3	1	3	3	1	2	**3**	0.9	**I**	+
b	Class I or II	6	3	4	6	3	7	7	6	2	5	4	3	3	3	3	3	4	**4**	1.3	**U**	
c	Class III or IV	7	6	5	7	4	7	8	7	4	7	6	4	5	5	6	6	4	**6**	1.1	**U**	

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
49	• One or more stenoses in saphenous vein graft(s) • Low-risk findings on non-invasive testing including normal LV systolic function • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	3	4	5	3	3	6	4	1	4	2	4	2	5	4	1	2	4	1.2	U	
b	Class I or II	7	5	6	6	4	7	7	6	5	5	6	4	6	7	6	5	5	6	0.8	U	+
c	Class III or IV	7	7	7	7	5	7	8	7	7	7	7	5	8	7	7	7	6	7	0.4	A	+
50	• One or more stenoses in saphenous vein graft(s) • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	5	4	4	4	4	4	7	5	1	4	3	4	2	7	4	1	4	4	1.0	U	
b	Class I or II	6	6	6	6	5	7	7	6	2	5	6	4	3	7	6	2	5	6	1.1	U	
c	Class III or IV	7	7	7	7	6	7	8	7	4	7	7	5	6	7	7	5	6	7	0.6	A	
51	• One or more stenoses in saphenous vein graft(s) • Intermediate-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	6	4	4	6	4	4	7	6	1	4	3	4	3	7	4	1	4	4	1.2	U	
b	Class I or II	7	7	6	7	7	7	7	7	5	6	7	5	6	7	7	5	6	7	0.6	A	
c	Class III or IV	8	8	8	8	8	8	8	8	7	8	8	7	8	7	8	7	7	8	0.3	A	+
52	• One or more stenoses in saphenous vein graft(s) • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	7	4	6	7	5	4	7	7	1	6	6	5	5	7	6	2	5	6	1.3	U	
b	Class I or II	8	6	7	8	6	7	7	7	2	7	7	6	5	7	7	5	6	7	0.9	A	
c	Class III or IV	9	8	7	9	7	7	8	7	7	8	7	7	7	7	7	5	7	7	0.5	A	+
53	• One or more stenoses in saphenous vein graft(s) • High-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	8	7	7	9	6	6	7	7	3	7	7	6	5	8	7	1	5	7	1.2	A	
b	Class I or II	9	8	8	9	7	8	8	8	6	8	8	7	7	9	7	6	7	8	0.7	A	+
c	Class III or IV	9	9	9	9	8	9	8	9	8	9	9	8	8	9	9	7	8	9	0.5	A	+
54	• One or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Low-risk findings on non-invasive testing including normal LV systolic function • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a				
b	Class I or II	3	3	3	3	3	3	6	5	2	3	4	3	4	4	3	2	3	3	0.6	I	
c	Class III or IV	4	6	6	5	4	7	8	7	5	6	6	5	7	6	6	6	3	6	0.9	U	

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

	Indication	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
55	• One or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Low-risk findings on non-invasive testing including normal LV systolic function • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	3	3	3	3	2	3	3	5	1	3	3	3	1	5	2	2	3	**3**	0.6	**I**	+
b	Class I or II	5	4	5	5	4	7	6	6	4	5	5	4	5	6	5	5	5	**5**	0.5	**U**	+
c	Class III or IV	7	7	7	7	6	8	9	7	7	7	7	7	8	6	7	7	7	**7**	0.4	**A**	+
56	• One or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Intermediate-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	3	3	3	2	3	3	3	6	1	3	3	3	3	5	3	1	3	**3**	0.6	**I**	+
b	Class I or II	5	4	4	4	3	7	5	7	5	5	5	3	5	6	5	2	4	**5**	0.9	**U**	
c	Class III or IV	6	7	7	6	4	7	7	8	7	7	7	4	6	6	7	5	5	**7**	0.9	**A**	
57	• One or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • Intermediate-risk findings on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	5	4	4	5	5	3	5	6	1	3	3	4	3	7	4	1	3	**4**	1.2	**U**	
b	Class I or II	7	5	6	7	6	8	7	7	7	5	6	5	6	7	7	5	6	**6**	0.8	**U**	
c	Class III or IV	8	7	7	8	7	9	8	8	8	7	8	7	8	7	8	7	7	**8**	0.5	**A**	+
58	• One or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • High-risk findings on non-invasive testing • Receiving no or minimal anti-ischemic medical therapy																					
a	Asymptomatic	6	6	6	6	5	4	6	7	3	6	5	4	5	8	6	1	5	**6**	1.1	**U**	+
b	Class I or II	7	7	7	7	6	7	7	8	6	7	7	6	7	8	7	2	6	**7**	0.6	**A**	
c	Class III or IV	8	8	8	8	7	8	8	9	7	8	8	8	8	8	8	5	7	**8**	0.4	**A**	+
59	• One or more lesions in native coronary arteries without bypass grafts • All bypass grafts patent and without significant disease • High-risk finding on non-invasive testing • Receiving a course of maximal anti-ischemic medical therapy																					
a	Asymptomatic	7	6	5	7	6	4	7	7	4	3	7	5	5	7	5	2	5	**5**	1.2	**U**	
b	Class I or II	8	7	8	8	7	9	8	8	7	8	8	7	8	9	8	7	7	**8**	0.5	**A**	+
c	Class III or IV	9	8	9	9	8	9	9	9	8	9	9	8	9	9	9	8	9	**9**	0.3	**A**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

	Indication	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
Table 4. Method of Revascularization																						
60	• Two vessel coronary artery disease with proximal LAD stenosis • No diabetes and normal LVEF																					
	PCI	8	7	4	8	7	9	9	8	7	8	8	7	8	8	8	7	8	**8**	0.6	**A**	+
	CABG	8	8	8	9	7	7	6	7	8	8	7	8	7	8	8	8	8	**8**	0.5	**A**	+
61	• Two vessel coronary artery disease with proximal LAD stenosis • Diabetes																					
	PCI	6	5	5	6	6	9	7	7	5	7	7	7	7	7	7	6	5	**7**	0.8	**A**	
	CABG	8	9	8	9	8	7	8	8	8	8	8	8	7	8	8	8	8	**8**	0.2	**A**	+
62	• Two vessel coronary artery disease with proximal LAD stenosis • Depressed LVEF																					
	PCI	6	5	7	7	6	9	9	7	5	7	6	7	7	7	7	7	5	**7**	0.8	**A**	
	CABG	9	9	8	9	8	7	9	8	8	8	8	9	7	9	8	8	8	**8**	0.5	**A**	+
63	• Three vessel coronary artery disease • No diabetes and normal LVEF																					
	PCI	5	5	5	6	6	7	7	6	5	5	6	6	7	8	6	6	5	**6**	0.6	**U**	+
	CABG	8	9	8	9	8	9	7	8	7	8	8	9	8	9	8	8	8	**8**	0.4	**A**	+
64	• Three vessel coronary artery disease • Diabetes																					
	PCI	4	4	6	5	4	7	7	5	5	5	5	6	6	7	6	6	5	**5**	0.8	**U**	+
	CABG	9	9	9	9	9	9	8	8	7	9	9	9	8	9	9	9	9	**9**	0.3	**A**	+
65	• Three vessel coronary artery disease • Depressed LVEF																					
	PCI	3	3	3	3	4	7	6	4	3	3	4	6	6	6	4	6	3	**4**	1.2	**U**	
	CABG	9	9	9	9	9	9	9	9	8	9	9	9	9	9	9	9	9	**9**	0.1	**A**	+
66	• Isolated left main stenosis • No diabetes and normal LVEF																					
	PCI	2	2	4	3	3	6	7	4	3	3	4	4	4	4	3	1	3	**3**	1.0	**I**	
	CABG	9	9	9	9	9	9	9	9	8	9	9	8	8	9	9	9	9	**9**	0.2	**A**	+
67	• Isolated left main stenosis • Diabetes																					
	PCI	2	1	2	3	3	6	6	4	3	3	3	3	4	4	3	1	3	**3**	0.9	**I**	
	CABG	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.0	**A**	+
68	• Isolated left main stenosis • Depressed LVEF																					
	PCI	1	1	3	2	3	6	6	3	3	3	3	3	4	4	3	1	3	**3**	0.9	**I**	+
	CABG	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	**9**	0.0	**A**	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

Table A1: Appropriateness Criteria for Revascularization Ratings

Indication		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Median	MADM	R	Agree
69	• Left main stenosis and additional coronary artery disease • No diabetes and normal LVEF																					
	PCI	2	1	3	3	3	3	7	2	3	2	3	3	4	2	3	1	3	3	0.8	I	+
	CABG	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	0.1	A	+
70	• Left main stenosis and additional coronary artery disease • Diabetes																					
	PCI	1	1	2	3	3	2	6	2	2	2	3	3	4	1	3	1	3	2	0.9	I	+
	CABG	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	0.1	A	+
71	• Left main stenosis and additional coronary artery disease • Depressed LVEF																					
	PCI	1	1	2	2	3	2	6	2	1	3	2	2	4	1	2	1	3	2	0.8	I	+
	CABG	9	9	9	9	9	9	9	9	9	9	9	9	8	9	9	9	9	9	0.1	A	+
72	• Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts • LIMA remains patent to a native coronary artery • Depressed LVEF																					
	PCI	7	1	6	7	9	9	8	7	7	7	7	4	6	7	7	6	5	7	1.1	A	
	CABG	7	9	7	7	3	5	5	4	5	6	3	5	6	6	7	8	6	6	1.2	U	
73	• Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts • LIMA was used as a graft but is no longer functional • Depressed LVEF																					
	PCI	7	1	6	6	6	7	6	7	4	7	6	4	6	7	7	6	6	6	0.9	U	
	CABG	8	9	8	8	6	7	9	7	7	6	8	9	8	7	8	8	7	8	0.7	A	+

Agreement Column Key

"+" sign: Indicates agreement between panelists. Agreement is reached when four or fewer panelists' ratings fell outside the 3-point region containing the median appropriateness criteria score.

"-" sign: Indicates disagreement between panelists. Disagreement is reached when at least five panelists' ratings fell in the appropriate category AND at least five panelists' ratings fell in the inappropriate category for a specific indication.

Blank: Indicates neither agreement nor disagreement as defined above. For indications where neither a "+" or "-" sign appear, more than four panelists rated outside the 3-point region containing the median appropriateness criteria score; but scores were not so disperse to meet the requirements of disagreement noted above.

CORONARY REVASCULARIZATION APPROPRIATENESS CRITERIA (BY APPROPRIATENESS CATEGORY)

Appropriate Indications (Median Score 7-9)

Patients with Acute Coronary Syndromes		
		Appropriateness Score (1-9)
1.	▪ STEMI ▪ Less than or equal to 12 hours from onset of symptoms ▪ Revascularization of the culprit artery	**9 (A)**
2.	▪ STEMI ▪ Onset of symptoms within the prior 12 to 24 hours ▪ Severe HF, persistent ischemic symptoms or hemodynamic or electrical instability present	**9 (A)**
4.	▪ STEMI with presumed successful treatment with fibrinolysis ▪ Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present ▪ One vessel coronary artery disease, presumed to be the culprit artery	**9 (A)**
6.	▪ STEMI with presumed successful treatment with fibrinolysis ▪ Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation ▪ Depressed LVEF ▪ Three vessel coronary artery disease ▪ Elective/semi-elective revascularization	**8 (A)**
8.	▪ STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization ▪ Symptoms of recurrent myocardial ischemia and/or high-risk findings on non-invasive stress testing performed after index hospitalization ▪ Revascularization of one or more additional coronary arteries	**8 (A)**
9.	▪ UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI ▪ Revascularization of the presumed culprit artery	**9 (A)**
10.	▪ UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI ▪ Revascularization of multiple coronary arteries when the culprit artery cannot be clearly determined	**9 (A)**

11.	▪ Patients with acute myocardial infarction (STEMI or NSTEMI) ▪ Evidence of cardiogenic shock ▪ Revascularization of one or more coronary arteries			**8 (A)**
Patients without Prior Bypass Surgery				
	CCS Angina Class	**Asymptomatic**	**I or II**	**III or IV**
		Appropriateness Score (1-9)		
13.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy			**7 (A)**
15.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Intermediate risk-findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
16.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
17.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**7 (A)**	**8 (A)**	**9 (A)**
18.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ No non-invasive testing performed			**7 (A)**
20.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR less than 0.75 and/or IVUS with significant reduction in cross sectional area.			**7 (A)**
25.	▪ Chronic total occlusion of one major epicardial			**7 (A)**

	coronary artery, without other coronary stenoses ▪ Intermediate-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy			
26.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
27.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
28.	▪ One vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
29.	▪ One vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
30.	▪ One vessel disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
31.	▪ One vessel disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy		**8 (A)**	**9 (A)**
32.	▪ One vessel disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**7 (A)**	**8 (A)**	**9 (A)**
33.	▪ One vessel disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy	**7 (A)**	**9 (A)**	**9 (A)**

34.	▪ Two vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
35.	▪ Two vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
36.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
37.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy		**7 (A)**	**9 (A)**
38.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**7 (A)**	**8 (A)**	**9 (A)**
39.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**8 (A)**	**9 (A)**	**9 (A)**
40.	▪ Three vessel coronary artery disease (no left main) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
41.	▪ Three vessel coronary artery disease (no left main) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy		**7 (A)**	**8 (A)**

42.	▪ Three vessel coronary artery disease (no left main) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**7 (A)**	**7 (A)**	**8 (A)**
43.	▪ Three vessel coronary artery disease (no left main) ▪ Intermediate risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**7 (A)**	**8 (A)**	**9 (A)**
44.	▪ Three vessel coronary artery disease (no left main) ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**7 (A)**	**8 (A)**	**9 (A)**
45.	▪ Three vessel coronary artery disease (no left main) ▪ High risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**8 (A)**	**9 (A)**	**9 (A)**
46.	▪ Three vessel coronary artery disease (no left main) ▪ Abnormal LV systolic function	**8 (A)**	**9 (A)**	**9 (A)**
47.	▪ Left Main Stenosis	**9 (A)**	**9 (A)**	**9 (A)**

Patients with Prior Bypass Surgery (Without Acute Coronary Syndromes)

	CCS Angina Class	**Asymptomatic**	**I or II**	**III or IV**
49.	▪ One or more stenoses in saphenous vein graft(s) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy			**7 (A)**
50.	▪ One or more stenoses in saphenous vein graft(s) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
51.	▪ One or more stenoses in saphenous vein graft(s) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy		**7 (A)**	**8 (A)**

52.	▪ One or more stenoses in saphenous vein graft(s) ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy		**7 (A)**	**7 (A)**
53.	▪ One or more stenoses in saphenous vein graft(s) ▪ High-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**7 (A)**	**8 (A)**	**9 (A)**
55.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy			**7 (A)**
56.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**7 (A)**
57.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy			**8 (A)**
58.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy		**7 (A)**	**8 (A)**
59.	▪ One or more lesions in native coronary arteries		**8 (A)**	**9 (A)**

	without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ High-risk finding on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy			

Method of Revascularization: Advanced Coronary Disease, CCS Angina Greater than or Equal to Class III and/or Evidence of Intermediate- to High-Risk Findings on Non-Invasive Testing*

		PCI Appropriateness Rating	CABG Appropriateness Rating
		Appropriateness Score (1-9)	
60.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ No diabetes and normal LVEF	**8 (A)**	**8 (A)**
61.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ Diabetes	**7 (A)**	**8 (A)**
62.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ Depressed LVEF	**7 (A)**	**8 (A)**
63.	▪ Three vessel coronary artery disease ▪ No diabetes and normal LVEF		**8 (A)**
64.	▪ Three vessel coronary artery disease ▪ Diabetes		**9 (A)**
65.	▪ Three vessel coronary artery disease ▪ Depressed LVEF		**9 (A)**
66.	▪ Isolated left main stenosis ▪ No diabetes and normal LVEF		**9 (A)**
67.	▪ Isolated left main stenosis ▪ Diabetes		**9 (A)**
68.	▪ Isolated left main stenosis ▪ Depressed LVEF		**9 (A)**
69.	▪ Left main stenosis and additional coronary artery disease		**9 (A)**

	▪ No diabetes and normal LVEF		
70.	▪ Left main stenosis and additional coronary artery disease ▪ Diabetes		**9 (A)**
71.	▪ Left main stenosis and additional coronary artery disease ▪ Depressed LVEF		**9 (A)**
72.	▪ Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts ▪ LIMA remains patent to a native coronary artery ▪ Depressed LVEF	**7 (A)**	
73.	▪ Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts ▪ LIMA was used as a graft but is no longer functional ▪ Depressed LVEF		**8 (A)**

Uncertain Indications (Median Score 4-6)

Patients with Acute Coronary Syndromes				
				Appropriateness Score (1-9)
5.	▪ STEMI with presumed successful treatment with fibrinolysis ▪ Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias ▪ Normal LVEF ▪ One vessel coronary artery disease presumed to be the culprit artery			**5 (U)**
Patients without Prior Bypass Surgery				
	CCS Angina Class	**Asymptomatic**	**I or II**	**III or IV**
		Appropriateness Score (1-9)		
12.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			**5 (U)**
13.	▪ One or two vessel coronary artery disease		**5 (U)**	

	without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy			
14.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy		**5 (U)**	**6 (U)**
15.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Intermediate risk-findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**4 (U)**		
16.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**6 (U)**		
18.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ No non-invasive testing performed		**5 (U)**	
20.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR less than 0.75 and/or IVUS with significant reduction in cross sectional area.		**6 (U)**	
23.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy		**4 (U)**	**6 (U)**
24.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses		**4 (U)**	**6 (U)**

	▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy			
25.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Intermediate-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**4 (U)**	**5 (U)**	
26.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**4 (U)**	**5 (U)**	
27.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**5 (U)**		
28.	▪ One vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**4 (U)**	**5 (U)**	
29.	▪ One vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy	**4 (U)**		
30.	▪ One vessel disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**4 (U)**	**6 (U)**	

31.	▪ One vessel disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy	**5 (U)**		
34.	▪ Two vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**4 (U)**	**6 (U)**	
35.	▪ Two vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**5 (U)**		
36.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**5 (U)**		
37.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**6 (U)**		
40.	▪ Three vessel coronary artery disease (no left main) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy	**5 (U)**	**6 (U)**	
41.	▪ Three vessel coronary artery disease (no left main) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic	**5 (U)**		

	medical therapy			
Patients with Prior Bypass Surgery (Without Acute Coronary Syndromes)				
		Appropriateness Score (1-9)		
48.	▪ One or more stenoses in saphenous vein graft(s) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy		**4 (U)**	**6 (U)**
49.	▪ One or more stenoses in saphenous vein graft(s) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy	**4 (U)**	**6 (U)**	
50.	▪ One or more stenoses in saphenous vein graft(s) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**4 (U)**	**6 (U)**	
51.	▪ One or more stenoses in saphenous vein graft(s) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**4 (U)**		
52.	▪ One or more stenoses in saphenous vein graft(s) ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**6 (U)**		
54.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function			**6 (U)**

	▪ Receiving no or minimal anti-ischemic medical therapy			
55.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy		**5 (U)**	
56.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy		**5 (U)**	
57.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**4 (U)**	**6 (U)**	
58.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**6 (U)**		
59.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ High-risk finding on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**5 (U)**		

Method of Revascularization: Advanced Coronary Disease, CCS Angina Greater than or Equal to Class III and/or Evidence of Intermediate- to High-Risk Findings on Non-Invasive Testing*			
		PCI Appropriateness Rating	**CABG Appropriateness Rating**
		Appropriateness Score (1-9)	
63.	▪ Three vessel coronary artery disease ▪ No diabetes and normal LVEF	**6 (U)**	
64.	▪ Three vessel coronary artery disease ▪ Diabetes	**5 (U)**	
65.	▪ Three vessel coronary artery disease ▪ Depressed LVEF	**4 (U)**	
72.	▪ Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts ▪ LIMA remains patent to a native coronary artery ▪ Depressed LVEF		**6 (U)**
73.	▪ Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts ▪ LIMA was used as a graft but is no longer functional ▪ Depressed LVEF	**6 (U)**	

Inappropriate Indications (Median Score 1-3)

Patients with Acute Coronary Syndromes		
		Appropriateness Score (1-9)
3.	▪ STEMI ▪ Greater than 12 hours from symptom onset ▪ Asymptomatic; no hemodynamic instability and no electrical instability	**3 (I)**

7.	▪ STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis. ▪ Asymptomatic; no HF, no evidence of recurrent or provocable ischemia or no unstable ventricular arrhythmias during index hospitalization ▪ Normal LVEF ▪ Revascularization of a non-infarct related artery during index hospitalization	**2 (I)**

	Patients without Prior Bypass Surgery			
	CCS Angina Class	**Asymptomatic**	**I or II**	**III or IV**
		Appropriateness Score (1-9)		
12.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**1 (I)**	**2 (I)**	
13.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**2 (I)**		
14.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**3 (I)**		
19.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed ▪ No further invasive evaluation performed (i.e. FFR, IVUS)		**2 (I)**	**3 (I)**
20.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR less than 0.75 and/or IVUS with significant reduction in cross sectional area.	**3 (I)**		

21.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR or IVUS findings do not meet criteria for significant stenosis	**1 (I)**	**2 (I)**	**2 (I)**
22.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**1 (I)**	**2 (I)**	**3 (I)**
23.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy	**1 (I)**		
24.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**3 (I)**		
Patients with Prior Bypass Surgery (Without Acute Coronary Syndromes)				
	CCS Angina Class	**Asymptomatic**	**I or II**	**III or IV**
		Appropriateness Score (1-9)		
48.	▪ One or more stenoses in saphenous vein graft(s) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy	**3 (I)**		

54.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy		**3 (I)**	
55.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy	**3 (I)**		
56.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy	**3 (I)**		

Method of Revascularization: Advanced Coronary Disease, CCS Angina Greater than or Equal to Class III and/or Evidence of Intermediate- to High-Risk Findings on Non-Invasive Testing*

		PCI Appropriateness Rating	**CABG Appropriateness Rating**
		Appropriateness Score (1-9)	
66.	▪ Isolated left main stenosis ▪ No diabetes and normal LVEF	**3 (I)**	
67.	▪ Isolated left main stenosis ▪ Diabetes	**3 (I)**	
68.	▪ Isolated left main stenosis ▪ Depressed LVEF	**3 (I)**	

69.	▪ Left main stenosis and additional coronary artery disease ▪ No diabetes and normal LVEF	**3 (I)**	
70.	▪ Left main stenosis and additional coronary artery disease ▪ Diabetes	**2 (I)**	
71.	▪ Left main stenosis and additional coronary artery disease ▪ Depressed LVEF	**2 (I)**	

Relevant Literature Search for Revascularization

Table 1. Patients with Acute Coronary Syndromes

Evaluation of Chest Pain Syndrome or Anginal Equivalent	
1.	▪ STEMI ▪ Less than or equal to 12 hours from onset of symptoms ▪ Revascularization of the culprit artery
2.	▪ STEMI ▪ Onset of symptoms within the prior 12 to 24 hours ▪ Severe HF, persistent ischemic symptoms or hemodynamic or electrical instability present
3.	▪ STEMI ▪ Greater than 12 hours from symptom onset ▪ Asymptomatic; no hemodynamic instability and no electrical instability
4.	▪ STEMI with presumed successful treatment with fibrinolysis ▪ Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present ▪ One vessel coronary artery disease, presumed to be the culprit artery
5.	▪ STEMI with presumed successful treatment with fibrinolysis ▪ Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias ▪ Normal LVEF ▪ One vessel coronary artery disease presumed to be the culprit artery

6.	▪ STEMI with presumed successful treatment with fibrinolysis ▪ Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation ▪ Depressed LVEF ▪ Three vessel coronary artery disease ▪ Elective/semi-elective revascularization
7.	▪ STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis. ▪ Asymptomatic; no HF, no evidence of recurrent or provocable ischemia or no unstable ventricular arrhythmias during index hospitalization ▪ Normal LVEF ▪ Revascularization of a non-infarct related artery during index hospitalization
8.	▪ STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization ▪ Symptoms of recurrent myocardial ischemia and/or high-risk findings on non-invasive stress testing performed after index hospitalization ▪ Revascularization of one or more additional coronary arteries
9.	▪ UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI ▪ Revascularization of the presumed culprit artery
10.	▪ UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI ▪ Revascularization of multiple coronary arteries when the culprit artery cannot be clearly determined
11.	▪ Patients with acute myocardial infarction (STEMI or NSTEMI) ▪ Evidence of cardiogenic shock ▪ Revascularization of one or more coronary arteries

High Relevance:

Boden WE. “Routine invasive" versus "selective invasive" approaches to non-ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. *J Am Coll Cardiol*. 2003 Feb 19;41(4 Suppl S):113S-122S. Review. PMID: 12644349 [PubMed - indexed for MEDLINE]

Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O'Neill WW, Lansky AJ, Griffin JJ; CADILLAC Investigators. Comparative early and late outcomes after primary percutaneous coronary intervention in ST- segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). *Am J Cardiol*. 2006 Aug 1;98(3):331-7. Epub 2006 Jun 9. PMID: 16860018 [PubMed - indexed for MEDLINE]

Di Mario C, Mara S, Flavio A, Imad S, Antonio M, Anna P, Emanuela P, Stefano DS, Angelo R, Stefania C, Anna F, Carmelo C, Antonio C, Monzini N, Bonardi MA. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. *Int J Cardiovasc Intervent*. 2004;6(3-4):128-33. PMID: 16146905 [PubMed - indexed for MEDLINE]

Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA*. 2002 Dec 25;288(24):3124-9. PMID: 12495392 [PubMed - indexed for MEDLINE]

Hoenig MR, Doust JA, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. *Cochrane Database Syst Rev*. 2006 Jul 19;3:CD004815. Review. PMID: 16856061 [PubMed - indexed for MEDLINE]

Ijsselmuiden AJ, Ezechiels J, Westendorp IC, Tijssen JG, Kiemeneij F, Slagboom T, van der Wieken R, Tangelder G, Serruys PW, Laarman G. Complete versus culprit vessel percutaneous coronary intervention in multivessel disease: a randomized comparison. *Am Heart J*. 2004 Sep;148(3):467-74. PMID: 15389234 [PubMed - indexed for MEDLINE]

Kunadian B, Sutton AG, Vijayalakshmi K, Thornley AR, Gray JC, Grech ED, Hall JA, Harcombe AA, Wright RA, Smith RH, Murphy JJ, Shyam-Sundar A, Stewart MJ, Davies A, Linker NJ, de Belder MA. Early invasive versus conservative treatment in patients with failed fibrinolysis--no late survival benefit: the final analysis of the Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) randomized trial. *Am Heart J*. 2007 May;153(5):763-71.PMID: 17452151 [PubMed - indexed for MEDLINE]

Labinaz M, Kaul P, Harrington RA, Chang WC, Kleiman NS, Simoons ML, Boersma E, Akkerhuis KM, Califf RM, Armstrong PW; PURSUIT investigators. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. *Can J Cardiol*. 2004 Jun;20(8):773-8. PMID: 15229770 [PubMed - indexed for MEDLINE]

McKay RG. "Ischemia-guided" versus "early invasive" strategies in the management of acute coronary syndrome/non-ST-segment elevation myocardial infarction: the interventionalist's perspective. *J Am Coll Cardiol*. 2003 Feb 19;41(4 Suppl S):96S-102S. Review. PMID: 12644347 [PubMed - indexed for MEDLINE]

Nicolau JC, Marin-Neto JA, Giraldez RR, Golin V, Rabelo A Jr, Ramires JA; InTIME-2 investigators. A comparison of percutaneous coronary intervention and surgical revascularization after fibrinolysis for acute myocardial infarction. Insights from the InTIME-2 trial. *Int J Cardiol*. 2007 Apr 4;116(3):383-8. Epub 2006 Oct 17. PMID: 17049642 [PubMed - indexed for MEDLINE]

Other Literature:

Assali AR, Moustapha A, Sdringola S, Denktas AE, Willerson JT, Holmes DR Jr, Smalling RW. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). *Am J Cardiol*. 2006 Sep 15;98(6):729-33. Epub 2006 Jul 26. PMID: 16950172 [PubMed - indexed for MEDLINE]

Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW; CADILLAC Investigators. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). *Am J Cardiol*. 2004 Oct 15;94(8):983-8. PMID: 15476608 [PubMed - indexed for MEDLINE]

De Luca G, Suryapranata H, Grimaldi R, Chiariello M. Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction. *QJM*. 2005 Sep;98(9):633-41. Epub 2005 Jul 22. Review. PMID: 16040669 [PubMed - indexed for MEDLINE]

Horowitz N, Kapeliovich M, Beyar R, Hammerman H. Stenting in acute myocardial infarction: in hospital and long-term follow-up. *Isr Med Assoc J*. 2003 Feb;5(2):107-11. PMID: 12674660 [PubMed - indexed for MEDLINE]

Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation*. 2005 Apr 5;111(13):1611-8. PMID: 15811868 [PubMed - indexed for MEDLINE]

Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP Jr, Cohen DJ, Ho KK, Cutlip DE. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). *Am J Cardiol*. 2006 Sep 15;98(6):718-21. Epub 2006 Jul 13. PMID: 16950169 [PubMed - indexed for MEDLINE]

Mattichak SJ, Harjai KJ, Dutcher JR, Boura JA, Stone G, Cox D, Brodie BR, O'Neill WW, Grines CL. Left ventricular remodeling and systolic deterioration in acute myocardial infarction: findings from the Stent-PAMI Study. *J Interv Cardiol*. 2005 Aug;18(4):255-60. PMID: 16115154 [PubMed - indexed for MEDLINE]

McLellan CS, Le May MR, Labinaz M. Current reperfusion strategies for ST elevation myocardial infarction: a Canadian perspective. *Can J Cardiol*. 2004 Apr;20(5):525-33. Review. PMID: 15100755 [PubMed - indexed for MEDLINE]

Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, Schmitt C, Seyfarth M, Dirschinger J, Schomig A. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. *JAMA*. 2003 Sep 24;290(12):1593-9. PMID: 14506118 [PubMed - indexed for MEDLINE]

Parodi G, Sciagra R, Migliorini A, Memisha G, Moschi G, Valenti R, Pupi A, Antoniucci D. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. *Am Heart J*. 2005 Aug;150(2):220. PMID: 16086921 [PubMed - indexed for MEDLINE]

Quinn MJ, Brener SJ. Early invasive strategies for acute coronary syndromes.
Curr Cardiol Rep. 2002 Jul;4(4):334-40. Review. PMID: 12052273 [PubMed - indexed for MEDLINE]

Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson CM, Cannon CP. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. *Circulation*. 2005 Mar 15;111(10):1217-24. PMID: 15769761 [PubMed - indexed for MEDLINE]

Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, Stone GW, McClure R, Roffi M, Moliterno DJ; TARGET Investigators. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. *Am J Cardiol*. 2006 Jun 1;97(11):1585-90. Epub 2006 Apr 6. PMID: 16728219 [PubMed - indexed for MEDLINE]

Singh M, Williams BA, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Cutlip DE, Holmes DR Jr. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. *J Am Coll Cardiol*. 2006 Jan 3;47(1):34-9. PMID: 16386661 [PubMed - indexed for MEDLINE]

Soares PR, Hueb WA, Lemos PA, Lopes N, Martinez EE, Cesar LA, Oliveira SA, Ramires JA. Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II). *Circulation*. 2006 Jul 4;114(1 Suppl):I420-4. PMID: 16820611 [PubMed - indexed for MEDLINE]

Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL; CADILLAC investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol*. 2005 Jan 1;95(1):1-7. PMID: 15619385 [PubMed - indexed for MEDLINE]

Unger F, Serruys PW, Yacoub MH, Ilsley C, Paulsen PK, Nielsen TT, Eysmann L, Kiemeneij F. Revascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. *J Thorac Cardiovasc Surg*. 2003 Apr;125(4):809-20. PMID: 12698143 [PubMed - indexed for MEDLINE]

Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF. Outcomes of primary percutaneous coronary intervention for acute ST-elevation myocardial infarction in patients aged over 75 years. *Chin Med J (Engl)*. 2006 Jul 20;119(14):1151-6. PMID: 16863605 [PubMed - indexed for MEDLINE]

Zhang Z, Weintraub WS, Mahoney EM, Spertus JA, Booth J, Nugara F, Stables RH, Vaccarino V. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). *Am J Cardiol*. 2004 Feb 15;93(4):404-9. PMID: 14969611 [PubMed - indexed for MEDLINE]

Table 2. Patients without Prior Bypass Surgery

12.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
13.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
14.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
15.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ Intermediate risk-findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
16.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
17.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
18.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ No non-invasive testing performed

19.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed ▪ No further invasive evaluation performed (i.e. FFR, IVUS)
20.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR less than 0.75 and/or IVUS with significant reduction in cross sectional area.
21.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR or IVUS findings do not meet criteria for significant stenosis
22.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
23.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
24.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
25.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Intermediate-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy

26.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
27.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
28.	▪ One vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
29.	▪ One vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy
30.	▪ One vessel disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
31.	▪ One vessel disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy
32.	▪ One vessel disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy

33.	▪ One vessel disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving maximal anti-ischemic medical therapy
34.	▪ Two vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
35.	▪ Two vessel disease involving the proximal LAD ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
36.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
37.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
38.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
39.	▪ Two vessel coronary artery disease involving the proximal LAD ▪ High-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy

40.	▪ Three vessel coronary artery disease (no left main) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy
41.	▪ Three vessel coronary artery disease (no left main) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy
42.	▪ Three vessel coronary artery disease (no left main) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
43.	▪ Three vessel coronary artery disease (no left main) ▪ Intermediate risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
44.	▪ Three vessel coronary artery disease (no left main) ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
45.	▪ Three vessel coronary artery disease (no left main) ▪ High risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
46.	▪ Three vessel coronary artery disease (no left main) ▪ Abnormal LV systolic function
47.	▪ Left Main Stenosis

High Relevance:
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med* 2007;356:1503-16.

Dzavik V, Buller CE, Lamas GA, Rankin JM, Mancini GB, Cantor WJ, Carere RJ, Ross JR, Atchison D, Forman S, Thomas B, Buszman P, Vozzi C, Glanz A, Cohen EA, Meciar P, Devlin G, Mascette A, Sopko G, Knatterud GL, Hochman JS; TOSCA-2 Investigators. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. *Circulation*. 2006 Dec 5;114(23):2449-57. Epub 2006 Nov 14. PMID: 17105848 [PubMed - indexed for MEDLINE]

Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med* 2006;355:2395-407.

Soares PR, Hueb WA, Lemos PA, Lopes N, Martinez EE, Cesar LA, Oliveira SA, Ramires JA. Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II). *Circulation*. 2006 Jul 4;114(1 Suppl):I420-4. PMID: 16820611 [PubMed - indexed for MEDLINE]

Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, Johnson WL, Rutherford BD. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001;38:409-414.

Other Literature:
Agostoni P, Valgimigli M, Biondi-Zoccai GG, Abbate A, Garcia Garcia HM, Anselmi M, Turri M, McFadden EP, Vassanelli C, Serruys PW, Colombo A. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: insights from a systematic overview of randomized trials in light of the drug-eluting stent era. *Am Heart J*. 2006 Mar;151(3):682-9. PMID: 16504632 [PubMed - indexed for MEDLINE]

Blankenship JC, Haldis T, Feit F, Hu T, Kleiman NS, Topol EJ, Lincoff AM; REPLACE-2 Investigators. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). *Am J Cardiol*. 2006 Jun 1;97(11):1591-6. Epub 2006 Apr 7. PMID: 16728220 [PubMed - indexed for MEDLINE]

Chieffo A, Colombo A. Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial? *Nat Clin Pract Cardiovasc Med*. 2005 Aug;2(8):396-400. Review. PMID: 16119701 [PubMed - indexed for MEDLINE]

Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005;95:1088-1091.

Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, Mehran R, Russell ME, Stone GW; TAXUS-IV Investigators. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. *J Am Coll Cardiol*. 2005 Apr 19;45(8):1186-92. PMID: 15837247 [PubMed - indexed for MEDLINE]

Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus eluting stents to prevent restenosis in diabetic patients. *N Engl J Med*. 2005 Aug 18;353(7):663-70. Epub 2005 Aug 16. PMID: 16105990 [PubMed - indexed for MEDLINE]

Haude M, Konorza TF, Kalnins U, Erglis A, Saunamaki K, Glogar HD, Grube E, Gil R, Serra A, Richardt HG, Sick P, Erbel R; Heparin-COAted STents in small coronary arteries Trial Investigators. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. *Circulation*. 2003 Mar 11;107(9):1265-70. PMID: 12628946 [PubMed - indexed for MEDLINE]

Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. *Circulation*. 2004 Feb 10;109(5):634-40. PMID: 14769686 [PubMed - indexed for MEDLINE]

Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. Eur Heart J. 2005;26:2630-2636.

Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP Jr, Cohen DJ, Ho KK, Cutlip DE. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). *Am J Cardiol*. 2006 Sep 15;98(6):718-21. Epub 2006 Jul 13. PMID: 16950169 [PubMed - indexed for MEDLINE]

Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. *Circulation*. 2004 Feb 3;109(4):476-80. Epub 2004 Jan 19. PMID: 14732749 [PubMed - indexed for MEDLINE]

Mehilli J, Kastrati A, Dirschinger J, Dotzer F, Pache J, Hausleiter J, Kramer W, Schuhlen H, Schomig A. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. *Am J Med*. 2002 Jan;112(1):13-8. PMID: 1812401 [PubMed - indexed for MEDLINE]

Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. *Circulation*. 2004 May 18;109(19):2273-8. Epub 2004 May 3. PMID: 15123524 [PubMed - indexed for MEDLINE]

Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, Feringa HH, Dunkelgrun M, de Jaegere P, Maat A, van Sambeek MR, Kertai MD, Boersma E; DECREASE Study Group. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. *J Am Coll Cardiol*. 2007 May 1;49(17):1763-9. Epub 2007 Apr 16. PMID: 17466225 [PubMed - indexed for MEDLINE]

Rahel BM, Suttorp MJ, Laarman GJ, Kiemeneij F, Bal ET, Rensing BJ, Ernst SM, ten Berg JM, Kelder JC, Plokker HW. Primary stenting of occluded native coronary arteries: final results of the Primary Stenting of Occluded Native Coronary Arteries (PRISON) study. *Am Heart J*. 2004 May;147(5):e22. PMID: 15131557 [PubMed - indexed for MEDLINE]

Roffi M, Moliterno DJ; TARGET Investigators. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. *Am J Cardiol*. 2006 Jun 1;97(11):1585-90. Epub 2006 Apr 6. PMID: 16728219 [PubMed - indexed for MEDLINE]

Sawhney N, Moses JW, Leon MB, Kuntz RE, Popma JJ, Bachinsky W, Bass T,DeMaio S, Fry E, Holmes DR Jr, Teirstein PS. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. *Circulation*. 2004 Jul 27;110(4):374-9. Epub 2004 Jul 12. PMID: 15249503 [PubMed - indexed for MEDLINE]

Singh M, Williams BA, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Cutlip DE, Holmes DR Jr. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. *J Am Coll Cardiol*. 2006 Jan 3;47(1):34-9. PMID: 16386661 [PubMed - indexed for MEDLINE]

Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, Stone GW, McClure R, Roffi M, Moliterno DJ; TARGET Investigators. Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. *Am J Cardiol*. 2006 Jun 1;97(11):1585-90. Epub 2006 Apr 6. PMID: 16728219 [PubMed - indexed for MEDLINE]

Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of Quality of Life Benefit after Percutaneous Coronary Intervention. *Circulation* 2004, 110:3789-94

Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL; CADILLAC investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol*. 2005 Jan 1;95(1):1-7. PMID: 15619385 [PubMed - indexed for MEDLINE]

Table 3. Patients with Prior Bypass Surgery (Without Acute Coronary Syndromes)

48.	▪ One or more stenoses in saphenous vein graft(s) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy
49.	▪ One or more stenoses in saphenous vein graft(s) ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy
50.	▪ One or more stenoses in saphenous vein graft(s) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
51.	▪ One or more stenoses in saphenous vein graft(s) ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
52.	▪ One or more stenoses in saphenous vein graft(s) ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
53.	▪ One or more stenoses in saphenous vein graft(s) ▪ High-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy

54.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving no or minimal anti-ischemic medical therapy
55.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Low-risk findings on non-invasive testing including normal LV systolic function ▪ Receiving a course of maximal anti-ischemic medical therapy
56.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
57.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
58.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
59.	▪ One or more lesions in native coronary arteries without bypass grafts ▪ All bypass grafts patent and without significant disease ▪ High-risk finding on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy

High Relevance:

Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP Jr, Cohen DJ, Ho KK, Cutlip DE. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). *Am J Cardiol*. 2006 Sep 15;98(6):718-21. Epub 2006 Jul 13. PMID: 16950169 [PubMed - indexed for MEDLINE]

Tamai H, Berger PB, Tsuchikane E, Suzuki T, Nishikawa H, Aizawa T, Fujii K, Nozaki Y, Kyo E, Kobayashi T, Reiber J, Van Weert AW; MAJIC Investigators. Frequency and time course of reocclusion and restenosis in coronary artery occlusions after balloon angioplasty versus Wiktor stent implantation: results from the Mayo-Japan Investigation for Chronic Total Occlusion (MAJIC) trial. *Am Heart J*. 2004 Mar;147(3):E9. PMID: - TABLE 2 for CTO - but not here14999211 [PubMed - indexed for MEDLINE]

Thiele H, Oettel S, Jacobs S, Hambrecht R, Sick P, Gummert JF, Mohr FW, Schuler G, Falk V. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. *Circulation*. 2005 Nov 29;112(22): (PCI-CABG trial)

Table 4. Method of Revascularization
Advanced Coronary Disease*, CCS Angina Greater than or equal to Class III and/or evidence of intermediate to high risk findings on non-invasive testing

60.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ No diabetes and normal LVEF
61.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ Diabetes
62.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ Depressed LVEF
63.	▪ Three vessel coronary artery disease ▪ No diabetes and normal LVEF
64.	▪ Three vessel coronary artery disease ▪ Diabetes

65.	▪ Three vessel coronary artery disease ▪ Depressed LVEF
66.	▪ Isolated left main stenosis ▪ No diabetes and normal LVEF
67.	▪ Isolated left main stenosis ▪ Diabetes
68.	▪ Isolated left main stenosis ▪ Depressed LVEF
69.	▪ Left main stenosis and additional coronary artery disease ▪ No diabetes and normal LVEF
70.	▪ Left main stenosis and additional coronary artery disease ▪ Diabetes
71.	▪ Left main stenosis and additional coronary artery disease ▪ Depressed LVEF
72.	▪ Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts ▪ LIMA remains patent to a native coronary artery ▪ Depressed LVEF
73.	▪ Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts ▪ LIMA was used as a graft but is no longer functional ▪ Depressed LVEF

High Relevance:

Almeda FQ, Snell RJ. Coronary revascularization in multivessel disease. Which is better, stents or surgery? Postgrad Med. 2005 Dec;118(6):11-7. Review. PMID: 16382760 [PubMed - indexed for MEDLINE]

Aoki J, Ong AT, Arampatzis CA, Vijaykumar M, Rodriguez Granillo GA, Disco CM, Serruys PW. Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial). *Am J Cardiol*. 2004 Sep 1;94(5):627-31. PMID: 15342295 [PubMed - indexed for MEDLINE]

Aoki J, Ong AT, Hoye A, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Lindeboom W, Unger F, Serruys PW. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J. 2005 Aug;26(15):1488-93. Epub 2005 Apr 28. PMID: 15860519 [PubMed - indexed for MEDLINE]

Aziz O, Rao C, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ. 2007 Mar 24;334(7594):617. Epub 2007 Mar 2. PMID: 17337458 [PubMed - indexed for MEDLINE]

Biondi-Zoccai GG, Abbate A, Agostoni P, Parisi Q, Turri M, Anselmi M, Vassanelli C, Zardini P, Biasucci LM. Stenting versus surgical bypass grafting for coronary artery disease: systematic overview and meta-analysis of randomized trials. Ital Heart J. 2003 Apr;4(4):271-80. Review. PMID: 12784781 [PubMed - indexed for MEDLINE]

Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. *Circulation*. 2004 May 18;109(19):2290-5. Epub 2004 Apr 26. PMID: 15117846 [PubMed - indexed for MEDLINE]

Cisowski M, Drzewiecki J, Drzewiecka-Gerber A, Jaklik A, Kruczak W, Szczeklik M, Bochenek A. Primary stenting versus MIDCAB: preliminary report-comparision of two methods of revascularization in single left anterior descending coronary artery stenosis. *Ann Thorac Surg*. 2002 Oct;74(4):S1334-9. PMID: 12400812 [PubMed - indexed for MEDLINE]

Diegeler A, Thiele H, Falk V, Hambrecht R, Spyrantis N, Sick P, Diederich KW, Mohr FW, Schuler G. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. *N Engl J Med*. 2002 Aug 22;347(8):561-6. PMID: 12192015 [PubMed - indexed for MEDLINE]

Drenth DJ, Veeger NJ, Grandjean JG, Mariani MA, van Boven AJ, Boonstra PW. Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? *Eur J Cardiothorac Surg*. 2004 Apr;25(4):567-71. PMID: 15037273 [PubMed - indexed for MEDLINE]

Drenth DJ, Veeger NJ, Winter JB, Grandjean JG, Mariani MA, Boven van AJ, Boonstra PW. A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. *J Am Coll Cardiol*. 2002 Dec 4;40(11):1955-60. PMID: 12475455 [PubMed - indexed for MEDLINE]

Drenth DJ, Winter JB, Veeger NJ, Monnink SH, van Boven AJ, Grandjean JG, Mariani MA, Boonstra PW. Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. *J Thorac Cardiovasc Surg*. 2002 Jul;124(1):130-5. PMID: 12091818 [PubMed - indexed for MEDLINE]

de Feyter PJ, Serruys PW, Unger F, Beyar R, de Valk V, Milo S, Simon R, Regensburger D, Crean PA, McGovern E, van den Heuvel P, van Cauwelaert C, Penn I, Tyers GF, Lindeboom W. Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. Circulation. 2002 May 21;105(20):2367-72. PMID: 12021222 [PubMed - indexed for MEDLINE]

Diegeler A, Thiele H, Falk V, Hambrecht R, Spyrantis N, Sick P, Diederich KW, Mohr FW, Schuler G. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med. 2002 Aug 22;347(8):561-6. PMID: 12192015 [PubMed - indexed for MEDLINE]

Drenth DJ, Veeger NJ, Grandjean JG, Mariani MA, van Boven AJ, Boonstra PW. Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? *Eur J Cardiothorac Surg*. 2004 Apr;25(4):567-71. PMID: 15037273 [PubMed - indexed for MEDLINE]

Drenth DJ, Winter JB, Veeger NJ, Monnink SH, van Boven AJ, Grandjean JG, Mariani MA, Boonstra PW. Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. J Thorac Cardiovasc Surg. 2002 Jul;124(1):130-5. PMID: 12091818 [PubMed - indexed for MEDLINE]

Gruberg L, Mercado N, Milo S, Boersma E, Disco C, van Es GA, Lemos PA, Ben Tzvi M, Wijns W, Unger F, Beyar R, Serruys PW; Arterial Revascularization Therapies Study Investigators. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II? Am J Cardiol. 2005 Feb 15;95(4):439-44. PMID: 15695125 [PubMed - indexed for MEDLINE]

Gruberg L, Milo S, Ben Tzvi M, Lotan C, Merin G, Braun S, Mohr R, Tzivoni D, Bitran D, Beyar R; Israel Arterial Revascularization Therapy Study Group. Comparison of bypass surgery and stenting for the treatment of multivessel disease: results from the ARTS trial in Israel. *Isr Med Assoc J*. 2003 Aug;5(8):539-42. PMID: 12929288 [PubMed - indexed for MEDLINE]

Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med*. 2005 May 26;352(21):2174-83. PMID: 15917382 [PubMed - indexed for MEDLINE]

Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. *J Am Coll Cardiol*. 2003 Apr 16;41(8):1293-304. PMID: 12706924 [PubMed - indexed for MEDLINE]

Hong SJ, Lim DS, Seo HS, Kim YH, Shim WJ, Park CG, Oh DJ, Ro YM. Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. *Catheter Cardiovasc Interv*. 2005 Jan;64(1):75-81. [PMID: 15619278 [PubMed - indexed for MEDLINE]

Hueb W, Soares PR, Gersh BJ, CÃ©sar LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JA. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J. *Am. Coll. Cardiol*. 2004 May 19;43(10):1743-51.

Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2007 Mar 6;115(9):1082-9. PMID: 17339566 [PubMed - indexed for MEDLINE]

Kappetein AP, Dawkins KD, Mohr FW, Morice MC, Mack MJ, Russell ME, Pomar J, Serruys PW. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg. 2006 Apr;29(4):486-91. Epub 2006 Feb 23. PMID: 16497510 [PubMed - indexed for MEDLINE]

Kapur A, Malik IS, Bagger JP, Anderson JR, Kooner JS, Thomas M, Punjabi P, Mayet J, Millane T, Goedicke J, Jamrozik K, de Belder MA, Hall RJ, Beatt KJ. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. *Am Heart J*. 2005 Jan;149(1):13-9. PMID: 15660030 [PubMed - indexed for MEDLINE]

Kaul S, Shah PK, Diamond GA. As time goes by: current status and future directions in the controversy over stenting. *J Am Coll Cardiol.* 2007 Jul 10;50(2):128-37. Epub 2007 May 22. PMID: 17616296 [PubMed - indexed for MEDLINE]

Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx B; Arterial Revascularization Therapy Study (ARTS) Investigators. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation. 2004 Mar 9;109(9):1114-20. Epub 2004 Mar 1. PMID: 14993134 [PubMed - indexed for MEDLINE]

Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, Helm RE, Kellett MA, Dauerman HL, Dacey LJ, Silver MT, VerLee PN, Weldner PW, Hettleman BD, Olmstead EM, Piper WD, O'Connor GT; Northern New England Cardiovascular Disease Study Group. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation. 2005 Aug 30;112(9 Suppl):I371-6. PMID: 16159849 [PubMed - indexed for MEDLINE]

Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, O'Neill WW, Rodriguez A, Lemos PA, Hueb WA, Gersh BJ, Booth J, Boersma E. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg. 2005 Aug;130(2):512-9. PMID: 16077421 [PubMed - indexed for MEDLINE]

Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, Esposito R, Ramanathan K, Weiman D, Saucedo J, Antakli T, Paramesh V, Pett S, Vernon S, Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D, Barbiere C, Lewis D; Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). *J Am Coll Cardiol*. 2001 Jul;38(1):143-9. PMID: 11451264 [PubMed - indexed for MEDLINE]

Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, Esposito R, Ramanathan KB, Weiman D, Talley JD, Saucedo J, Antakli T, Paramesh V, Pett S, Vernon S, Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D, Barbiere C, Lewis D; VA AWESOME (Angina With Extremely Serious Operative Mortality Evaluation) Multicenter Registry. Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial. *J Am Coll Cardiol*. 2002 Jan 16;39(2):266-73. PMID: 11788218 [PubMed - indexed for MEDLINE]

Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR Jr, Mack MJ, van den Brand M, Morel MA, van Es GA, Kleijne J, Koglin J, Russell ME. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006 Jun;151(6):1194-204. PMID: 16781219 [PubMed - indexed for MEDLINE]

Pohl T, Giehrl W, Reichart B, Kupatt C, Raake P, Paul S, Reichenspurner H, Steinbeck G, Boekstegers P. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv. 2004 Jul;62(3):323-30. PMID: 15224298 [Pubmed - indexed for MEDLINE]

Rao C, Aziz O, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. *BMJ*. 2007 Mar 24;334(7594):621. Epub 2007 Mar 2. PMID: 17337457 [PubMed - indexed for MEDLINE]

Reeves BC, Angelini GD, Bryan AJ, Taylor FC, Cripps T, Spyt TJ, Samani NJ, Roberts JA, Jacklin P, Seehra HK, Culliford LA, Keenan DJ, Rowlands DJ, Clarke B, Stanbridge R, Foale R. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. *Health Technol Assess*. 2004 Apr;8(16):1-43.

Reul RM. Will drug-eluting stents replace coronary artery bypass surgery? Tex Heart Inst J. 2005;32(3):323-30. Review. PMID: 16392212 [PubMed - indexed for MEDLINE]

Rodriguez AE, Baldi J, Fernandez Pereira C, Navia J, Rodriguez Alemparte M, Delacasa A, Vigo F, Vogel D, O'Neill W, Palacios IF; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005 Aug 16;46(4):582-8. PMID: 16098419 [PubMed - indexed for MEDLINE]

Rodriguez A, Rodriguez Alemparte M, Baldi J, Navia J, Delacasa A, Vogel D, Oliveri R, Fernandez Pereira C, Bernardi V, O'Neill W, Palacios IF. Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. Heart. 2003 Feb;89(2):184-8. PMID: 12527674 [PubMed - indexed for MEDLINE]

Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W, Hlatky M, Sethi G, Morrison DA; Department of Veterans Affairs Angina With Extremely Serious Operative Mortality (AWESOME) Investigators. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. *J Am Coll Cardiol*. 2003 May 21;41(10):1732-8. PMID: 12767656 [PubMed - indexed for MEDLINE]

Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. *J Am Coll Cardiol*. 2005 Aug 16;46(4):575-81. PMID: 16098418 [PubMed - indexed for MEDLINE]

Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, Lilly RE, Sketch MH, Peterson ED, Jones RH. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. *Ann Thorac Surg*. 2006 Oct;82(4):1420-8; discussion 1428-9. PMID: 16996946 [PubMed - indexed for MEDLINE]

SOS Investigators, Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. *Lancet*. 2002 Sep 28;360(9338):965-70

Soares PR, Hueb WA, Lemos PA, Lopes N, Martinez EE, Cesar LA, Oliveira SA, Ramires JA. Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II). *Circulation*. 2006 Jul 4;114(1 Suppl):I420-4. PMID: 16820611 [PubMed - indexed for MEDLINE]

Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Lyttle C, Hynes DM, Henderson WG; Investigators of Veterans Affairs Cooperative Studies Program #385 (AWESOME: Angina With Extremely Serious Operative Mortality Evaluation). Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. *Circulation*. 2006 Sep 19;114(12):1251-7. Epub 2006 Sep 11. PMID: 16966588 [PubMed - indexed for MEDLINE]

Thiele H, Oettel S, Jacobs S, Hambrecht R, Sick P, Gummert JF, Mohr FW, Schuler G, Falk V. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. *Circulation*. 2005 Nov 29;112(22):3445-50. PMID: 16316966 [PubMed - indexed for MEDLINE]

Versaci F, Gaspardone A, Tomai F, Proietti I, Ghini AS, Altamura L, Ando G, Crea F, Gioffre PA, Chiariello L. A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery: five year clinical follow up. *Heart*. 2004 Jun;90(6):672-5. PMID: 15145877 [PubMed - indexed for MEDLINE]

Unger F, Serruys PW, Yacoub MH, Ilsley C, Paulsen PK, Nielsen TT, Eysmann L, Kiemeneij F. Revascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. J Thorac Cardiovasc Surg. 2003 Apr;125(4):809-20. PMID: 12698143 [PubMed - indexed for MEDLINE]

Wahrborg P, Booth JE, Clayton T, Nugara F, Pepper J, Weintraub WS, Sigwart U, Stables RH; SoS Neuropsychology Substudy Investigators. Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial. Circulation. 2004 Nov 30;110(22):3411-7. Epub 2004 Nov 22. PMID: 15557380 [PubMed - indexed for MEDLINE]

Yee KM, Buller CE, Catellier D, Cohen EA, Carere RC, Anderson T, Berger P, Burton JR, Barbeau G, Teo KK, Dzavik V; Total Occlusion Study of Canada (TOSCA) Investigators. Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing

percutaneous coronary intervention of nonacute occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). *Catheter Cardiovasc Interv*. 2005 Oct;66(2):178-84. PMID: 15977265 [PubMed - indexed for MEDLINE]

Yock CA, Boothroyd DB, Owens DK, Garber AM, Hlatky MA. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med. 2003 Oct 1;115(5):382-9. PMID: 14553874 [PubMed - indexed for MEDLINE]

Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WS. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation. 2003 Oct 7;108(14):1694-700. Epub 2003 Sep 15. PMID: 12975252 [PubMed - indexed for MEDLINE]

Zhang Z, Spertus JA, Mahoney EM, Booth J, Nugara F, Stables RH, Weintraub WS. The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial. Am Heart J. 2005 Jul;150(1):175-81. PMID: 16084166 [PubMed - indexed for MEDLINE]

Zhang Z, Weintraub WS, Mahoney EM, Spertus JA, Booth J, Nugara F, Stables RH, Vaccarino V. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). Am J Cardiol. 2004 Feb 15;93(4):404-9. PMID: 14969611 [PubMed - indexed for MEDLINE]

Table 1. Patients with Acute Coronary Syndromes

Indication	Guideline Recommendations
1. ▪ STEMI ▪ Less than or equal to 12 hours from onset of symptoms ▪ Revascularization of the culprit artery	
	STEMI (p. e24) **Prehospital Destination Protocols** **Class I** Patients with STEMI who have contraindications to fibrinolytic therapy should be brought immediately or secondarily transferred promptly (i.e., primary receiving hospital door-to-departure time less than 30 minutes) to facilities capable of cardiac catheterization and rapid revascularization (PCI or CABG). *(Level of Evidence B)* ***STEMI (p. e129)*** **Coronary Artery Bypass Graft Surgery for Recurrent Ischemia After STEMI** **Class I** Urgent CABG is indicated if the coronary angiogram reveals anatomy that is unsuitable for PCI. *(Level of Evidence: B)* ***PCI (p. e43)*** **Patients With STEMI: General and Specific Considerations** **Class I** If immediately available, primary PCI should be performed in patients with STEMI (including true posterior MI) or MI with new or presumably new left bundle- branch block who can undergo PCI of the infarct artery within 12 hours of symptom onset, if performed in a timely fashion (balloon inflation goal within 90 minutes of presentation) by persons skilled in the procedure (individuals who perform more than 75 PCI procedures per year, ideally at least 11 PCIs per year for STEMI). The procedure should be supported by experienced personnel in an appropriate laboratory environment (one that performs more than 200 PCI procedures per year, of which at least 36 are primary PCI for STEMI, and that has cardiac surgery capability). *(Level of Evidence: A)* Primary PCI should be performed as quickly as possible, with a goal of a medical contact-to-balloon or door-to-balloon time within 90 minutes. *(Level of Evidence: B)* ***PCI (p. e49)*** **PCI in Fibrinolytic-Ineligible Patients** **Class I** Primary PCI should be performed in fibrinolytic-ineligible patients who present with STEMI within 12 hours of symptom onset. *(Level of Evidence C)* ***CABG (P. e281)*** **ST-Segment Elevation MI (STEMI)** CABG may be performed as primary reperfusion in patients who have suitable anatomy and who are not candidates for or who have had failed fibrinolysis/PCI and who are in the early hours (6 to 12 hours) of evolving STEMI. *(Level of Evidence: B)*

2.
- STEMI
- Onset of symptoms within the prior 12 to 24 hours
- Severe HF, persistent ischemic symptoms or hemodynamic or electrical instability present

STEMI (p. e129)
Coronary Artery Bypass Graft Surgery for Recurrent Ischemia After STEMI
Class I
Urgent CABG is indicated if the coronary angiogram reveals anatomy that is unsuitable for PCI. *(Level of Evidence: B)*

CABG (p. e281)
ST-Segment Elevation MI (STEMI)
Class I
Emergency or urgent CABG in patients with STEMI should be undertaken in the following circumstances:

a. Persistent or recurrent ischemia refractory to medical therapy in patients who have coronary anatomy suitable for surgery, who have a significant area of myocardium at risk, and who are not candidates for PCI. *(Level of Evidence: B)*
b. Cardiogenic shock in patients less than 75 years old with ST-segment elevation or left bundle bundle-branch block or posterior MI who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of patient's wishes or contraindications/ unsuitability for further invasive care *(Level of Evidence: A)*

PCI (p. e43)
Patients With STEMI: General and Specific Considerations
Class I
Primary PCI should be performed for patients less than 75 years old with ST elevation or presumably new left bundle-branch block who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. *(Level of Evidence: A)*

3.
- STEMI
- Greater than 12 hours from symptom onset
- Asymptomatic; no hemodynamic instability and no electrical instability

PCI (p. e43)
Patients With STEMI: General and Specific Considerations
Class III
Primary PCI should not be performed in asymptomatic patients more than 12 hours after onset of STEMI who are hemodynamically and electrically stable. *(Level of Evidence: C)*

CABG (p. e281)
Class III
- Emergency CABG should not be performed in patients with persistent angina and a small area of myocardium at risk who are hemodynamically stable. *(Level of Evidence: C)*
- Emergency CABG should not be performed in patients with successful epicardial reperfusion but unsuccessful microvascular reperfusion. *(Level of Evidence: C)*

4.
- STEMI with presumed successful treatment with fibrinolysis
- Evidence of HF, recurrent ischemia, or unstable ventricular arrhythmias present
- One vessel coronary artery disease, presumed to be the culprit artery

STEMI (p. e63)
Rescue PCI
Class I
- Rescue PCI should be performed in patients less than 75 years old with ST elevation or LBBB who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. *(Level of Evidence: B)*
- Rescue PCI should be performed in patients with severe CHF and/or pulmonary edema (Killip class 3) and onset of symptoms within 12 hours. *(Level of Evidence: B)*

STEMI (p. e65)
Percutaneous Coronary Intervention After Fibrinolysis
Class I
In patients whose anatomy is suitable, PCI should be performed for moderate or severe spontaneous or provocable myocardial ischemia during recovery from STEMI. *(Level of Evidence: B)*

Class IIa
It is reasonable to perform routine PCI in patients with LVEF less than or equal to 0.40, CHF, or serious ventricular arrhythmias. *(Level of Evidence: C)*

STEMI (p. e124-e125)
Recurrent Ischemia/Infarction
Class I
- In addition to escalation of medical therapy, patients with recurrent ischemic-type chest discomfort and signs of hemodynamic instability, poor LV function, or a large area of myocardium at risk should be referred urgently for cardiac catheterization and undergo revascularization as needed. Insertion of an IABP should also be considered. *(Level of Evidence: C)*
- Patients with recurrent ischemic-type chest discomfort who are considered candidates for revascularization should undergo coronary arteriography and PCI or CABG as dictated by coronary anatomy. *(Level of Evidence: B)*

PCI (p. e53)
PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Class I
- In patients whose anatomy is suitable, PCI should be performed when there is objective evidence of recurrent MI. *(Level of Evidence: C)*
- In patients whose anatomy is suitable, PCI should be performed for moderate or severe spontaneous or provocable myocardial ischemia during recovery from STEMI. *(Level of Evidence: B)*
- In patients whose anatomy is suitable, PCI should be performed for cardiogenic shock or hemodynamic instability. *(Level of Evidence: B)*

Class IIa
- It is reasonable to perform routine PCI in patients with LV ejection fraction less than or equal to 0.40, HF, or serious ventricular arrhythmias. *(Level of Evidence: C)*
- It is reasonable to perform PCI when there is documented clinical heart failure during the acute episode, even though subsequent evaluation shows preserved LV function (LV ejection fraction greater than 0.40). *(Level of Evidence: C)*

Class IIb
PCI might be considered as part of an invasive strategy after fibrinolytic therapy. *(Level of Evidence: C)*

CABG (p. e281)
ST-Segment Elevation MI (STEMI)
Class I
Emergency or urgent CABG in patients with STEMI should be undertaken in the following circumstances:
a. Failed angioplasty with persistent pain or hemodynamic instability in patients with coronary anatomy suitable for surgery. *(Level of Evidence: B)*
b. Persistent or recurrent ischemia refractory to medical therapy in patients who have coronary anatomy suitable for

surgery, who have a significant area of myocardium at risk, and who are not candidates for PCI. *(Level of Evidence: B*)
c. At the time of surgical repair of postinfarction ventricular septal rupture or mitral valve insufficiency. *(Level of Evidence: B)*
d. Cardiogenic shock in patients less than 75 years old with ST-segment elevation or left bundle branch block or posterior MI who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of patient's wishes or contraindications/unsuitability for further invasive care *(Level of Evidence: A)*
e. Life-threatening ventricular arrhythmias in the presence of greater than or equal to 50% left main stenosis and/or triple-vessel disease *(Level of Evidence: B)*

Class IIa

- CABG may be performed as primary reperfusion in patients who have suitable anatomy and who are not candidates for or who have had failed fibrinolysis/PCI and who are in the early hours (6 to 12 hours) of evolving STEMI. (Level of Evidence: B)
- In patients who have had an STEMI or NSTEMI, CABG mortality is elevated for the first 3 to 7 days after infarction, and the benefit of revascularization must be balanced against this increased risk. Beyond 7 days after infarction, the criteria for revascularization described in previous sections are applicable. (Level of Evidence: B)

5.

- STEMI with presumed successful treatment with fibrinolysis
- Asymptomatic; no HF or no recurrent ischemic symptoms, or no unstable ventricular arrhythmias
- Normal LVEF
- One vessel coronary artery disease presumed to be the culprit artery

STEMI (p. e65)
Percutaneous Coronary Intervention After Fibrinolysis
Class IIb
Routine PCI might be considered as part of an invasive strategy after fibrinolytic therapy. *(Level of Evidence: B)*

PCI (p. e53)
PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Class IIb
PCI might be considered as part of an invasive strategy after fibrinolytic therapy. *(Level of Evidence: C)*

6.

- STEMI with presumed successful treatment with fibrinolysis
- Asymptomatic; no HF, no recurrent ischemic symptoms, or no unstable ventricular arrhythmias at time of presentation
- Depressed LVEF
- Three vessel coronary artery disease
- Elective/semi-elective revascularization

STEMI (p. e65)
Percutaneous Coronary Intervention After Fibrinolysis
Class IIa
It is reasonable to perform routine PCI in patients with LVEF less than or equal to 0.40, CHF, or serious ventricular arrhythmias. *(Level of Evidence: C)*

PCI (p. e53)
PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Class IIa
It is reasonable to perform routine PCI in patients with LV ejection fraction less than or equal to 0.40, HF, or serious ventricular arrhythmias. *(Level of Evidence: C)*

CABG (p. e281)
ST-Segment Elevation MI (STEMI)
Class IIa
In patients who have had an STEMI or NSTEMI, CABG mortality is elevated for the first 3 to 7 days after infarction, and the benefit of revascularization must be balanced against this increased risk. Beyond 7 days after infarction, the criteria for revascularization described in previous sections are applicable. *(Level of Evidence: B)*

7.

- STEMI with successful treatment of the culprit artery by primary PCI or fibrinolysis.
- Asymptomatic; no HF, no evidence of recurrent or provocable ischemia or no unstable ventricular arrhythmias during index hospitalization
- Normal LVEF
- Revascularization of a non-infarct related artery during index hospitalization

STEMI (p. e56)
Primary PCI
Class III
PCI should not be performed in a noninfarct artery at the time of primary PCI in patients without hemodynamic compromise. *(Level of Evidence: C)*

STEMI (p. e65)
Percutaneous Coronary Intervention After Fibrinolysis
Class IIb
Routine PCI might be considered as part of an invasive strategy after fibrinolytic therapy. *(Level of Evidence: B)*

PCI (p. e43)
Patients With STEMI – General and Specific Conditions
Class III
Elective PCI should not be performed in a noninfarct-related artery at the time of primary PCI of the infarct related artery in patients without hemodynamic compromise. *(Level of Evidence: C)*

CABG (p. e281)
ST-Segment Elevation MI (STEMI)
Class IIa
In patients who have had an STEMI or NSTEMI, CABG mortality is elevated for the first 3 to 7 days after infarction, and the benefit of revascularization must be balanced against this increased risk. Beyond 7 days after infarction, the criteria for revascularization described in previous sections are applicable. *(Level of Evidence: B)*

Class III
Emergency CABG should not be performed in patients with successful epicardial reperfusion but unsuccessful microvascular reperfusion. *(Level of Evidence: C)*

8.
- STEMI or NSTEMI and successful PCI of culprit artery during index hospitalization
- Symptoms of recurrent myocardial ischemia and/or high-risk findings on non-invasive stress testing performed after index hospitalization
- Revascularization of one or more additional coronary arteries

STEMI (p. e130)
Elective CABG After STEMI in Patients With Angina
Class I
Coronary artery bypass graft surgery is beneficial for patients with stable angina who have 1- or 2-vessel coronary disease without significant proximal LAD stenosis but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: B)*

PCI (p.e41)
Patients With CCS Class III Angina
Class IIa
- It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. *(Level of Evidence: B)*
- It is reasonable that PCI be performed in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy with focal saphenous vein graft lesions or multiple stenoses who are poor candidates for reoperative surgery. *(Level of Evidence: C)*
- Use of PCI is reasonable in patients with CCS class III angina with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG. *(Level of Evidence: B)*

Class IIb
- PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. *(Level of Evidence: B)*
- PCI may be considered in patients with CCS class III angina and no evidence of ischemia on noninvasive testing or who are undergoing medical therapy and have 2- or 3-vessel CAD with significant proximal LAD CAD and treated diabetes or abnormal LV function. *(Level of Evidence: B)*

CABG (p. e281)
ST-Segment Elevation MI (STEMI)
Class IIa
In patients who have had an STEMI or NSTEMI, CABG mortality is elevated for the first 3 to 7 days after infarction, and the benefit of revascularization must be balanced against this increased risk. Beyond 7 days after infarction, the criteria for revascularization described in previous sections are applicable. *(Level of Evidence: B)*

Class III
- Emergency CABG should not be performed in patients with persistent angina and a small area of myocardium at risk who are hemodynamically stable. (Level of Evidence: C)
- Emergency CABG should not be performed in patients with successful epicardial reperfusion but unsuccessful microvascular reperfusion. (Level of Evidence: C)

9. ▪ UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI
▪ Revascularization of the presumed culprit artery

UA/NSTEMI (p. e83)
Recommendations for PCI
Class I
- An early invasive PCI strategy is indicated for patients with UA/NSTEMI who have no serious comorbidity and who have coronary lesions amenable to PCI and any of the high-risk features listed in Section 3.3. (See Section 3.3 for specific recommendations and their Level of Evidence.)
- Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
- Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)

Class IIa
- Percutaneous coronary intervention (or CABG) is reasonable for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)
- Percutaneous coronary intervention (or CABG) can be beneficial compared with medical therapy for UA/NSTEMI patients with 1-vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)
- Use of PCI is reasonable in patients with UA/NSTEMI with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG or who require emergent intervention at angiography for hemodynamic instability. (Level of Evidence: B)

Recommendations for CABG
Class I
- Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients with significant left main CAD (greater than 50% stenosis). (Level of Evidence: A)
- Coronary artery bypass graft surgery is recommended for UA/ NSTEMI patients with 3-vessel disease; the survival benefit is greater in patients with abnormal LV function (LVEF less than 0.50). (Level of Evidence: A)
- Coronary artery bypass graft surgery is recommended for UA/ NSTEMI patients with 2-vessel disease with significant proximal left anterior descending CAD and either abnormal LV function (LVEF less than 0.50) or ischemia on noninvasive testing. (Level of Evidence: A)
- Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients in whom percutaneous revascularization is not optimal or possible and who have ongoing ischemia not responsive to maximal nonsurgical therapy. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)

Class IIa
- For patients with UA/NSTEMI and multivessel disease, CABG with use of the internal mammary arteries can be beneficial over PCI in patients being treated for diabetes. (Level of Evidence: B)
- It is reasonable to perform CABG with the internal mammary artery for UA/NSTEMI patients with multivessel disease and treated diabetes mellitus. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) is reasonable for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) can be beneficial compared with medical therapy for UA/NSTEMI patients with 1-vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)
- Coronary artery bypass surgery (or PCI with stenting) is reasonable for patients with multivessel disease and symptomatic myocardial ischemia. (Level of Evidence: B)

Class IIb
Percutaneous coronary intervention may be considered for UA/NSTEMI patients who are undergoing medical therapy who

have 2-or 3-vessel disease, significant proximal left anterior descending CAD, and treated diabetes or abnormal LV function, with anatomy suitable for catheter-based therapy. *(Level of Evidence: B)*

PCI (p. e41-42)
Patients With UA/NSTEMI
Class I
An early invasive PCI strategy is indicated for patients with UA/NSTEMI who have no serious co-morbidity and coronary lesions amenable to PCI. Patients must have any of the following high-risk features:

a. Recurrent ischemia despite intensive anti-ischemic therapy. *(Level of Evidence: A)*
b. Elevated troponin level. *(Level of Evidence: A)*
c. New ST-segment depression. *(Level of Evidence: A)*
d. HF symptoms or new or worsening MR. *(Level of Evidence: A)*
e. Depressed LV systolic function. *(Level of Evidence: A)*
f. Hemodynamic instability. *(Level of Evidence: A)*
g. Sustained ventricular tachycardia. *(Level of Evidence: A)*
h. PCI within 6 months. *(Level of Evidence: A)*
i. Prior CABG. *(Level of Evidence: A)*

Class IIa
Use of PCI is reasonable in patients with UA/NSTEMI with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG. *(Level of Evidence: B)*

Class IIb
PCI may be considered in patients with UA/NSTEMI who are undergoing medical therapy who have 2- or 3-vessel disease, significant proximal LAD CAD, and treated diabetes or abnormal LV function. *(Level of Evidence: B)*

CABG (p. e280-181)
Unstable Angina/Non–ST-Segment Elevation MI (NSTEMI)
Class I

- CABG should be performed for patients with unstable angina/NSTEMI with significant left main coronary artery stenosis. (Level of Evidence: A)
- CABG should be performed for patients with unstable angina/NSTEMI who have left main equivalent: significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. (Level of Evidence: A)

Class IIa
CABG is probably indicated for patients with unstable angina/NSTEMI who have proximal LAD stenosis with 1- or 2-vessel disease. *(Level of Evidence: A)*

10.
- UA/NSTEMI and high-risk features for short term risk of death or nonfatal MI
- Revascularization of multiple coronary arteries when the culprit artery cannot be clearly determined

UA/NSTEMI (p. e83)

Recommendations for PCI

Class I

- An early invasive PCI strategy is indicated for patients with UA/NSTEMI who have no serious comorbidity and who have coronary lesions amenable to PCI and any of the high-risk features listed in Section 3.3. (See Section 3.3 for specific recommendations and their Level of Evidence.)
- Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
- Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A*)*

Class IIa

- Percutaneous coronary intervention (or CABG) is reasonable for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)
- Percutaneous coronary intervention (or CABG) can be beneficial compared with medical therapy for UA/NSTEMI patients with 1-vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)
- Use of PCI is reasonable in patients with UA/NSTEMI with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG or who require emergent intervention at angiography for hemodynamic instability. (Level of Evidence: B)

Recommendations for CABG

Class I

- Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients with significant left main CAD (greater than 50% stenosis). (Level of Evidence: A)
- Coronary artery bypass graft surgery is recommended for UA/ NSTEMI patients with 3-vessel disease; the survival benefit is greater in patients with abnormal LV function (LVEF less than 0.50). (Level of Evidence: A)
- Coronary artery bypass graft surgery is recommended for UA/ NSTEMI patients with 2-vessel disease with significant proximal left anterior descending CAD and either abnormal LV function (LVEF less than 0.50) or ischemia on noninvasive testing. (Level of Evidence: A)
- Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients in whom percutaneous revascularization is not optimal or possible and who have ongoing ischemia not responsive to maximal nonsurgical therapy. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)

Class IIa

- For patients with UA/NSTEMI and multivessel disease, CABG with use of the internal mammary arteries can be beneficial over PCI in patients being treated for diabetes. (Level of Evidence: B)
- It is reasonable to perform CABG with the internal mammary artery for UA/NSTEMI patients with multivessel disease and treated diabetes mellitus. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) is reasonable for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)
- Coronary artery bypass graft surgery (or PCI) can be beneficial compared with medical therapy for UA/NSTEMI patients with 1-vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)
- Coronary artery bypass surgery (or PCI with stenting) is reasonable for patients with multivessel disease and symptomatic myocardial ischemia. (Level of Evidence: B)

Class IIb

Percutaneous coronary intervention may be considered for UA/NSTEMI patients who are undergoing medical therapy who

have 2-or 3-vessel disease, significant proximal left anterior descending CAD, and treated diabetes or abnormal LV function, with anatomy suitable for catheter-based therapy. *(Level of Evidence: B)*

PCI (p. e42)
Patients With UA/NSTEMI
Class IIb
PCI may be considered in patients with UA/NSTEMI who are undergoing medical therapy who have 2- or 3-vessel disease, significant proximal LAD CAD, and treated diabetes or abnormal LV function. *(Level of Evidence: B)*

CABG (p. e280-181)
Unstable Angina/Non–ST-Segment Elevation MI (NSTEMI)
Class I
CABG should be performed for patients with unstable angina/NSTEMI with significant left main coronary artery stenosis. *(Level of Evidence: A)*
CABG should be performed for patients with unstable angina/NSTEMI who have left main equivalent: significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*

Class IIa
CABG is probably indicated for patients with unstable angina/NSTEMI who have proximal LAD stenosis with 1- or 2-vessel disease. *(Level of Evidence: A)*

11.
- Patients with acute myocardial infarction (STEMI or NSTEMI)
- Evidence of cardiogenic shock
- Revascularization of one or more coronary arteries

STEMI (p. e64)
PCI for Cardiogenic Shock
Class I
Primary PCI is recommended for patients less than 75 years old with ST elevation or LBBB who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. *(Level of Evidence: A)*

STEMI (p. e66)
Acute Surgical Reperfusion
Class I
Emergency or urgent CABG in patients with STEMI should be undertaken in the following circumstances:
Cardiogenic shock in patients less than 75 years old with ST elevation or left bundle branch block or posterior MI who develop shock within 36 hours of STEMI, have severe multivessel or left main disease, and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of the patient's wishes or contraindications/ unsuitability for further invasive care *(Level of Evidence: A)*

STEMI (p. e98)
Cardiogenic Shock
Class I
Early revascularization, either PCI or CABG, is recommended for patients less than 75 years old with ST elevation or LBBB who develop shock within 36 hours of MI and who are suitable for revascularization that can be performed within 18 hours of shock unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. *(Level of Evidence: A)*

Class IIa
Early revascularization, either PCI or CABG, is reasonable for selected patients 75 years or older with ST elevation or LBBB who develop shock within 36 hours of MI and who are suitable for revascularization that can be performed within 18 hours of shock. Patients with good prior functional status who agree to invasive care may be selected for such an invasive strategy. *(Level of Evidence: B)*

PCI (p. e54)
PCI for Cardiogenic Shock
Class I
Primary PCI is recommended for patients less than 75 years old with ST elevation or left bundle-branch block who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. *(Level of Evidence: A)*

CABG (p. e281)
ST-Segment Elevation MI (STEMI)
Class I
Cardiogenic shock in patients less than 75 years old with ST-segment elevation or left bundle branch block or posterior MI who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of patient's wishes or contraindications/unsuitability for further invasive care *(Level of Evidence: A)*

Table 2. Patients without Prior Bypass Surgery

12.
- One or two vessel coronary artery disease without involvement of proximal LAD
- Low-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class III
Use of PCI or CABG for patients with one- or two vessel CAD without significant proximal LAD CAD, who have mild symptoms that are unlikely due to myocardial ischemia, or who have not received an adequate trial of medical therapy and
a. have only a small area of viable myocardium or
b. have no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class III
- Use of PCI or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD and
  a. only a small area of viable myocardium or
  b. no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*
- Use of PCI or CABG for patients with borderline coronary stenoses (50% to 60% diameter in locations other than the left main coronary artery) and no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIb
CABG may be considered for patients with asymptomatic or mild angina who have 1- or 2-vessel disease not involving the proximal LAD (If a large area of viable myocardium and high-risk criteria are met on noninvasive testing, this recommendation becomes (Class I). *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class III
CABG is not recommended for patients with stable angina who have 1- or 2-vessel disease not involving significant proximal LAD stenosis, patients who have mild symptoms that are unlikely due to myocardial ischemia, or patients who have not received an adequate trial of medical therapy and
a. have only a small area of viable myocardium or *(Level of Evidence: B)*
b. have no demonstrable ischemia on noninvasive testing. *(Level of Evidence: B)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class III
PCI is not recommended in patients with asymptomatic ischemia or CCS class I or II angina who do not meet the criteria as listed under the class II recommendations or who have 1 or more of the following:
a. Only a small area of viable myocardium at risk
b. No objective evidence of ischemia.
c. Lesions that have a low likelihood of successful dilatation.
d. Mild symptoms that are unlikely to be due to myocardial ischemia.
e. Factors associated with increased risk of morbidity or mortality.
f. Left main disease and eligibility for CABG.
g. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*

13.
- One or two vessel coronary artery disease without involvement of proximal LAD
- Low-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with one- or two-vessel CAD without significant proximal LAD CAD who have survived sudden cardiac death or sustained ventricular tachycardia. *(Level of Evidence: C)*
Class III
Use of PCI or CABG for patients with one- or two vessel CAD without significant proximal LAD CAD, who have mild symptoms that are unlikely due to myocardial ischemia, or who have not received an adequate trial of medical therapy and
c. have only a small area of viable myocardium or
d. have no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class III
- Use of PCI or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD and
  c. only a small area of viable myocardium or
  d. no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*
- Use of PCI or CABG for patients with borderline coronary stenoses (50% to 60% diameter in locations other than the left main coronary artery) and no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIb
CABG may be considered for patients with asymptomatic or mild angina who have 1- or 2-vessel disease not involving the proximal LAD (If a large area of viable myocardium and high-risk criteria are met on noninvasive testing, this recommendation becomes (Class I). *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*
Class III
CABG is not recommended for patients with stable angina who have 1- or 2-vessel disease not involving significant proximal LAD stenosis, patients who have mild symptoms that are unlikely due to myocardial ischemia, or patients who have not received an adequate trial of medical therapy and
c. have only a small area of viable myocardium or *(Level of Evidence: B)*
d. have no demonstrable ischemia on noninvasive testing. *(Level of Evidence: B)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class III
PCI is not recommended in patients with asymptomatic ischemia or CCS class I or II angina who do not meet the criteria as listed under the class II recommendations or who have 1 or more of the following:
a. Only a small area of viable myocardium at risk
b. No objective evidence of ischemia.
c. Lesions that have a low likelihood of successful dilatation.
d. Mild symptoms that are unlikely to be due to myocardial ischemia.
e. Factors associated with increased risk of morbidity or mortality.
f. Left main disease and eligibility for CABG.
g. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*

14.
- One or two vessel coronary artery disease without involvement of proximal LAD
- Intermediate-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD but with a moderate area of viable myocardium and demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Angina Class I or II
Class IIa
PCI is reasonable in patients with asymptomatic ischemia or CCS Class I or II angina and with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a moderate to large area of viable myocardium or be associated with a moderate to severe degree of ischemia on noninvasive testing. *(Level of Evidence: B)*

Class IIb
PCI might be considered for patients with asymptomatic ischemia or CCS class I or II angina with nonproximal LAD CAD that subtends a moderate area of viable myocardium and demonstrates ischemia on noninvasive testing. *(Level of Evidence: C)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIb
CABG may be considered for patients with asymptomatic or mild angina who have 1- or 2-vessel disease not involving the proximal LAD (If a large area of viable myocardium and high-risk criteria are met on noninvasive testing, this recommendation becomes Class I). *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class IIa
CABG may be useful for patients with stable angina who have 1- or 2-vessel CAD without significant proximal LAD stenosis but who have a moderate area of viable myocardium and demonstrable ischemia on noninvasive testing. *(Level of Evidence: B)*

15.
- One or two vessel coronary artery disease without involvement of proximal LAD
- Intermediate risk-findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Percutaneous coronary intervention or CABG for patients who have not been successfully treated by medical therapy (see text) and can undergo revascularization with acceptable risk. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD but with a moderate area of viable myocardium and demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Angina Class I or II
Class IIa
PCI is reasonable in patients with asymptomatic ischemia or CCS Class I or II angina and with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a moderate to large area of viable myocardium or be associated with a moderate to severe degree of ischemia on noninvasive testing. *(Level of Evidence: B)*

Class IIb
PCI might be considered for patients with asymptomatic ischemia or CCS class I or II angina with nonproximal LAD CAD that subtends a moderate area of viable myocardium and demonstrates ischemia on noninvasive testing. *(Level of Evidence: C)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIb
CABG may be considered for patients with asymptomatic or mild angina who have 1- or 2-vessel disease not involving the proximal LAD (If a large area of viable myocardium and high-risk criteria are met on noninvasive testing, this recommendation becomes Class I). *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*

Class IIa
CABG may be useful for patients with stable angina who have 1- or 2-vessel CAD without significant proximal LAD stenosis but who have a moderate area of viable myocardium and demonstrable ischemia on noninvasive testing. *(Level of Evidence: B)*

16.
- One or two vessel coronary artery disease without involvement of proximal LAD
- High-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: B)*
- In patients with prior PCI, CABG or PCI for recurrent stenosis associated with a large area of viable myocardium or high-risk criteria on noninvasive testing. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class I
Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Angina Class I or II
Class IIa
PCI is reasonable in patients with asymptomatic ischemia or CCS Class I or II angina and with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a moderate to large area of viable myocardium or be associated with a moderate to severe degree of ischemia on noninvasive testing. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIb
CABG may be considered for patients with asymptomatic or mild angina who have 1- or 2-vessel disease not involving the proximal LAD (**If a large area of viable myocardium and high-risk criteria are met on noninvasive testing, this recommendation becomes Class I**). *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is beneficial for patients with stable angina who have 1- or 2-vessel CAD without significant proximal LAD stenosis but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (Level of Evidence: B)

17.

- One or two vessel coronary artery disease without involvement of proximal LAD
- High-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I

- Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: B)*
- In patients with prior PCI, CABG or PCI for recurrent stenosis associated with a large area of viable myocardium or high-risk criteria on noninvasive testing. *(Level of Evidence: C)*
- Percutaneous coronary intervention or CABG for patients who have not been successfully treated by medical therapy (see text) and can undergo revascularization with acceptable risk. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class I
Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Angina Class I or II
Class IIa
PCI is reasonable in patients with asymptomatic ischemia or CCS Class I or II angina and with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a moderate to large area of viable myocardium or be associated with a moderate to severe degree of ischemia on noninvasive testing. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIb
CABG may be considered for patients with asymptomatic or mild angina who have 1- or 2-vessel disease not involving the proximal LAD (If a large area of viable myocardium and high-risk criteria are met on noninvasive testing, this recommendation becomes Class I). *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I

- CABG is beneficial for patients with stable angina who have 1- or 2-vessel CAD without significant proximal LAD stenosis but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (Level of Evidence: B)

18.	▪ One or two vessel coronary artery disease without involvement of proximal LAD ▪ No non-invasive testing performed
No relevant guideline recommendation	
19.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed ▪ No further invasive evaluation performed (i.e. FFR, IVUS)
Chronic Stable Angina (p. 90-91) **Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients** **Class III** Use of PCI or CABG for patients with borderline coronary stenoses (50% to 60% diameter in locations other than the left main coronary artery) and no demonstrable ischemia on noninvasive testing. *(Level of Evidence: C)*	
20.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR less than 0.75 and/or IVUS with significant reduction in cross sectional area.
No relevant guideline recommendation	
21.	▪ One or two vessel coronary artery disease with borderline stenosis “50%-60%” ▪ No non-invasive testing performed or equivocal test results present ▪ FFR or IVUS findings do not meet criteria for significant stenosis
No relevant guideline recommendation	
22.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
No relevant guideline recommendation	
23.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Low-risk findings on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
No relevant guideline recommendation	

24.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Intermediate-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
No relevant guideline recommendation	
25.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ Intermediate-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
No relevant guideline recommendation	
26.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk findings on non-invasive testing ▪ Receiving no or minimal anti-ischemic medical therapy
No relevant guideline recommendation	
27.	▪ Chronic total occlusion of one major epicardial coronary artery, without other coronary stenoses ▪ High-risk criteria on non-invasive testing ▪ Receiving a course of maximal anti-ischemic medical therapy
No relevant guideline recommendation	

28.
- One vessel disease involving the proximal LAD
- Low-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (P. 77)
Revascularization for Chronic Stable Angina
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

Chronic Stable Angina (P. 90)
Revascularization with PCI and CABG in Asymptomatic Patients
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

PCI (p.e40)
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (Level of Evidence: B)

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (**This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.)** (Level of Evidence: A)

CABG (p.e280)
Class IIa
Stable Angina
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). (Level of Evidence: A)

29.
- One vessel disease involving the proximal LAD
- Low-risk findings on non-invasive testing
- Receiving maximal anti-ischemic medical therapy

Chronic Stable Angina (P. 77)
Revascularization for Chronic Stable Angina
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

Chronic Stable Angina (P. 90)
Revascularization with PCI and CABG in Asymptomatic Patients
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

PCI (p.e40)
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (Level of Evidence: B)

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) (Level of Evidence: A)

30.
- One vessel disease involving the proximal LAD
- Intermediate-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (P. 77)
Revascularization for Chronic Stable Angina
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

Chronic Stable Angina (P. 90)
Revascularization with PCI and CABG in Asymptomatic Patients
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

PCI (p.e40)
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (Level of Evidence: B)

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) (Level of Evidence: A)

CABG (p.e280)
Class IIa
Stable Angina
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). (Level of Evidence: A)

31.
- One vessel disease involving the proximal LAD
- Intermediate-risk findings on non-invasive testing
- Receiving maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77)
Revascularization for Chronic Stable Angina
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90)
Revascularization with PCI and CABG in Asymptomatic Patients
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

PCI (p.e40)
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (Level of Evidence: B)

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) (Level of Evidence: A)

CABG (p.e280)
Class IIa
Stable Angina
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). (Level of Evidence: A)

32.
- One vessel disease involving the proximal LAD
- High-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Stable Angina (p. 77)
Revascularization for Chronic Stable Angina
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

Stable Angina (p. 90)
Revascularization with PCI and CABG in Asymptomatic Patients
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

PCI (p. e40)
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (Level of Evidence: B)

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (**This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) (**Level of Evidence: A)

CABG (p. e280)
Class IIa
Stable Angina
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). (Level of Evidence: A)

33.
- One vessel disease involving the proximal LAD
- High-risk findings on non-invasive testing
- Receiving maximal anti-ischemic medical therapy

Chronic Stable Angina (P. 77)
Revascularization for Chronic Stable Angina
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

Chronic Stable Angina (P. 90)
Revascularization with PCI and CABG in Asymptomatic Patients
Class IIa
Use of PCI or CABG for patients with one-vessel disease with significant proximal LAD disease. *(Level of Evidence: B)*

PCI (p.e40)
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (Level of Evidence: B)

CABG (p. e279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (**This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50**.) (Level of Evidence: A)

CABG (p.e280)
Class IIa
Stable Angina
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). (Level of Evidence: A)

34.
- Two vessel disease involving the proximal LAD
- Low-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) *(Level of Evidence: A)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*

Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

35.
- Two vessel disease involving the proximal LAD
- Low-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) *(Level of Evidence: A)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*

Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

36.
- Two vessel coronary artery disease involving the proximal LAD
- Intermediate-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) *(Level of Evidence: A)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*

Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

37.
- Two vessel coronary artery disease involving the proximal LAD
- Intermediate-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) *(Level of Evidence: A)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

38.
- Two vessel coronary artery disease involving the proximal LAD
- High-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) *(Level of Evidence: A)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*

Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

39.
- Two vessel coronary artery disease involving the proximal LAD
- High-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal LV function (ejection fraction less than 50%) or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: C)*

CABG (p. e 279)
Asymptomatic or Mild Angina
Class IIa
CABG can be beneficial for patients with asymptomatic or mild angina who have proximal LAD stenosis with 1- or 2-vessel disease. (This recommendation becomes a Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50.) *(Level of Evidence: A)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. *(Level of Evidence: A)*

Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

40.
- Three vessel coronary artery disease (no left main)
- Low-risk findings on non-invasive testing including normal LV systolic function
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class IIa
It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. *(Level of Evidence: B)*
Class IIb
PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class I
CABG is useful in patients with asymptomatic ischemia or mild angina who have 3-vessel disease. (Survival benefit is greater in patients with abnormal LV function; e.g., EF less than 0.50 and/or large areas of demonstrable myocardial ischemia.) *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*

41.
- Three vessel coronary artery disease (no left main)
- Low-risk findings on non-invasive testing including normal LV systolic function
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class IIa
It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. *(Level of Evidence: B)*
Class IIb
PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class I
CABG is useful in patients with asymptomatic ischemia or mild angina who have 3-vessel disease. (Survival benefit is greater in patients with abnormal LV function; e.g., EF less than 0.50 and/or large areas of demonstrable myocardial ischemia.) *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*

42.
- Three vessel coronary artery disease (no left main)
- Intermediate-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*
Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class I
CABG is useful in patients with asymptomatic ischemia or mild angina who have 3-vessel disease. (Survival benefit is greater in patients with abnormal LV function; e.g., EF less than 0.50 and/or large areas of demonstrable myocardial ischemia.) *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*

43.
- Three vessel coronary artery disease (no left main)
- Intermediate-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*
Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class IIa
It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. *(Level of Evidence: B)*
Class IIb
PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class I
CABG is useful in patients with asymptomatic ischemia or mild angina who have 3-vessel disease. (Survival benefit is greater in patients with abnormal LV function; e.g., EF less than 0.50 and/or large areas of demonstrable myocardial ischemia.) *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*

44.
- Three vessel coronary artery disease (no left main)
- High-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class I
CABG is useful in patients with asymptomatic ischemia or mild angina who have 3-vessel disease. (Survival benefit is greater in patients with abnormal LV function; e.g., EF less than 0.50 and/or large areas of demonstrable myocardial ischemia.) *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*

45.
- Three vessel coronary artery disease (no left main)
- High-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
(These recommendations are identical to those for symptomatic patients.)
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: C)*

PCI (p. e40)
Patients With Asymptomatic Ischemia or CCS Class I or II Angina
Class IIb
The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class IIa
It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. *(Level of Evidence: B)*

Class IIb
PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. *(Level of Evidence: B)*

CABG (p. e279)
Asymptomatic or Mild Angina
Class I
- CABG is useful in patients with asymptomatic ischemia or mild angina who have 3-vessel disease. (Survival benefit is greater in patients with abnormal LV function; e.g., EF less than 0.50 and/or large areas of demonstrable myocardial ischemia.) *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*

46.	▪ Three vessel coronary artery disease (no left main) ▪ Abnormal LV systolic function
No relevant guideline recommendations.	
47.	▪ Left Main Stenosis
Chronic Stable Angina (p. 77-78) **Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina** **Class I** Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)* ***CABG (p. e279)*** **Clinical Subsets: Asymptomatic or Mild Angina** **Class I** CABG should be performed in patients with asymptomatic or mild angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)* ***CABG (p. e279)*** **Asymptomatic or Mild Angina** **Class I** CABG should be performed in patients with asymptomatic or mild angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)* ***CABG (p. e280)*** **Stable Angina** **Class I** CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*	

Table 3. Patients with Prior Bypass Surgery (Without Acute Coronary Syndromes)

48.
- One or more stenoses in saphenous vein graft(s)
- Low-risk findings on non-invasive testing including normal LV systolic function
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class IIa
- Repeat CABG for patients with multiple saphenous vein graft stenoses, especially when there is significant stenosis of a graft supplying the LAD. It may be appropriate to use PCI for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
- PCI is reasonable in patients with ischemia that occurs 1 to 3 years after CABG and who have preserved LV function with discrete lesions in graft conduits. *(Level of Evidence: B)*
- PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*
- PCI is reasonable in patients with diseased vein grafts more than 3 years after CABG. *(Level of Evidence: B)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
Coronary bypass should be performed in patients with prior CABG without patent bypass grafts but with Class I indications for surgery for native-vessel CAD (significant left main coronary stenosis, left main equivalent, 3-vessel disease). *(Level of Evidence: B)*

Class II
Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

49.
- One or more stenoses in saphenous vein graft(s)
- Low-risk findings on non-invasive testing including normal LV systolic function
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class IIa
- Repeat CABG for patients with multiple saphenous vein graft stenoses, especially when there is significant stenosis of a graft supplying the LAD. It may be appropriate to use PCI for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

PCI (p. e41)
Patients With CCS Class III Angina
Class IIa
It is reasonable that PCI be performed in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy with focal saphenous vein graft lesions or multiple stenoses who are poor candidates for reoperative surgery. *(Level of Evidence: C)*

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
- PCI is reasonable in patients with ischemia that occurs 1 to 3 years after CABG and who have preserved LV function with discrete lesions in graft conduits. *(Level of Evidence: B)*
- PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*
- PCI is reasonable in patients with diseased vein grafts more than 3 years after CABG. *(Level of Evidence: B)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
- Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*
- Coronary bypass should be performed in patients with prior CABG without patent bypass grafts but with Class I indications for surgery for native-vessel CAD (significant left main coronary stenosis, left main equivalent, 3-vessel disease). *(Level of Evidence: B)*

Class II
Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

50.
- One or more stenoses in saphenous vein graft(s)
- Intermediate-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class IIa
- Repeat CABG for patients with multiple saphenous vein graft stenoses, especially when there is significant stenosis of a graft supplying the LAD. It may be appropriate to use PCI for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
- PCI is reasonable in patients with ischemia that occurs 1 to 3 years after CABG and who have preserved LV function with discrete lesions in graft conduits. *(Level of Evidence: B)*
- PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*
- PCI is reasonable in patients with diseased vein grafts more than 3 years after CABG. *(Level of Evidence: B)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
- Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*
- Coronary bypass should be performed in patients with prior CABG without patent bypass grafts but with Class I indications for surgery for native-vessel CAD (significant left main coronary stenosis, left main equivalent, 3-vessel disease). *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients with prior CABG and bypassable distal vessel(s) with a large area of threatened myocardium by noninvasive studies. *(Level of Evidence: B)*
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

51.
- One or more stenoses in saphenous vein graft(s)
- Intermediate-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class IIa
- Repeat CABG for patients with multiple saphenous vein graft stenoses, especially when there is significant stenosis of a graft supplying the LAD. It may be appropriate to use PCI for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
- Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*
- Coronary bypass should be performed in patients with prior CABG without patent bypass grafts but with Class I indications for surgery for native-vessel CAD (significant left main coronary stenosis, left main equivalent, 3-vessel disease). *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients with prior CABG and bypassable distal vessel(s) with a large area of threatened myocardium by noninvasive studies. *(Level of Evidence: B)*
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

52.
- One or more stenoses in saphenous vein graft(s)
- High-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class IIa
- Repeat CABG for patients with multiple saphenous vein graft stenoses, especially when there is significant stenosis of a graft supplying the LAD. It may be appropriate to use PCI for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Repeat CABG for patients with multiple saphenous vein graft stenoses, with high-risk criteria on noninvasive testing, especially when there is significant stenosis of a graft supplying the LAD. Percutaneous coronary intervention may be appropriate for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
- PCI is reasonable in patients with ischemia that occurs 1 to 3 years after CABG and who have preserved LV function with discrete lesions in graft conduits. *(Level of Evidence: B)*
- PCI is reasonable in patients with diseased vein grafts more than 3 years after CABG. *(Level of Evidence: B)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
-
- Coronary bypass should be performed in patients with prior CABG without patent bypass grafts but with Class I indications for surgery for native-vessel CAD (significant left main coronary stenosis, left main equivalent, 3-vessel disease). *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients with prior CABG and bypassable distal vessel(s) with a large area of threatened myocardium by noninvasive studies. *(Level of Evidence: B)*
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

53.
- One or more stenoses in saphenous vein graft(s)
- High-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class IIa
- Repeat CABG for patients with multiple saphenous vein graft stenoses, especially when there is significant stenosis of a graft supplying the LAD. It may be appropriate to use PCI for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Repeat CABG for patients with multiple saphenous vein graft stenoses, with high-risk criteria on noninvasive testing, especially when there is significant stenosis of a graft supplying the LAD. Percutaneous coronary intervention may be appropriate for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
- Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*
- Coronary bypass should be performed in patients with prior CABG without patent bypass grafts but with Class I indications for surgery for native-vessel CAD (significant left main coronary stenosis, left main equivalent, 3-vessel disease). *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients with prior CABG and bypassable distal vessel(s) with a large area of threatened myocardium by noninvasive studies. *(Level of Evidence: B)*
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

54.
- One or more lesions in native coronary arteries without bypass grafts
- All bypass grafts patent and without significant disease
- Low-risk findings on non-invasive testing including normal LV systolic function
- Receiving no or minimal anti-ischemic medical therapy

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
Class II
Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

55.
- One or more lesions in native coronary arteries without bypass grafts
- All bypass grafts patent and without significant disease
- Low-risk findings on non-invasive testing including normal LV systolic function
- Receiving a course of maximal anti-ischemic medical therapy

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*

Class II
Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

56.
- One or more lesions in native coronary arteries without bypass grafts
- All bypass grafts patent and without significant disease
- Intermediate-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*

57.
- One or more lesions in native coronary arteries without bypass grafts
- All bypass grafts patent and without significant disease
- Intermediate-risk findings on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

PCI (p. e56)
5.5. Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
- Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

58.
- One or more lesions in native coronary arteries without bypass grafts
- All bypass grafts patent and without significant disease
- High-risk findings on non-invasive testing
- Receiving no or minimal anti-ischemic medical therapy

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Repeat CABG for patients with multiple saphenous vein graft stenoses, with high-risk criteria on noninvasive testing, especially when there is significant stenosis of a graft supplying the LAD. Percutaneous coronary intervention may be appropriate for focal saphenous vein graft lesions or multiple stenoses in poor candidates for reoperative surgery. *(Level of Evidence: C)*

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
- Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients with prior CABG and bypassable distal vessel(s) with a large area of threatened myocardium by noninvasive studies. *(Level of Evidence: B)*
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

59.
- One or more lesions in native coronary arteries without bypass grafts
- All bypass grafts patent and without significant disease
- High-risk finding on non-invasive testing
- Receiving a course of maximal anti-ischemic medical therapy

PCI (p. e56)
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class IIa
PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. *(Level of Evidence: C)*

CABG (p. e284-285)
Patients With Previous CABG
Class I
Coronary bypass should be performed in patients with prior CABG for disabling angina despite optimal nonsurgical therapy. (If angina is not typical, then objective evidence of ischemia should be obtained.) *(Level of Evidence: B)*

Class II
- Coronary bypass is reasonable in patients with prior CABG and bypassable distal vessel(s) with a large area of threatened myocardium by noninvasive studies. *(Level of Evidence: B)*
- Coronary bypass is reasonable in patients who have prior CABG if atherosclerotic vein grafts with stenoses greater than 50% supplying the LAD coronary artery or large areas of myocardium are present. *(Level of Evidence: B)*

Table 4. Method of Revascularization
Advanced Coronary Disease, CCS Angina Greater than or equal to Class III and/or evidence of intermediate to high risk findings on non-invasive testing

60.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ No diabetes and normal LVEF
	Chronic Stable Angina (p. 77-78) **Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina** **Class I** ▪ Coronary artery bypass grafting for patients with two-vessel disease with significant proximal LAD CAD and either abnormal ventricular function (ejection fraction less than 50%) or demonstrable ischemia on non-invasive testing**.** *(Level of Evidence: A)* ▪ Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)* ▪ Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: B)* ***CABG (p. e280)*** **Stable Angina** **Class I** CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*
61.	▪ Two vessel coronary artery disease with proximal LAD stenosis ▪ Diabetes
	Chronic Stable Angina (p. 77-78) **Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina** **Class IIb** Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

62.
- Two vessel coronary artery disease with proximal LAD stenosis
- Depressed LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and **normal LV function and who do not have treated diabetes.** *(Level of Evidence: B)*
- Percutaneous coronary intervention or CABG for patients with one- or two-vessel CAD without significant proximal LAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. *(Level of Evidence: B)*

Class IIb
- Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*
- Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended in patients with stable angina who have 2-vessel disease with significant proximal LAD stenosis and either EF less than 0.50 or demonstrable ischemia on noninvasive testing. (Level of Evidence: A)
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*

Class IIa
CABG is reasonable in patients with stable angina who have proximal LAD stenosis with 1-vessel disease. (This recommendation becomes Class I if extensive ischemia is documented by noninvasive study and/or LVEF is less than 0.50). *(Level of Evidence: A)*

CABG (p. e283)
Poor LV Function
Class I
CABG should be performed in patients with poor LV function who have proximal LAD stenosis with 2- or 3-vessel disease. *(Level of Evidence: B)*

63.
- Three vessel coronary artery disease
- No diabetes and normal LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
- Percutaneous coronary intervention for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy and normal LV function and who do not have treated diabetes. *(Level of Evidence: B)*
- Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

CABG (p. e 280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) (Level of Evidence: A)
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (Level of Evidence: B)

64.
- Three vessel coronary artery disease
- Diabetes

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. (Level of Evidence: C)
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success.(Level of Evidence: C)
c. A high risk of procedure-related morbidity or mortality.(Level of Evidence: C)
d. Insignificant disease (less than 50% coronary stenosis). (Level of Evidence: C)
e. Significant left main CAD and candidacy for CABG. (Level of Evidence: C)

CABG (p. e 280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*

65.
- Three vessel coronary artery disease
- Depressed LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with three-vessel disease. The survival benefit is greater in patients with abnormal LV function (ejection fraction less than 50%). *(Level of Evidence: A)*

Class IIb
Compared with CABG, PCI for patients with two- or three-vessel disease with significant proximal LAD CAD, who have anatomy suitable for catheter-based therapy, and who have treated diabetes or abnormal LV function. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. *(Level of Evidence: B)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) (Level of Evidence: A)

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

66.
- Isolated left main stenosis
- No diabetes and normal LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Class III
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

67.
- Isolated left main stenosis
- Diabetes

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

68.
- Isolated left main stenosis
- Depressed LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

CABG (p. e283)
Poor LV Function
Class I
CABG should be performed in patients with poor LV function who have significant left main coronary artery stenosis. *(Level of Evidence: B)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Class III
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

69.
- Left main stenosis and additional coronary artery disease
- No diabetes and normal LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:
a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

70.
- Left main stenosis and additional coronary artery disease
- Diabetes

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

71.
- Left main stenosis and additional coronary artery disease
- Depressed LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

CABG (p. e283)
Poor LV Function
Class I
CABG should be performed in patients with poor LV function who have significant left main coronary artery stenosis. *(Level of Evidence: B)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Class III
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

72.
- Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts
- LIMA remains patent to a native coronary artery
- Depressed LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

CABG (p. e283)
Poor LV Function
Class I
CABG should be performed in patients with poor LV function who have significant left main coronary artery stenosis. *(Level of Evidence: B)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Class III
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*

73.
- Prior bypass surgery with native three-vessel disease and failure of multiple bypass grafts
- LIMA was used as a graft but is no longer functional
- Depressed LVEF

Chronic Stable Angina (p. 77-78)
Recommendations for Revascularization With PCI (or Other Catheter-Based Techniques) and CABG in Patients With Stable Angina
Class I
Coronary artery bypass grafting for patients with significant left main coronary disease. *(Level of Evidence: A)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Chronic Stable Angina (p. 90-91)
Recommendations for Revascularization with PCI and CABG in Asymptomatic Patients
Class IIb
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

CABG (p. e280)
Stable Angina
Class I
- CABG is recommended for patients with stable angina who have left main equivalent: Significant (greater than or equal to 70%) stenosis of the proximal LAD and proximal left circumflex artery. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have significant left main coronary artery stenosis. *(Level of Evidence: A)*
- CABG is recommended for patients with stable angina who have 3-vessel disease. (Survival benefit is greater when LVEF is less than 0.50.) *(Level of Evidence: A)*
- CABG is beneficial for patients with stable angina who have developed disabling angina despite maximal noninvasive therapy, when surgery can be performed with acceptable risk. If angina is not typical, objective evidence of ischemia should be obtained. (*Level of Evidence: B)*

CABG (p. e283)
Poor LV Function
Class I
CABG should be performed in patients with poor LV function who have significant left main coronary artery stenosis. *(Level of Evidence: B)*

Class IIb
Use of PCI for patients with significant left main coronary disease who are not candidates for CABG. *(Level of Evidence: C)*

Class III
Use of PCI in patients with significant left main coronary artery disease who are candidates for CABG. *(Level of Evidence: B)*

PCI (p. e41)
Patients With CCS Class III Angina
Class III
PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

a. Only a small area of myocardium at risk. *(Level of Evidence: C)*
b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. *(Level of Evidence: C)*
c. A high risk of procedure-related morbidity or mortality. *(Level of Evidence: C)*
d. Insignificant disease (less than 50% coronary stenosis). *(Level of Evidence: C)*
e. Significant left main CAD and candidacy for CABG. *(Level of Evidence: C)*